[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8oP9t2kpU9VQjt-6yATNC9-YpadRdKku2beHbp8u9j4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Incyte Corporation",[4],281,false,59,60,48991,69,4,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Solid Tumors",24,{"name":18,"count":19},"Healthy Participants",16,{"name":21,"count":22},"Atopic Dermatitis",15,{"name":24,"count":25},"Lung Cancer",11,{"name":27,"count":28},"Melanoma",9,{"name":30,"count":28},"MPN (Myeloproliferative Neoplasms)",{"name":32,"count":28},"Lymphoma",{"name":34,"count":28},"Ovarian Cancer",[36,41,46,51,56,61,65,69,74,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04205812","Platinum-Based Chemotherapy With\u002FWithout INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","2023-12-15","Retifanlimab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04680052","A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed\u002FRefractory (R\u002FR) Follicular Lymphoma or Marginal Zone Lymphoma.","2024-02-23","tafasitamab",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05222555","Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients","2024-07-17","Tafasitamab",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04455841","INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders","2025-04-01","INCB000928",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06113445","A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)","2026-02-24","Povorcitinib",{"nctId":62,"briefTitle":63,"date":64,"intervention":60},"NCT06113471","A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)","2026-03-17",{"nctId":66,"briefTitle":67,"date":68,"intervention":50},"NCT05429268","Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)","2026-03-30",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT04463771","Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.","2026-04-14","retifanlimab",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT06873789","A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors","2026-05-08","INCB177054",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06909162","A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants","2026-05-17","INCB123667",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,273,755,1049,1128,1197,1294,1343,1397,1607,1646,1683,1709,1781,1855,1885,1926,1956,1978,2054,2115,2167,2205,2247,2269,2291,2313,2331,2349,2367,2385,2403,2482,2531,2689,2860,2894,2946,2972,2994,3012,3030,3048,3066,3084,3110,3128,3348,3459,3494,3533,3563,3597,3619,3641,3663,3698,3723,3745,3769,3787,3805,3823,3841,3859,3877,3902,3920,3938,3956,4033,4095,4137,4178,4208,4234,4260,4282,4304,4322,4340,4358,4376,4394,4412,4430,4448,4466,4484,4509,4527,4545,4563,4589,4668,4708,4742,4782,4818,4857,4897,4945,4978,5017,5043,5087,5109,5131,5153,5180,5202,5224,5249,5271,5299,5321,5348,5366,5384,5402,5420,5438,5456,5474,5492,5510,5528,5546,5569,5587,5605,5623,5641,5659,5677,5695,5713,5731,5749,5767,5785,5807,5830,5848,5872,5890,5908,5931,5949,5967,5985,6003,6021,6050,6068,6086,6104,6122,6140,6164,6182,6200,6218,6236,6254,6272,6295,6313,6335,6353,6392,6424,6446,6477,6499,6521,6543,6561,6593,6611,6629,6647,6665,6683,6701,6725,6743,6761,6785,6803,6821,6839,6857,6880,6898,6919,6937,6963,6987,7011,7033],{"intervention":60,"totalTrials":19,"cells":93},{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":153,"PHASE3":195,"PHASE4":269,"NA":271},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":152,"soonestReadout":124},[99,109,119,130,139],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":16,"conditions":106,"interventions":107},"NCT06380205","A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel\u002FEthinyl Estradiol in Healthy Adult Females","COMPLETED",[86],"2024-06-07","2024-05-07",[18],[60,108],"Levonorgestrel\u002FEthinyl estradiol",{"nctId":110,"briefTitle":111,"status":102,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":117},"NCT06441318","A Study to Evaluate the Effect of Povorcitinib on the QT\u002FQTc Interval in Healthy Participants",[86],"2024-09-10","2024-07-12",128,[18],[60,118],"Moxifloxacin",{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":16,"conditions":127,"interventions":128},"NCT07588139","A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants","RECRUITING",[86],"2026-09-03","2026-09-19","2026-05-18",[18],[60,129],"Ruxolitinib",{"nctId":131,"briefTitle":132,"status":102,"phases":133,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":138},"NCT06505265","A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants",[86],"2024-09-18","2024-08-12",18,[18],[60],{"nctId":140,"briefTitle":141,"status":102,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},"NCT06416800","A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants",[86],"2025-01-15","2024-06-19",71,[18],[148,149,150,60,151],"Digoxin","Rosuvastatin","Metformin","Probenecid",1,{"trials":154,"activeCount":194,"soonestReadout":175},[155,171,184],{"nctId":156,"briefTitle":157,"status":102,"phases":158,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":170},"NCT05936567","Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria",[87],"2025-02-28","2025-10-09","2023-07-31",136,[164,165,166,167,168,169],"Urticaria","Chronic Spontaneous Urticaria","Chronic Idiopathic Urticaria","Hives","Angioedema","Pruritis",[60],{"nctId":172,"briefTitle":173,"status":122,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":181},"NCT05851443","A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma",[87],"2026-06-15","2027-01-31","2023-07-11",240,[180],"Moderate to Severe Asthma",[182,183],"povorcitinib","ICS-LABA",{"nctId":185,"briefTitle":186,"status":122,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT07213973","Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa",[87],"2028-03-25","2026-02-02",40,[192],"Hidradenitis Suppurativa (HS)",[60],2,{"trials":196,"activeCount":268,"soonestReadout":59},[197,205,215,224,234,241,252,261],{"nctId":198,"briefTitle":199,"status":122,"phases":200,"primaryCompletion":201,"completion":201,"start":159,"enrollment":202,"conditions":203,"interventions":204},"NCT06855498","Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib",[88],"2028-02-28",600,[192],[182],{"nctId":206,"briefTitle":207,"status":102,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":214},"NCT05620836","A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)",[88],"2025-01-07","2025-11-21","2023-02-22",619,[192],[60],{"nctId":62,"briefTitle":63,"status":216,"phases":217,"primaryCompletion":64,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},"ACTIVE_NOT_RECRUITING",[88],"2027-03-16","2023-11-27",450,[222],"NonSegmental Vitiligo",[60],{"nctId":225,"briefTitle":226,"status":102,"phases":227,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":233},"NCT05620823","A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa",[88],"2025-02-03","2025-12-23","2022-12-19",608,[192],[60],{"nctId":57,"briefTitle":58,"status":216,"phases":235,"primaryCompletion":59,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":240},[88],"2027-02-24","2023-11-29",467,[222],[60],{"nctId":242,"briefTitle":243,"status":216,"phases":244,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":251},"NCT06516952","A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)",[88],"2026-10-19","2027-05-03","2024-10-10",349,[250],"Prurigo Nodularis",[60],{"nctId":253,"briefTitle":254,"status":216,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":260},"NCT06212999","A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa",[88],"2026-12-26","2024-01-30",617,[192],[60],{"nctId":262,"briefTitle":263,"status":216,"phases":264,"primaryCompletion":245,"completion":246,"start":247,"enrollment":265,"conditions":266,"interventions":267},"NCT06516965","A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)",[88],346,[250],[60],6,{"trials":270,"activeCount":96},[],{"trials":272,"activeCount":96},[],{"intervention":129,"totalTrials":274,"cells":275},43,{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":344,"PHASE3":589,"PHASE4":731,"NA":733},{"trials":277,"activeCount":96},[],{"trials":279,"activeCount":12,"soonestReadout":124},[280,296,305,321,332,336],{"nctId":281,"briefTitle":282,"status":283,"phases":284,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":291},"NCT01822756","An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors","TERMINATED",[86],"2015-09","2016-08","2013-04",42,[15,290],"Pancreatic Cancer",[292,293,294,295],"ruxolitinib","gemcitabine","nab-paclitaxel","filgrastim",{"nctId":297,"briefTitle":298,"status":102,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":11,"conditions":302,"interventions":304},"NCT01317875","Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)",[86],"2019-12-31","2011-03-31",[303],"Myelofibrosis",[129],{"nctId":306,"briefTitle":307,"status":216,"phases":308,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":319},"NCT04279847","Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms",[86],"2027-04-30","2021-02-23",140,[303,313,314,315,316,317,318],"Myelodysplastic Syndrome","Myelodysplastic\u002FMyeloproliferative Neoplasm Overlap Syndrome","Myeloproliferative Neoplasm","Relapsed or Refractory Primary Myelofibrosis","Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)","ET (Essential Thrombocythemia)",[320,129],"INCB057643",{"nctId":322,"briefTitle":323,"status":122,"phases":324,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":330},"NCT06034002","A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms",[86],"2028-10-29","2023-12-04",290,[329],"Myeloproliferative Neoplasms",[331,129],"INCA033989",{"nctId":120,"briefTitle":121,"status":122,"phases":333,"primaryCompletion":124,"completion":125,"start":126,"enrollment":16,"conditions":334,"interventions":335},[86],[18],[60,129],{"nctId":337,"briefTitle":323,"status":122,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":343},"NCT05936359",[86],"2028-02-29","2023-09-25",225,[329],[331,129],{"trials":345,"activeCount":588,"soonestReadout":54},[346,356,366,377,389,400,412,423,435,445,454,468,479,501,510,520,533,546,556,567,578],{"nctId":52,"briefTitle":53,"status":216,"phases":347,"primaryCompletion":54,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":355},[86,87],"2027-11-26","2021-03-19",84,[352,353,354],"Anemia","Post-essential Thrombocythemia Myelofibrosis","Post-polycythemia Vera Myelofibrosis",[55,292],{"nctId":357,"briefTitle":358,"status":102,"phases":359,"primaryCompletion":360,"completion":361,"start":362,"enrollment":162,"conditions":363,"interventions":364},"NCT01423604","Study of Ruxolitinib in Pancreatic Cancer Patients",[87],"2013-06","2016-11","2011-07",[290],[365,129],"Capecitabine",{"nctId":367,"briefTitle":368,"status":102,"phases":369,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":376},"NCT00617994","Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis",[87],"2009-04-30","2009-05-31","2007-08-31",25,[375],"Psoriasis",[129],{"nctId":378,"briefTitle":379,"status":102,"phases":380,"primaryCompletion":381,"completion":287,"start":382,"enrollment":383,"conditions":384,"interventions":388},"NCT01445769","Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis",[87],"2013-03","2011-09",45,[385,386,387],"Primary Myelofibrosis","Post-Polycythemia Vera Myelofibrosis","Post-Essential Thrombocythemia Myelofibrosis",[129],{"nctId":390,"briefTitle":391,"status":283,"phases":392,"primaryCompletion":393,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":398},"NCT02718300","A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis",[87],"2021-01-28","2022-04-29","2017-02-08",74,[30],[399,399,129,399,399],"Parsaclisib",{"nctId":401,"briefTitle":402,"status":102,"phases":403,"primaryCompletion":404,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":411},"NCT00509899","Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera\u002FEssential Thrombocythemia Myelofibrosis",[86,87],"2007-12","2017-02","2007-06",154,[303,409,410],"Polycythemia Vera","Thrombocytosis",[129],{"nctId":413,"briefTitle":414,"status":102,"phases":415,"primaryCompletion":416,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":421},"NCT03144687","A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis",[87],"2020-03-14","2021-06-01","2018-01-26",23,[30],[422,129],"Itacitinib",{"nctId":424,"briefTitle":425,"status":283,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":433},"NCT02119676","Study of Ruxolitinib in Colorectal Cancer Patients",[87],"2016-02","2016-12","2014-03",396,[432],"CRC (Colorectal Cancer)",[129,434],"Regorafenib",{"nctId":436,"briefTitle":437,"status":283,"phases":438,"primaryCompletion":427,"completion":439,"start":440,"enrollment":441,"conditions":442,"interventions":444},"NCT02120417","A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer",[87],"2017-01","2014-05",149,[443],"Breast Cancer",[129,365],{"nctId":446,"briefTitle":447,"status":102,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":453},"NCT01348490","Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)",[87],"2018-12-19","2011-06-15",66,[30],[129],{"nctId":455,"briefTitle":456,"status":283,"phases":457,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":461,"interventions":462},"NCT02711137","Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",[86,87],"2019-02-13","2016-05-18",137,[15],[320,463,464,465,466,129,467],"Gemcitabine","Paclitaxel","Rucaparib","Abiraterone","Azacitidine",{"nctId":469,"briefTitle":470,"status":102,"phases":471,"primaryCompletion":472,"completion":473,"start":474,"enrollment":145,"conditions":475,"interventions":477},"NCT02953678","A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)",[87],"2018-01-31","2019-08-14","2016-12-30",[476],"Graft-versus-host Disease (GVHD)",[129,478],"Prednisone or methylprednisolone",{"nctId":480,"briefTitle":481,"status":102,"phases":482,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":488},"NCT02723994","A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia",[87],"2026-03-03","2016-09-30",171,[487],"Leukemia",[129,489,490,491,492,493,494,495,496,497,498,499,500],"Asparaginase Erwinia Chrysanthemi","Cyclophosphamide","Cytarabine","Dexamethasone","Doxorubicin","Leucovorin Calcium","Mercaptopurine","Methotrexate","Pegaspargase","Prednisone","Thioguanine","Vincristine Sulfate",{"nctId":502,"briefTitle":503,"status":102,"phases":504,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":509},"NCT01340651","Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients",[87],"2012-07","2011-03",41,[303],[129],{"nctId":511,"briefTitle":512,"status":283,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":519},"NCT00638378","Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer",[87],"2009-01","2008-02",22,[518],"Prostate Cancer",[129],{"nctId":521,"briefTitle":522,"status":216,"phases":523,"primaryCompletion":524,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":530},"NCT06388564","A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease",[87],"2027-06-01","2029-12-01","2024-10-11",130,[529],"Chronic Graft-versus-host-disease",[531,129,532],"Axatilimab","Corticosteroids",{"nctId":534,"briefTitle":535,"status":283,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":543},"NCT02119650","Ruxolitinib in Combination With Pemetrexed\u002FCisplatin in Non Small Cell Lung Cancer",[87],"2016-02-11","2016-06-21","2014-02-11",76,[542],"NSCLC (Non-small Cell Lung Carcinoma)",[129,544,545],"Pemetrexed","Cisplatin",{"nctId":547,"briefTitle":548,"status":216,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":555},"NCT02955940","An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib",[87],"2027-09-30","2016-11-30",10,[290,554,443,24],"Colorectal Cancer (CRC)",[129,365,434],{"nctId":557,"briefTitle":558,"status":283,"phases":559,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":566},"NCT00726232","Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia",[87],"2010-06-20","2018-08-20","2008-08-20",73,[565],"Myeloproliferative Neoplasm (MPN)",[129],{"nctId":568,"briefTitle":569,"status":283,"phases":570,"primaryCompletion":571,"completion":571,"start":572,"enrollment":573,"conditions":574,"interventions":575},"NCT02587598","Study of INCB053914 in Subjects With Advanced Malignancies",[86,87],"2020-08-11","2015-12-29",97,[15],[576,577,467,129],"INCB053914","I-DAC",{"nctId":579,"briefTitle":580,"status":283,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":586},"NCT03123588","Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)",[87],"2020-08-03","2017-11-14",12,[30],[129,587],"Anagrelide",3,{"trials":590,"activeCount":194,"soonestReadout":635},[591,600,612,631,641,654,664,673,683,694,704,711,721],{"nctId":592,"briefTitle":593,"status":283,"phases":594,"primaryCompletion":427,"completion":595,"start":596,"enrollment":597,"conditions":598,"interventions":599},"NCT02119663","A Study of Ruxolitinib in Pancreatic Cancer Patients",[88],"2016-10","2014-06",86,[290],[129,365],{"nctId":601,"briefTitle":602,"status":102,"phases":603,"primaryCompletion":429,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":608},"NCT01632904","Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study",[88],"2016-05","2012-06",110,[409],[129,609,610,611],"Hydroxyurea","HU-placebo","Ruxolitinib-placebo",{"nctId":613,"briefTitle":614,"status":102,"phases":615,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":621},"NCT03112603","A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)",[88],"2020-05-08","2022-12-15","2017-06-29",330,[476],[129,622,623,624,625,626,627,628,629,630],"Extracorporeal photopheresis","Low-dose methotrexate","Mycophenolate mofetil","mechanistic Target of Rapamycin","Infliximab","Rituximab","Pentostatin","Imatinib","Ibrutinib",{"nctId":632,"briefTitle":633,"status":122,"phases":634,"primaryCompletion":635,"completion":636,"start":637,"enrollment":178,"conditions":638,"interventions":639},"NCT06832618","A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to \u003C18 Years Old) With Moderate Atopic Dermatitis",[88],"2026-07-13","2028-05-18","2025-06-17",[21],[129,640],"Vehicle Cream",{"nctId":642,"briefTitle":643,"status":283,"phases":644,"primaryCompletion":645,"completion":646,"start":647,"enrollment":648,"conditions":649,"interventions":652},"NCT04551053","To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)",[88],"2023-08-16","2024-08-21","2021-05-26",177,[303,385,650,651],"Post Essential Thrombocythemia Myelofibrosis","Post Polycythemia Vera Myelofibrosis",[653,292],"parsaclisib",{"nctId":655,"briefTitle":656,"status":102,"phases":657,"primaryCompletion":658,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":663},"NCT00952289","COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial",[88],"2010-11","2015-10","2009-08",309,[30],[129],{"nctId":665,"briefTitle":666,"status":102,"phases":667,"primaryCompletion":668,"completion":669,"start":670,"enrollment":619,"conditions":671,"interventions":672},"NCT04921969","A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)",[88],"2023-05-10","2024-04-08","2021-07-19",[21],[129,640],{"nctId":674,"briefTitle":675,"status":122,"phases":676,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":681},"NCT06615050","A Study of Tacrolimus\u002FMethotrexate\u002FRuxolitinib Versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)",[88],"2031-01-17","2025-04-02",572,[476],[682,496,129,490,624],"Tacrolimus",{"nctId":684,"briefTitle":685,"status":102,"phases":686,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":692},"NCT04530344","Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo",[88],"2022-11-14","2020-09-24",458,[691],"Vitiligo",[292,693],"Vehicle",{"nctId":695,"briefTitle":696,"status":283,"phases":697,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":703},"NCT04377620","Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)",[88],"2021-02-26","2020-05-24",211,[702],"COVID-19",[129],{"nctId":705,"briefTitle":706,"status":283,"phases":707,"primaryCompletion":427,"completion":428,"start":429,"enrollment":708,"conditions":709,"interventions":710},"NCT02117479","Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)",[88],321,[290],[129,365],{"nctId":712,"briefTitle":713,"status":102,"phases":714,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":720},"NCT01243944","Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)",[88],"2014-01-15","2018-02-09","2010-10-27",222,[409],[292],{"nctId":722,"briefTitle":723,"status":283,"phases":724,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":730},"NCT04551066","To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)",[88],"2023-08-03","2024-11-25","2021-05-24",252,[303,385,650,651],[653,292],{"trials":732,"activeCount":96},[],{"trials":734,"activeCount":96},[735,742,748],{"nctId":736,"briefTitle":737,"status":738,"phases":739,"conditions":740,"interventions":741},"NCT03147742","An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant","APPROVED_FOR_MARKETING",[],[476],[129],{"nctId":743,"briefTitle":744,"status":738,"phases":745,"conditions":746,"interventions":747},"NCT05722912","Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD",[],[476],[129],{"nctId":749,"briefTitle":750,"status":751,"phases":752,"conditions":753,"interventions":754},"NCT04355793","Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection","NO_LONGER_AVAILABLE",[],[702],[129],{"intervention":756,"totalTrials":757,"cells":758},"Ruxolitinib cream",29,{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":789,"PHASE3":879,"PHASE4":1014,"NA":1025},{"trials":760,"activeCount":96},[],{"trials":762,"activeCount":152,"soonestReadout":775},[763,771,781],{"nctId":764,"briefTitle":765,"status":102,"phases":766,"primaryCompletion":767,"completion":767,"start":768,"enrollment":507,"conditions":769,"interventions":770},"NCT03920852","A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis",[86],"2019-12-26","2019-05-30",[21],[756],{"nctId":772,"briefTitle":773,"status":122,"phases":774,"primaryCompletion":775,"completion":775,"start":776,"enrollment":16,"conditions":777,"interventions":779},"NCT07049575","Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa",[86],"2026-12-09","2025-11-03",[778],"Hidradenitis Suppurativa",[780],"Ruxolitinib Cream",{"nctId":782,"briefTitle":783,"status":102,"phases":784,"primaryCompletion":785,"completion":785,"start":786,"enrollment":757,"conditions":787,"interventions":788},"NCT05034822","Study of Ruxolitinib Cream in Children With Atopic Dermatitis",[86],"2023-08-07","2021-12-16",[21],[756],{"trials":790,"activeCount":96},[791,803,813,822,831,841,850,859,868],{"nctId":792,"briefTitle":793,"status":102,"phases":794,"primaryCompletion":795,"completion":796,"start":797,"enrollment":798,"conditions":799,"interventions":801},"NCT05593445","A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus",[87],"2023-09-01","2023-12-21","2022-11-18",61,[800],"Lichen Sclerosus",[756,802],"Vehicle cream",{"nctId":804,"briefTitle":805,"status":102,"phases":806,"primaryCompletion":807,"completion":808,"start":161,"enrollment":809,"conditions":810,"interventions":812},"NCT05906628","Topical Ruxolitinib Evaluation in Chronic Hand Eczema",[87],"2024-07-15","2024-12-13",186,[811],"Hand Eczema",[756,693],{"nctId":814,"briefTitle":815,"status":102,"phases":816,"primaryCompletion":817,"completion":818,"start":819,"enrollment":11,"conditions":820,"interventions":821},"NCT05635838","Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa",[87],"2023-10-19","2024-03-14","2022-12-07",[778],[756,802],{"nctId":823,"briefTitle":824,"status":102,"phases":825,"primaryCompletion":797,"completion":797,"start":826,"enrollment":827,"conditions":828,"interventions":829},"NCT04839380","The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis",[87],"2021-10-12",49,[21],[830],"ruxolitinib cream",{"nctId":832,"briefTitle":833,"status":102,"phases":834,"primaryCompletion":835,"completion":836,"start":837,"enrollment":838,"conditions":839,"interventions":840},"NCT03099304","A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo",[87],"2018-09-12","2021-09-08","2017-06-07",157,[691],[756,802],{"nctId":842,"briefTitle":843,"status":102,"phases":844,"primaryCompletion":845,"completion":845,"start":846,"enrollment":827,"conditions":847,"interventions":849},"NCT05750823","A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo",[87],"2025-03-06","2023-04-11",[848],"Nonsegmental Vitiligo With Genital Involvement",[780],{"nctId":851,"briefTitle":852,"status":102,"phases":853,"primaryCompletion":854,"completion":855,"start":856,"enrollment":9,"conditions":857,"interventions":858},"NCT04896385","A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)",[87],"2022-11-17","2023-07-10","2021-06-23",[691],[756,640],{"nctId":860,"briefTitle":861,"status":102,"phases":862,"primaryCompletion":725,"completion":863,"start":864,"enrollment":865,"conditions":866,"interventions":867},"NCT05127421","Ruxolitinib Cream in Participants With Facial and\u002For Neck Atopic Dermatitis Involvement",[87],"2023-09-29","2021-11-10",77,[21],[756,693],{"nctId":869,"briefTitle":870,"status":102,"phases":871,"primaryCompletion":872,"completion":873,"start":874,"enrollment":875,"conditions":876,"interventions":878},"NCT05593432","A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus",[87],"2023-10-02","2024-02-26","2022-11-23",64,[877],"Cutaneous Lichen Planus",[756,802],{"trials":880,"activeCount":12,"soonestReadout":975},[881,892,902,911,921,931,941,951,961,971,981,991,998,1005],{"nctId":882,"briefTitle":883,"status":102,"phases":884,"primaryCompletion":885,"completion":886,"start":887,"enrollment":888,"conditions":889,"interventions":891},"NCT05755438","A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)",[88],"2024-10-07","2025-08-13","2023-03-10",204,[890],"Prurigo",[780,640],{"nctId":893,"briefTitle":894,"status":102,"phases":895,"primaryCompletion":896,"completion":897,"start":898,"enrollment":619,"conditions":899,"interventions":901},"NCT04052425","Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)",[88],"2021-03-18","2021-10-21","2019-09-20",[900],"Non-segmental Vitiligo",[756,693],{"nctId":903,"briefTitle":904,"status":122,"phases":905,"primaryCompletion":309,"completion":906,"start":907,"enrollment":908,"conditions":909,"interventions":910},"NCT06804811","A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to \u003C 12 Years Old) With Nonsegmental Vitiligo",[88],"2027-12-01","2025-11-13",250,[222],[780,640],{"nctId":912,"briefTitle":913,"status":102,"phases":914,"primaryCompletion":915,"completion":916,"start":917,"enrollment":918,"conditions":919,"interventions":920},"NCT04057573","Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)",[88],"2021-03-15","2021-10-01","2019-10-03",344,[900],[756,693],{"nctId":922,"briefTitle":923,"status":102,"phases":924,"primaryCompletion":925,"completion":925,"start":926,"enrollment":927,"conditions":928,"interventions":930},"NCT05456529","Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis",[88],"2024-05-17","2022-09-01",103,[929],"Atopic Dermatitis (AD)",[780],{"nctId":932,"briefTitle":933,"status":934,"phases":935,"primaryCompletion":936,"completion":937,"start":938,"enrollment":96,"conditions":939,"interventions":940},"NCT05219864","Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1","WITHDRAWN",[88],"2024-04-25","2024-09-22","2023-01-31",[811],[756,693],{"nctId":942,"briefTitle":943,"status":122,"phases":944,"primaryCompletion":945,"completion":946,"start":947,"enrollment":948,"conditions":949,"interventions":950},"NCT06959225","Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)",[88],"2026-10-09","2027-07-11","2025-06-23",550,[778],[780,640],{"nctId":952,"briefTitle":953,"status":102,"phases":954,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":959,"interventions":960},"NCT03745638","Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis",[88],"2019-12-23","2020-12-01","2018-12-20",631,[21],[780,640],{"nctId":962,"briefTitle":963,"status":102,"phases":964,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":970},"NCT06238817","A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis",[88],"2025-05-21","2025-10-17","2024-04-26",241,[21],[780,640],{"nctId":972,"briefTitle":973,"status":122,"phases":974,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":980},"NCT06548360","A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo",[88],"2026-08-10","2027-03-13","2025-01-24",180,[222],[780,640],{"nctId":982,"briefTitle":983,"status":102,"phases":984,"primaryCompletion":985,"completion":986,"start":987,"enrollment":988,"conditions":989,"interventions":990},"NCT05764161","A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)",[88],"2024-12-30","2025-11-04","2023-06-12",190,[250],[780,640],{"nctId":992,"briefTitle":993,"status":934,"phases":994,"primaryCompletion":936,"completion":937,"start":938,"enrollment":96,"conditions":995,"interventions":997},"NCT05233410","Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2",[88],[996],"Chronic Hand Eczema (CHE)",[756,693],{"nctId":999,"briefTitle":1000,"status":122,"phases":1001,"primaryCompletion":945,"completion":946,"start":1002,"enrollment":948,"conditions":1003,"interventions":1004},"NCT06958211","Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)",[88],"2025-06-12",[778],[780,640],{"nctId":1006,"briefTitle":1007,"status":102,"phases":1008,"primaryCompletion":1009,"completion":1010,"start":957,"enrollment":1011,"conditions":1012,"interventions":1013},"NCT03745651","TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis",[88],"2019-11-18","2020-11-09",618,[21],[756,802],{"trials":1015,"activeCount":96},[1016],{"nctId":1017,"briefTitle":1018,"status":283,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1023,"interventions":1024},"NCT05696392","The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.",[89],"2025-01-22","2023-03-16",47,[21],[830],{"trials":1026,"activeCount":194,"soonestReadout":1031},[1027,1039],{"nctId":1028,"briefTitle":1029,"status":122,"phases":1030,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1037},"NCT06627335","An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis",[],"2027-08-15","2028-08-15","2023-03-27",5621,[1036,21],"Pregnancy Related",[780,1038],"TCS",{"nctId":1040,"briefTitle":1041,"status":122,"phases":1042,"primaryCompletion":1043,"completion":1044,"start":1045,"enrollment":1046,"conditions":1047,"interventions":1048},"NCT06259669","Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population",[],"2032-08-01","2033-08-01","2023-09-13",958,[1036,21],[780],{"intervention":640,"totalTrials":19,"cells":1050},{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1077,"PHASE4":1124,"NA":1126},{"trials":1052,"activeCount":96},[],{"trials":1054,"activeCount":96},[],{"trials":1056,"activeCount":96},[1057,1061,1065,1069,1073],{"nctId":792,"briefTitle":793,"status":102,"phases":1058,"primaryCompletion":795,"completion":796,"start":797,"enrollment":798,"conditions":1059,"interventions":1060},[87],[800],[756,802],{"nctId":814,"briefTitle":815,"status":102,"phases":1062,"primaryCompletion":817,"completion":818,"start":819,"enrollment":11,"conditions":1063,"interventions":1064},[87],[778],[756,802],{"nctId":832,"briefTitle":833,"status":102,"phases":1066,"primaryCompletion":835,"completion":836,"start":837,"enrollment":838,"conditions":1067,"interventions":1068},[87],[691],[756,802],{"nctId":851,"briefTitle":852,"status":102,"phases":1070,"primaryCompletion":854,"completion":855,"start":856,"enrollment":9,"conditions":1071,"interventions":1072},[87],[691],[756,640],{"nctId":869,"briefTitle":870,"status":102,"phases":1074,"primaryCompletion":872,"completion":873,"start":874,"enrollment":875,"conditions":1075,"interventions":1076},[87],[877],[756,802],{"trials":1078,"activeCount":1123,"soonestReadout":635},[1079,1083,1087,1091,1095,1099,1103,1107,1111,1115,1119],{"nctId":882,"briefTitle":883,"status":102,"phases":1080,"primaryCompletion":885,"completion":886,"start":887,"enrollment":888,"conditions":1081,"interventions":1082},[88],[890],[780,640],{"nctId":903,"briefTitle":904,"status":122,"phases":1084,"primaryCompletion":309,"completion":906,"start":907,"enrollment":908,"conditions":1085,"interventions":1086},[88],[222],[780,640],{"nctId":632,"briefTitle":633,"status":122,"phases":1088,"primaryCompletion":635,"completion":636,"start":637,"enrollment":178,"conditions":1089,"interventions":1090},[88],[21],[129,640],{"nctId":665,"briefTitle":666,"status":102,"phases":1092,"primaryCompletion":668,"completion":669,"start":670,"enrollment":619,"conditions":1093,"interventions":1094},[88],[21],[129,640],{"nctId":942,"briefTitle":943,"status":122,"phases":1096,"primaryCompletion":945,"completion":946,"start":947,"enrollment":948,"conditions":1097,"interventions":1098},[88],[778],[780,640],{"nctId":952,"briefTitle":953,"status":102,"phases":1100,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1101,"interventions":1102},[88],[21],[780,640],{"nctId":962,"briefTitle":963,"status":102,"phases":1104,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":1105,"interventions":1106},[88],[21],[780,640],{"nctId":972,"briefTitle":973,"status":122,"phases":1108,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":1109,"interventions":1110},[88],[222],[780,640],{"nctId":982,"briefTitle":983,"status":102,"phases":1112,"primaryCompletion":985,"completion":986,"start":987,"enrollment":988,"conditions":1113,"interventions":1114},[88],[250],[780,640],{"nctId":999,"briefTitle":1000,"status":122,"phases":1116,"primaryCompletion":945,"completion":946,"start":1002,"enrollment":948,"conditions":1117,"interventions":1118},[88],[778],[780,640],{"nctId":1006,"briefTitle":1007,"status":102,"phases":1120,"primaryCompletion":1009,"completion":1010,"start":957,"enrollment":1011,"conditions":1121,"interventions":1122},[88],[21],[756,802],5,{"trials":1125,"activeCount":96},[],{"trials":1127,"activeCount":96},[],{"intervention":83,"totalTrials":268,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1168,"PHASE3":1180,"PHASE4":1193,"NA":1195},{"trials":1131,"activeCount":96},[],{"trials":1133,"activeCount":588,"soonestReadout":82},[1134,1144,1152,1161],{"nctId":1135,"briefTitle":1136,"status":1137,"phases":1138,"primaryCompletion":1139,"completion":1139,"start":1140,"enrollment":19,"conditions":1141,"interventions":1143},"NCT07559396","A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease","NOT_YET_RECRUITING",[86],"2027-01-04","2026-05-15",[1142],"Renal Impairment",[83],{"nctId":80,"briefTitle":81,"status":122,"phases":1145,"primaryCompletion":82,"completion":82,"start":1146,"enrollment":1147,"conditions":1148,"interventions":1149},[86],"2025-05-05",51,[18],[83,1150,1151],"itraconazole","carbamazepine",{"nctId":1153,"briefTitle":1154,"status":1137,"phases":1155,"primaryCompletion":1156,"completion":1156,"start":1140,"enrollment":19,"conditions":1157,"interventions":1160},"NCT07559474","A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment",[86],"2027-04-13",[1158,1159],"Hepatic Insufficiency","Liver Diseases",[83],{"nctId":1162,"briefTitle":1163,"status":102,"phases":1164,"primaryCompletion":1165,"completion":1165,"start":907,"enrollment":28,"conditions":1166,"interventions":1167},"NCT07218744","Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants",[86],"2025-12-10",[18],[83],{"trials":1169,"activeCount":152,"soonestReadout":1174},[1170],{"nctId":1171,"briefTitle":1172,"status":122,"phases":1173,"primaryCompletion":1174,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1179},"NCT07023627","A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression",[87],"2027-04-27","2027-10-24","2025-11-12",160,[34],[83],{"trials":1181,"activeCount":152,"soonestReadout":1186},[1182],{"nctId":1183,"briefTitle":1184,"status":122,"phases":1185,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":1190,"interventions":1191},"NCT07214779","Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression",[88],"2028-11-15","2029-05-14","2025-12-09",466,[34],[83,1192],"Investigator's choice of chemotherapy",{"trials":1194,"activeCount":96},[],{"trials":1196,"activeCount":96},[],{"intervention":50,"totalTrials":1198,"cells":1199},8,{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1235,"PHASE4":1281,"NA":1283},{"trials":1201,"activeCount":96},[],{"trials":1203,"activeCount":96},[],{"trials":1205,"activeCount":194,"soonestReadout":49},[1206,1217,1226],{"nctId":1207,"briefTitle":1208,"status":283,"phases":1209,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":1212,"conditions":1213,"interventions":1216},"NCT04809467","A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed\u002FRefractory Non Hodgkin Lymphoma (R\u002FR NHL) or Chronic Lymphocytic Leukemia (CLL)",[86,87],"2024-10-22","2021-09-16",54,[1214,1215],"Chronic Lymphocytic Leukemia","Non Hodgkin Lymphoma",[45,653],{"nctId":1218,"briefTitle":1219,"status":122,"phases":1220,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":373,"conditions":1223,"interventions":1225},"NCT06465433","Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab",[87],"2027-08-29","2022-11-08",[1224],"Hematologic Malignancies",[50],{"nctId":47,"briefTitle":48,"status":216,"phases":1227,"primaryCompletion":49,"completion":1228,"start":1229,"enrollment":1230,"conditions":1231,"interventions":1233},[86,87],"2027-11-30","2022-07-19",53,[1232],"Diffuse Large B Cell Lymphoma",[50,1234],"Lenalidomide",{"trials":1236,"activeCount":588,"soonestReadout":44},[1237,1246,1260,1270],{"nctId":66,"briefTitle":67,"status":216,"phases":1238,"primaryCompletion":68,"completion":1239,"start":1240,"enrollment":1241,"conditions":1242,"interventions":1245},[88],"2027-04-01","2022-12-23",82,[1243,1244],"Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma",[50,1234],{"nctId":1247,"briefTitle":1248,"status":216,"phases":1249,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":1253,"conditions":1254,"interventions":1256},"NCT04824092","Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients",[88],"2026-09-01","2027-11-01","2021-05-11",899,[1255],"Diffuse Large B-cell Lymphoma",[50,1234,627,490,493,1257,498,1258,1259],"Vincristine","Tafasitamab placebo","Lenalidomide placebo",{"nctId":1261,"briefTitle":1262,"status":102,"phases":1263,"primaryCompletion":1264,"completion":1264,"start":1265,"enrollment":1266,"conditions":1267,"interventions":1268},"NCT02763319","A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",[87,88],"2024-06-21","2016-11-28",453,[1255],[627,50,1269],"Bendamustine",{"nctId":42,"briefTitle":43,"status":216,"phases":1271,"primaryCompletion":44,"completion":1272,"start":1273,"enrollment":1274,"conditions":1275,"interventions":1278},[88],"2028-08-09","2021-04-15",654,[1276,1277],"Follicular Lymphoma","Marginal Zone Lymphoma",[45,1279,1280],"rituximab","lenalidomide",{"trials":1282,"activeCount":96},[],{"trials":1284,"activeCount":96},[1285],{"nctId":1286,"briefTitle":1287,"status":102,"phases":1288,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1293},"NCT04981795","realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL",[],"2026-01-23","2021-09-20",102,[1255],[50],{"intervention":1234,"totalTrials":1123,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1325,"PHASE4":1339,"NA":1341},{"trials":1297,"activeCount":96},[],{"trials":1299,"activeCount":96},[],{"trials":1301,"activeCount":152,"soonestReadout":49},[1302,1321],{"nctId":1303,"briefTitle":1304,"status":283,"phases":1305,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":1309,"interventions":1312},"NCT02265510","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",[86,87],"2019-02-27","2014-09-10",83,[15,1310,1311],"Advanced Malignancies","Metastatic Cancer",[1313,293,294,1314,1315,1316,1280,1317,1313,1318,1319,1320],"INCB052793","dexamethasone","Carfilzomib","bortezomib","azacitidine","pomalidomide","INCB050465","INCB039110",{"nctId":47,"briefTitle":48,"status":216,"phases":1322,"primaryCompletion":49,"completion":1228,"start":1229,"enrollment":1230,"conditions":1323,"interventions":1324},[86,87],[1232],[50,1234],{"trials":1326,"activeCount":588,"soonestReadout":44},[1327,1331,1335],{"nctId":66,"briefTitle":67,"status":216,"phases":1328,"primaryCompletion":68,"completion":1239,"start":1240,"enrollment":1241,"conditions":1329,"interventions":1330},[88],[1243,1244],[50,1234],{"nctId":1247,"briefTitle":1248,"status":216,"phases":1332,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":1253,"conditions":1333,"interventions":1334},[88],[1255],[50,1234,627,490,493,1257,498,1258,1259],{"nctId":42,"briefTitle":43,"status":216,"phases":1336,"primaryCompletion":44,"completion":1272,"start":1273,"enrollment":1274,"conditions":1337,"interventions":1338},[88],[1276,1277],[45,1279,1280],{"trials":1340,"activeCount":96},[],{"trials":1342,"activeCount":96},[],{"intervention":1344,"totalTrials":12,"cells":1345},"INCA034176",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1372,"PHASE4":1393,"NA":1395},{"trials":1347,"activeCount":96},[],{"trials":1349,"activeCount":96},[],{"trials":1351,"activeCount":194,"soonestReadout":1356},[1352,1362],{"nctId":1353,"briefTitle":1354,"status":122,"phases":1355,"primaryCompletion":1356,"completion":1357,"start":1358,"enrollment":1359,"conditions":1360,"interventions":1361},"NCT06843408","A Ph1b\u002F2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD",[86,87],"2026-07-03","2027-12-31","2025-06-25",30,[529],[1344],{"nctId":1363,"briefTitle":1364,"status":122,"phases":1365,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":9,"conditions":1369,"interventions":1370},"NCT07124078","A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)",[87],"2029-01-31","2029-07-31","2026-05-20",[529],[1344,1371],"Best available Treatment",{"trials":1373,"activeCount":194,"soonestReadout":1388},[1374,1384],{"nctId":1375,"briefTitle":1376,"status":216,"phases":1377,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":28,"conditions":1381,"interventions":1382},"NCT06821542","A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy",[88],"2028-05-31","2032-11-30","2025-06-04",[529],[1344,1383],"Best Available Therapy",{"nctId":1385,"briefTitle":1386,"status":122,"phases":1387,"primaryCompletion":1388,"completion":1389,"start":1390,"enrollment":178,"conditions":1391,"interventions":1392},"NCT06585774","A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease",[88],"2027-09-28","2030-03-31","2025-01-21",[529],[1344,532],{"trials":1394,"activeCount":96},[],{"trials":1396,"activeCount":96},[],{"intervention":40,"totalTrials":1398,"cells":1399},17,{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1467,"PHASE3":1560,"PHASE4":1596,"NA":1598},{"trials":1401,"activeCount":96},[],{"trials":1403,"activeCount":152,"soonestReadout":1408},[1404,1420,1431,1441,1455],{"nctId":1405,"briefTitle":1406,"status":122,"phases":1407,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":1411,"interventions":1412},"NCT06179160","A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",[86],"2027-01-01","2024-01-04",710,[15],[1413,1414,40,1415,1416,1417,1418,1419],"INCB161734","Cetuximab","GEMNabP","mFOLFIRINOX","FOLFOX","FOLFIRI","INCA33890",{"nctId":1421,"briefTitle":1422,"status":102,"phases":1423,"primaryCompletion":1424,"completion":1424,"start":1425,"enrollment":1426,"conditions":1427,"interventions":1430},"NCT03059823","A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors",[86],"2024-05-22","2016-11-15",325,[1428,1429],"Locally Advanced Solid Tumors","Metastatic Solid Tumors",[73],{"nctId":1432,"briefTitle":1433,"status":102,"phases":1434,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":1308,"conditions":1437,"interventions":1439},"NCT03589651","INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors",[86],"2022-11-21","2018-08-17",[1438],"Unresectable or Metastatic Solid Tumors",[40,1440,1319],"Epacadostat",{"nctId":1442,"briefTitle":1443,"status":283,"phases":1444,"primaryCompletion":1445,"completion":1445,"start":1446,"enrollment":1447,"conditions":1448,"interventions":1452},"NCT04989387","Study of INCA 0186 in Subjects With Advanced Solid Tumors",[86],"2024-09-19","2021-10-04",57,[1449,1450,1451],"Advanced Solid Tumors","Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Gastrointestinal (GI) Malignancies",[1453,40,1454],"INCA00186","INCB106385",{"nctId":1456,"briefTitle":1457,"status":934,"phases":1458,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":96,"conditions":1461,"interventions":1465},"NCT03920839","INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)",[86],"2019-11-04","2019-07-15",[1462,1463,1464],"Advanced and\u002For Metastatic Solid Tumors","Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer","Advanced\u002FMetastatic Unresectable Malignant Pleural Mesothelioma",[40,463,545,544,1466,464],"Carboplatin",{"trials":1468,"activeCount":194,"soonestReadout":72},[1469,1479,1484,1496,1505,1516,1526,1542],{"nctId":1470,"briefTitle":1471,"status":102,"phases":1472,"primaryCompletion":1473,"completion":864,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1478},"NCT03597295","A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)",[87],"2020-06-08","2018-10-08",94,[1477],"Squamous Cell Carcinoma of Anal Canal",[40],{"nctId":75,"briefTitle":76,"status":216,"phases":1480,"primaryCompletion":77,"completion":77,"start":1481,"enrollment":28,"conditions":1482,"interventions":1483},[86,87],"2025-06-30",[15,1449,1429],[78,40],{"nctId":1485,"briefTitle":1486,"status":283,"phases":1487,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1359,"conditions":1490,"interventions":1492},"NCT04586244","An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma",[87],"2024-01-29","2022-01-14",[1491],"Urothelial Carcinoma",[73,1493,1494,1495],"epacadostat","INCAGN02385","INCAGN02390",{"nctId":70,"briefTitle":71,"status":216,"phases":1497,"primaryCompletion":72,"completion":1498,"start":1499,"enrollment":1500,"conditions":1501,"interventions":1503},[87],"2026-07-10","2021-01-26",206,[1502],"Endometrial Cancer",[73,1493,1504,1494,1495],"pemigatinib",{"nctId":1506,"briefTitle":1507,"status":102,"phases":1508,"primaryCompletion":1509,"completion":1510,"start":1511,"enrollment":1512,"conditions":1513,"interventions":1515},"NCT03599713","A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)",[87],"2022-01-21","2024-06-28","2019-02-25",107,[1514],"Metastatic Merkel Cell Carcinoma",[40],{"nctId":1517,"briefTitle":1518,"status":283,"phases":1519,"primaryCompletion":1520,"completion":1520,"start":1521,"enrollment":552,"conditions":1522,"interventions":1523},"NCT04949191","The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.",[87],"2024-04-11","2021-07-08",[1310],[1524,40,1525],"Pemigatinib","Pembrolizumab",{"nctId":1527,"briefTitle":1528,"status":102,"phases":1529,"primaryCompletion":1273,"completion":1530,"start":1531,"enrollment":1532,"conditions":1533,"interventions":1541},"NCT03679767","A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)",[87],"2022-06-28","2019-01-09",121,[1534,1535,1536,1537,1538,1539,1540],"Metastatic Non-small Cell Lung Cancer","Locally Advanced Urothelial Cancer","Metastatic Urothelial Cancer","Unresectable Melanoma","Metastatic Melanoma","Locally Advanced Renal Cell Carcinoma","Metastatic Clear-Cell Renal Cell Carcinoma",[40],{"nctId":1543,"briefTitle":1544,"status":283,"phases":1545,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":1549,"interventions":1557},"NCT02393248","Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)",[86,87],"2021-12-17","2015-02-27",201,[24,1550,1551,1552,1502,1553,329,443,1554,1555,1556],"Solid Tumor","Gastric Cancer","Urothelial Cancer","Multiple Myeloma","Cholangiocarcinoma","UC","MPN",[1524,463,1525,1558,1559,40,545],"Docetaxel","Trastuzumab",{"trials":1561,"activeCount":152,"soonestReadout":39},[1562,1575,1585],{"nctId":1563,"briefTitle":1564,"status":102,"phases":1565,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":1569,"conditions":1570,"interventions":1572},"NCT04472429","Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303\u002FInterAACT 2).",[88],"2024-04-15","2025-09-26","2021-01-12",308,[1571],"Squamous Cell Carcinoma of the Anal Canal",[1573,1574,73],"carboplatin","paclitaxel",{"nctId":37,"briefTitle":38,"status":216,"phases":1576,"primaryCompletion":39,"completion":1577,"start":1578,"enrollment":1579,"conditions":1580,"interventions":1583},[88],"2026-08-28","2020-09-11",583,[1581,1582],"Metastatic Squamous Non-Small Cell Lung Cancer","Metastatic Nonsquamous Non-Small Cell Lung Cancer",[40,544,545,1466,464,1584],"nab-Paclitaxel",{"nctId":1586,"briefTitle":1587,"status":934,"phases":1588,"primaryCompletion":1589,"completion":1590,"start":1591,"enrollment":96,"conditions":1592,"interventions":1594},"NCT04203511","INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)",[88],"2023-11-30","2025-01-31","2020-07-31",[1593],"Non-small Cell Lung Cancer",[40,544,545,1466,464,1595],"Etoposide",{"trials":1597,"activeCount":96},[],{"trials":1599,"activeCount":96},[1600],{"nctId":1601,"briefTitle":1602,"status":1603,"phases":1604,"conditions":1605,"interventions":1606},"NCT06910137","An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)","AVAILABLE",[],[1571],[73],{"intervention":1419,"totalTrials":588,"cells":1608},{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1627,"PHASE3":1629,"PHASE4":1642,"NA":1644},{"trials":1610,"activeCount":96},[],{"trials":1612,"activeCount":194,"soonestReadout":1408},[1613,1617],{"nctId":1405,"briefTitle":1406,"status":122,"phases":1614,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":1615,"interventions":1616},[86],[15],[1413,1414,40,1415,1416,1417,1418,1419],{"nctId":1618,"briefTitle":1619,"status":122,"phases":1620,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1624,"interventions":1625},"NCT05836324","A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors",[86],"2027-01-13","2023-07-24",408,[15,1449,1429],[1419,1626,1418,1417,1414],"bevacizumab",{"trials":1628,"activeCount":96},[],{"trials":1630,"activeCount":152,"soonestReadout":1635},[1631],{"nctId":1632,"briefTitle":1633,"status":122,"phases":1634,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1638,"conditions":1639,"interventions":1640},"NCT07284849","A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer",[88],"2028-12-29","2029-09-28","2026-03-05",700,[432],[1419,1641,1417],"Bevacizumab",{"trials":1643,"activeCount":96},[],{"trials":1645,"activeCount":96},[],{"intervention":1641,"totalTrials":588,"cells":1647},{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1671,"PHASE3":1673,"PHASE4":1679,"NA":1681},{"trials":1649,"activeCount":96},[],{"trials":1651,"activeCount":194,"soonestReadout":1621},[1652,1667],{"nctId":1653,"briefTitle":1654,"status":122,"phases":1655,"primaryCompletion":1656,"completion":1657,"start":1658,"enrollment":1659,"conditions":1660,"interventions":1661},"NCT05238922","Study of INCB123667 in Subjects With Advanced Solid Tumors",[86],"2027-07-27","2027-08-31","2022-07-05",604,[15],[1662,1663,1641,1664,464,1665,1666],"INCB0123667","Palbociclib","Olaparib","Ribociclib","Fulvestrant",{"nctId":1618,"briefTitle":1619,"status":122,"phases":1668,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1669,"interventions":1670},[86],[15,1449,1429],[1419,1626,1418,1417,1414],{"trials":1672,"activeCount":96},[],{"trials":1674,"activeCount":152,"soonestReadout":1635},[1675],{"nctId":1632,"briefTitle":1633,"status":122,"phases":1676,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1638,"conditions":1677,"interventions":1678},[88],[432],[1419,1641,1417],{"trials":1680,"activeCount":96},[],{"trials":1682,"activeCount":96},[],{"intervention":1417,"totalTrials":588,"cells":1684},{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1697,"PHASE3":1699,"PHASE4":1705,"NA":1707},{"trials":1686,"activeCount":96},[],{"trials":1688,"activeCount":194,"soonestReadout":1408},[1689,1693],{"nctId":1405,"briefTitle":1406,"status":122,"phases":1690,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":1691,"interventions":1692},[86],[15],[1413,1414,40,1415,1416,1417,1418,1419],{"nctId":1618,"briefTitle":1619,"status":122,"phases":1694,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1695,"interventions":1696},[86],[15,1449,1429],[1419,1626,1418,1417,1414],{"trials":1698,"activeCount":96},[],{"trials":1700,"activeCount":152,"soonestReadout":1635},[1701],{"nctId":1632,"briefTitle":1633,"status":122,"phases":1702,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1638,"conditions":1703,"interventions":1704},[88],[432],[1419,1641,1417],{"trials":1706,"activeCount":96},[],{"trials":1708,"activeCount":96},[],{"intervention":464,"totalTrials":28,"cells":1710},{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1723,"PHASE3":1754,"PHASE4":1777,"NA":1779},{"trials":1712,"activeCount":96},[],{"trials":1714,"activeCount":152,"soonestReadout":1656},[1715,1719],{"nctId":1653,"briefTitle":1654,"status":122,"phases":1716,"primaryCompletion":1656,"completion":1657,"start":1658,"enrollment":1659,"conditions":1717,"interventions":1718},[86],[15],[1662,1663,1641,1664,464,1665,1666],{"nctId":1456,"briefTitle":1457,"status":934,"phases":1720,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":96,"conditions":1721,"interventions":1722},[86],[1462,1463,1464],[40,463,545,544,1466,464],{"trials":1724,"activeCount":96},[1725,1739,1743],{"nctId":1726,"briefTitle":1727,"status":102,"phases":1728,"primaryCompletion":1729,"completion":1729,"start":1730,"enrollment":441,"conditions":1731,"interventions":1734},"NCT03314935","A Phase 1\u002F2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors",[86,87],"2022-11-28","2017-11-21",[1732,554,1502,1733,34,15],"Biliary Tract Cancer (BTC)","Gastroesophageal Cancer (GC)",[1735,1736,1737,1738,463,545,464],"INCB001158","Oxaliplatin","Leucovorin","5-Fluorouracil",{"nctId":455,"briefTitle":456,"status":283,"phases":1740,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":1741,"interventions":1742},[86,87],[15],[320,463,464,465,466,129,467],{"nctId":1744,"briefTitle":1745,"status":102,"phases":1746,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":1751,"interventions":1752},"NCT03085914","A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207\u002FKEYNOTE-723)",[86,87],"2019-01-25","2020-07-13","2017-05-02",70,[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],"Investigator's choice of platinum agent",{"trials":1755,"activeCount":152,"soonestReadout":39},[1756,1760,1764,1768],{"nctId":1563,"briefTitle":1564,"status":102,"phases":1757,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":1569,"conditions":1758,"interventions":1759},[88],[1571],[1573,1574,73],{"nctId":37,"briefTitle":38,"status":216,"phases":1761,"primaryCompletion":39,"completion":1577,"start":1578,"enrollment":1579,"conditions":1762,"interventions":1763},[88],[1581,1582],[40,544,545,1466,464,1584],{"nctId":1586,"briefTitle":1587,"status":934,"phases":1765,"primaryCompletion":1589,"completion":1590,"start":1591,"enrollment":96,"conditions":1766,"interventions":1767},[88],[1593],[40,544,545,1466,464,1595],{"nctId":1769,"briefTitle":1770,"status":283,"phases":1771,"primaryCompletion":1772,"completion":1772,"start":1773,"enrollment":194,"conditions":1774,"interventions":1775},"NCT03348904","Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer",[88],"2018-05-22","2017-12-27",[24],[1776,1440,1466,545,463,464,544],"Nivolumab",{"trials":1778,"activeCount":96},[],{"trials":1780,"activeCount":96},[],{"intervention":627,"totalTrials":1198,"cells":1782},{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1797,"PHASE3":1810,"PHASE4":1851,"NA":1853},{"trials":1784,"activeCount":96},[],{"trials":1786,"activeCount":96},[1787],{"nctId":1788,"briefTitle":1789,"status":102,"phases":1790,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":1793,"conditions":1794,"interventions":1796},"NCT03424122","INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",[86],"2022-06-27","2018-07-02",50,[1795],"B-cell Lymphoma",[399,627,1269,630],{"trials":1798,"activeCount":96},[1799],{"nctId":1800,"briefTitle":1801,"status":102,"phases":1802,"primaryCompletion":1803,"completion":1803,"start":1804,"enrollment":1805,"conditions":1806,"interventions":1808},"NCT02018861","A Phase 1\u002F2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)",[86,87],"2021-04-12","2016-09-22",88,[1807],"B-Cell Malignancies",[399,422,627,1809,1466,1595],"Ifosfamide",{"trials":1811,"activeCount":194,"soonestReadout":44},[1812,1824,1828,1832,1836,1840],{"nctId":1813,"briefTitle":1814,"status":934,"phases":1815,"primaryCompletion":1816,"completion":1817,"start":1818,"enrollment":96,"conditions":1819,"interventions":1822},"NCT04796922","To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R\u002FR Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)",[88],"2028-12-20","2032-08-25","2022-12-30",[1820,1821],"Follicular Lymphoma ( FL)","Marginal Zone Lymphoma (MZL)",[653,1279,1823],"obinutuzumab",{"nctId":613,"briefTitle":614,"status":102,"phases":1825,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":1826,"interventions":1827},[88],[476],[129,622,623,624,625,626,627,628,629,630],{"nctId":1247,"briefTitle":1248,"status":216,"phases":1829,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":1253,"conditions":1830,"interventions":1831},[88],[1255],[50,1234,627,490,493,1257,498,1258,1259],{"nctId":1261,"briefTitle":1262,"status":102,"phases":1833,"primaryCompletion":1264,"completion":1264,"start":1265,"enrollment":1266,"conditions":1834,"interventions":1835},[87,88],[1255],[627,50,1269],{"nctId":42,"briefTitle":43,"status":216,"phases":1837,"primaryCompletion":44,"completion":1272,"start":1273,"enrollment":1274,"conditions":1838,"interventions":1839},[88],[1276,1277],[45,1279,1280],{"nctId":1841,"briefTitle":1842,"status":934,"phases":1843,"primaryCompletion":1844,"completion":1845,"start":1846,"enrollment":96,"conditions":1847,"interventions":1849},"NCT04849715","A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma",[88],"2030-08-15","2034-07-07","2022-03-11",[1848],"Mantle Cell Lymphoma",[653,1279,1850],"bendamustine",{"trials":1852,"activeCount":96},[],{"trials":1854,"activeCount":96},[],{"intervention":490,"totalTrials":12,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1871,"PHASE4":1881,"NA":1883},{"trials":1858,"activeCount":96},[],{"trials":1860,"activeCount":96},[],{"trials":1862,"activeCount":96},[1863,1867],{"nctId":480,"briefTitle":481,"status":102,"phases":1864,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":1865,"interventions":1866},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"nctId":1744,"briefTitle":1745,"status":102,"phases":1868,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":1869,"interventions":1870},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"trials":1872,"activeCount":194,"soonestReadout":1250},[1873,1877],{"nctId":1247,"briefTitle":1248,"status":216,"phases":1874,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":1253,"conditions":1875,"interventions":1876},[88],[1255],[50,1234,627,490,493,1257,498,1258,1259],{"nctId":674,"briefTitle":675,"status":122,"phases":1878,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":1879,"interventions":1880},[88],[476],[682,496,129,490,624],{"trials":1882,"activeCount":96},[],{"trials":1884,"activeCount":96},[],{"intervention":1413,"totalTrials":588,"cells":1886},{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1908,"PHASE3":1910,"PHASE4":1922,"NA":1924},{"trials":1888,"activeCount":96},[],{"trials":1890,"activeCount":152,"soonestReadout":1408},[1891,1895],{"nctId":1405,"briefTitle":1406,"status":122,"phases":1892,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":1893,"interventions":1894},[86],[15],[1413,1414,40,1415,1416,1417,1418,1419],{"nctId":1896,"briefTitle":1897,"status":102,"phases":1898,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":1901,"conditions":1902,"interventions":1903},"NCT07018635","A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants",[86],"2025-09-29","2025-07-16",63,[18],[1413,1904,1905,1906,1907],"Itraconazole","Rifampin","Esomeprazole","Famotidine",{"trials":1909,"activeCount":96},[],{"trials":1911,"activeCount":152,"soonestReadout":1916},[1912],{"nctId":1913,"briefTitle":1914,"status":122,"phases":1915,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":1920,"interventions":1921},"NCT07522073","A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma",[88],"2028-09-15","2029-03-19","2026-04-09",588,[15],[1413,1192],{"trials":1923,"activeCount":96},[],{"trials":1925,"activeCount":96},[],{"intervention":532,"totalTrials":588,"cells":1927},{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1932,"PHASE3":1946,"PHASE4":1952,"NA":1954},{"trials":1929,"activeCount":96},[],{"trials":1931,"activeCount":96},[],{"trials":1933,"activeCount":152,"soonestReadout":524},[1934,1938],{"nctId":521,"briefTitle":522,"status":216,"phases":1935,"primaryCompletion":524,"completion":525,"start":526,"enrollment":527,"conditions":1936,"interventions":1937},[87],[529],[531,129,532],{"nctId":1939,"briefTitle":1940,"status":283,"phases":1941,"primaryCompletion":1942,"completion":1942,"start":300,"enrollment":194,"conditions":1943,"interventions":1945},"NCT03721965","Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects",[86,87],"2020-02-17",[1944],"Acute Graft-versus-host Disease",[422,532],{"trials":1947,"activeCount":152,"soonestReadout":1388},[1948],{"nctId":1385,"briefTitle":1386,"status":122,"phases":1949,"primaryCompletion":1388,"completion":1389,"start":1390,"enrollment":178,"conditions":1950,"interventions":1951},[88],[529],[1344,532],{"trials":1953,"activeCount":96},[],{"trials":1955,"activeCount":96},[],{"intervention":1192,"totalTrials":194,"cells":1957},{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1962,"PHASE3":1964,"PHASE4":1974,"NA":1976},{"trials":1959,"activeCount":96},[],{"trials":1961,"activeCount":96},[],{"trials":1963,"activeCount":96},[],{"trials":1965,"activeCount":194,"soonestReadout":1916},[1966,1970],{"nctId":1913,"briefTitle":1914,"status":122,"phases":1967,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":1968,"interventions":1969},[88],[15],[1413,1192],{"nctId":1183,"briefTitle":1184,"status":122,"phases":1971,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":1972,"interventions":1973},[88],[34],[83,1192],{"trials":1975,"activeCount":96},[],{"trials":1977,"activeCount":96},[],{"intervention":545,"totalTrials":25,"cells":1979},{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1988,"PHASE3":2006,"PHASE4":2050,"NA":2052},{"trials":1981,"activeCount":96},[],{"trials":1983,"activeCount":96},[1984],{"nctId":1456,"briefTitle":1457,"status":934,"phases":1985,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":96,"conditions":1986,"interventions":1987},[86],[1462,1463,1464],[40,463,545,544,1466,464],{"trials":1989,"activeCount":96},[1990,1994,1998,2002],{"nctId":1726,"briefTitle":1727,"status":102,"phases":1991,"primaryCompletion":1729,"completion":1729,"start":1730,"enrollment":441,"conditions":1992,"interventions":1993},[86,87],[1732,554,1502,1733,34,15],[1735,1736,1737,1738,463,545,464],{"nctId":1744,"briefTitle":1745,"status":102,"phases":1995,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":1996,"interventions":1997},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"nctId":534,"briefTitle":535,"status":283,"phases":1999,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":2000,"interventions":2001},[87],[542],[129,544,545],{"nctId":1543,"briefTitle":1544,"status":283,"phases":2003,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":2004,"interventions":2005},[86,87],[24,1550,1551,1552,1502,1553,329,443,1554,1555,1556],[1524,463,1525,1558,1559,40,545],{"trials":2007,"activeCount":152,"soonestReadout":39},[2008,2019,2030,2034,2038,2046],{"nctId":2009,"briefTitle":2010,"status":102,"phases":2011,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":2015,"conditions":2016,"interventions":2018},"NCT03358472","Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669\u002FECHO-304)",[88],"2018-07-19","2025-10-30","2017-12-01",89,[2017],"Head and Neck Cancer",[1525,1440,1414,545,1466,1738],{"nctId":2020,"briefTitle":2021,"status":283,"phases":2022,"primaryCompletion":2023,"completion":2023,"start":2024,"enrollment":2025,"conditions":2026,"interventions":2029},"NCT03656536","A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma",[88],"2025-07-07","2019-06-03",167,[2027,2028],"Unresectable Cholangiocarcinoma","Metastatic Cholangiocarcinoma",[1524,463,545],{"nctId":37,"briefTitle":38,"status":216,"phases":2031,"primaryCompletion":39,"completion":1577,"start":1578,"enrollment":1579,"conditions":2032,"interventions":2033},[88],[1581,1582],[40,544,545,1466,464,1584],{"nctId":1586,"briefTitle":1587,"status":934,"phases":2035,"primaryCompletion":1589,"completion":1590,"start":1591,"enrollment":96,"conditions":2036,"interventions":2037},[88],[1593],[40,544,545,1466,464,1595],{"nctId":2039,"briefTitle":2040,"status":934,"phases":2041,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":96,"conditions":2044,"interventions":2045},"NCT03342352","Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA\u002FECHO-310)",[88],"2018-04-20","2017-12-15",[2017],[1776,1440,1466,545,1414,1738],{"nctId":1769,"briefTitle":1770,"status":283,"phases":2047,"primaryCompletion":1772,"completion":1772,"start":1773,"enrollment":194,"conditions":2048,"interventions":2049},[88],[24],[1776,1440,1466,545,463,464,544],{"trials":2051,"activeCount":96},[],{"trials":2053,"activeCount":96},[],{"intervention":1466,"totalTrials":552,"cells":2055},{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2064,"PHASE3":2085,"PHASE4":2111,"NA":2113},{"trials":2057,"activeCount":96},[],{"trials":2059,"activeCount":96},[2060],{"nctId":1456,"briefTitle":1457,"status":934,"phases":2061,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":96,"conditions":2062,"interventions":2063},[86],[1462,1463,1464],[40,463,545,544,1466,464],{"trials":2065,"activeCount":96},[2066,2070,2081],{"nctId":1744,"briefTitle":1745,"status":102,"phases":2067,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":2068,"interventions":2069},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"nctId":2071,"briefTitle":2072,"status":283,"phases":2073,"primaryCompletion":2074,"completion":2074,"start":2075,"enrollment":2076,"conditions":2077,"interventions":2080},"NCT04003610","Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)",[87],"2021-04-18","2020-05-14",7,[2078,2079],"Metastatic Urothelial Carcinoma","Unresectable Urothelial Carcinoma",[1524,1525,463,1466],{"nctId":1800,"briefTitle":1801,"status":102,"phases":2082,"primaryCompletion":1803,"completion":1803,"start":1804,"enrollment":1805,"conditions":2083,"interventions":2084},[86,87],[1807],[399,422,627,1809,1466,1595],{"trials":2086,"activeCount":152,"soonestReadout":39},[2087,2091,2095,2099,2103,2107],{"nctId":1563,"briefTitle":1564,"status":102,"phases":2088,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":1569,"conditions":2089,"interventions":2090},[88],[1571],[1573,1574,73],{"nctId":2009,"briefTitle":2010,"status":102,"phases":2092,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":2015,"conditions":2093,"interventions":2094},[88],[2017],[1525,1440,1414,545,1466,1738],{"nctId":37,"briefTitle":38,"status":216,"phases":2096,"primaryCompletion":39,"completion":1577,"start":1578,"enrollment":1579,"conditions":2097,"interventions":2098},[88],[1581,1582],[40,544,545,1466,464,1584],{"nctId":1586,"briefTitle":1587,"status":934,"phases":2100,"primaryCompletion":1589,"completion":1590,"start":1591,"enrollment":96,"conditions":2101,"interventions":2102},[88],[1593],[40,544,545,1466,464,1595],{"nctId":2039,"briefTitle":2040,"status":934,"phases":2104,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":96,"conditions":2105,"interventions":2106},[88],[2017],[1776,1440,1466,545,1414,1738],{"nctId":1769,"briefTitle":1770,"status":283,"phases":2108,"primaryCompletion":1772,"completion":1772,"start":1773,"enrollment":194,"conditions":2109,"interventions":2110},[88],[24],[1776,1440,1466,545,463,464,544],{"trials":2112,"activeCount":96},[],{"trials":2114,"activeCount":96},[],{"intervention":294,"totalTrials":268,"cells":2116},{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2138,"PHASE3":2157,"PHASE4":2163,"NA":2165},{"trials":2118,"activeCount":96},[],{"trials":2120,"activeCount":96},[2121,2125],{"nctId":281,"briefTitle":282,"status":283,"phases":2122,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":2123,"interventions":2124},[86],[15,290],[292,293,294,295],{"nctId":2126,"briefTitle":2127,"status":283,"phases":2128,"primaryCompletion":2129,"completion":2129,"start":2130,"enrollment":1123,"conditions":2131,"interventions":2136},"NCT01929941","An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies",[86],"2014-08","2013-09",[1550,2132,2133,290,443,2134,2135,1311],"Hodgkin's Lymphoma","NHL (Non-Hodgkin Lymphoma)","UC (Ureter and Urethera)","Advanced Cancer",[2137,2137,463,294],"INCB047986",{"trials":2139,"activeCount":96},[2140,2149,2153],{"nctId":2141,"briefTitle":2142,"status":102,"phases":2143,"primaryCompletion":427,"completion":2144,"start":360,"enrollment":2145,"conditions":2146,"interventions":2147},"NCT01858883","Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors",[86,87],"2016-03",55,[15,290],[2148,463,294,295],"itacitinib",{"nctId":1303,"briefTitle":1304,"status":283,"phases":2150,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":2151,"interventions":2152},[86,87],[15,1310,1311],[1313,293,294,1314,1315,1316,1280,1317,1313,1318,1319,1320],{"nctId":1744,"briefTitle":1745,"status":102,"phases":2154,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":2155,"interventions":2156},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"trials":2158,"activeCount":152,"soonestReadout":39},[2159],{"nctId":37,"briefTitle":38,"status":216,"phases":2160,"primaryCompletion":39,"completion":1577,"start":1578,"enrollment":1579,"conditions":2161,"interventions":2162},[88],[1581,1582],[40,544,545,1466,464,1584],{"trials":2164,"activeCount":96},[],{"trials":2166,"activeCount":96},[],{"intervention":544,"totalTrials":268,"cells":2168},{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2177,"PHASE3":2187,"PHASE4":2201,"NA":2203},{"trials":2170,"activeCount":96},[],{"trials":2172,"activeCount":96},[2173],{"nctId":1456,"briefTitle":1457,"status":934,"phases":2174,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":96,"conditions":2175,"interventions":2176},[86],[1462,1463,1464],[40,463,545,544,1466,464],{"trials":2178,"activeCount":96},[2179,2183],{"nctId":1744,"briefTitle":1745,"status":102,"phases":2180,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":2181,"interventions":2182},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"nctId":534,"briefTitle":535,"status":283,"phases":2184,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":2185,"interventions":2186},[87],[542],[129,544,545],{"trials":2188,"activeCount":152,"soonestReadout":39},[2189,2193,2197],{"nctId":37,"briefTitle":38,"status":216,"phases":2190,"primaryCompletion":39,"completion":1577,"start":1578,"enrollment":1579,"conditions":2191,"interventions":2192},[88],[1581,1582],[40,544,545,1466,464,1584],{"nctId":1586,"briefTitle":1587,"status":934,"phases":2194,"primaryCompletion":1589,"completion":1590,"start":1591,"enrollment":96,"conditions":2195,"interventions":2196},[88],[1593],[40,544,545,1466,464,1595],{"nctId":1769,"briefTitle":1770,"status":283,"phases":2198,"primaryCompletion":1772,"completion":1772,"start":1773,"enrollment":194,"conditions":2199,"interventions":2200},[88],[24],[1776,1440,1466,545,463,464,544],{"trials":2202,"activeCount":96},[],{"trials":2204,"activeCount":96},[],{"intervention":498,"totalTrials":12,"cells":2206},{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2217,"PHASE4":2243,"NA":2245},{"trials":2208,"activeCount":96},[],{"trials":2210,"activeCount":96},[],{"trials":2212,"activeCount":96},[2213],{"nctId":480,"briefTitle":481,"status":102,"phases":2214,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":2215,"interventions":2216},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"trials":2218,"activeCount":152,"soonestReadout":1250},[2219,2230,2234],{"nctId":2220,"briefTitle":2221,"status":283,"phases":2222,"primaryCompletion":2223,"completion":2223,"start":2224,"enrollment":2225,"conditions":2226,"interventions":2228},"NCT03584516","GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease",[87,88],"2023-11-03","2019-01-17",155,[2227],"Chronic Graft-versus-host Disease",[422,2229,498],"Methylprednisolone",{"nctId":1247,"briefTitle":1248,"status":216,"phases":2231,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":1253,"conditions":2232,"interventions":2233},[88],[1255],[50,1234,627,490,493,1257,498,1258,1259],{"nctId":2235,"briefTitle":2236,"status":102,"phases":2237,"primaryCompletion":2238,"completion":1748,"start":2239,"enrollment":2240,"conditions":2241,"interventions":2242},"NCT03139604","GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease",[88],"2019-05-02","2017-07-19",439,[476],[422,498,2229],{"trials":2244,"activeCount":96},[],{"trials":2246,"activeCount":96},[],{"intervention":493,"totalTrials":194,"cells":2248},{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2253,"PHASE3":2259,"PHASE4":2265,"NA":2267},{"trials":2250,"activeCount":96},[],{"trials":2252,"activeCount":96},[],{"trials":2254,"activeCount":96},[2255],{"nctId":480,"briefTitle":481,"status":102,"phases":2256,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":2257,"interventions":2258},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"trials":2260,"activeCount":152,"soonestReadout":1250},[2261],{"nctId":1247,"briefTitle":1248,"status":216,"phases":2262,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":1253,"conditions":2263,"interventions":2264},[88],[1255],[50,1234,627,490,493,1257,498,1258,1259],{"trials":2266,"activeCount":96},[],{"trials":2268,"activeCount":96},[],{"intervention":496,"totalTrials":194,"cells":2270},{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2281,"PHASE4":2287,"NA":2289},{"trials":2272,"activeCount":96},[],{"trials":2274,"activeCount":96},[],{"trials":2276,"activeCount":96},[2277],{"nctId":480,"briefTitle":481,"status":102,"phases":2278,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":2279,"interventions":2280},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"trials":2282,"activeCount":152,"soonestReadout":677},[2283],{"nctId":674,"briefTitle":675,"status":122,"phases":2284,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":2285,"interventions":2286},[88],[476],[682,496,129,490,624],{"trials":2288,"activeCount":96},[],{"trials":2290,"activeCount":96},[],{"intervention":624,"totalTrials":194,"cells":2292},{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2297,"PHASE3":2299,"PHASE4":2309,"NA":2311},{"trials":2294,"activeCount":96},[],{"trials":2296,"activeCount":96},[],{"trials":2298,"activeCount":96},[],{"trials":2300,"activeCount":152,"soonestReadout":677},[2301,2305],{"nctId":613,"briefTitle":614,"status":102,"phases":2302,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":2303,"interventions":2304},[88],[476],[129,622,623,624,625,626,627,628,629,630],{"nctId":674,"briefTitle":675,"status":122,"phases":2306,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":2307,"interventions":2308},[88],[476],[682,496,129,490,624],{"trials":2310,"activeCount":96},[],{"trials":2312,"activeCount":96},[],{"intervention":1383,"totalTrials":152,"cells":2314},{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2319,"PHASE3":2321,"PHASE4":2327,"NA":2329},{"trials":2316,"activeCount":96},[],{"trials":2318,"activeCount":96},[],{"trials":2320,"activeCount":96},[],{"trials":2322,"activeCount":152,"soonestReadout":1378},[2323],{"nctId":1375,"briefTitle":1376,"status":216,"phases":2324,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":28,"conditions":2325,"interventions":2326},[88],[529],[1344,1383],{"trials":2328,"activeCount":96},[],{"trials":2330,"activeCount":96},[],{"intervention":1257,"totalTrials":152,"cells":2332},{"EARLY_PHASE1":2333,"PHASE1":2335,"PHASE2":2337,"PHASE3":2339,"PHASE4":2345,"NA":2347},{"trials":2334,"activeCount":96},[],{"trials":2336,"activeCount":96},[],{"trials":2338,"activeCount":96},[],{"trials":2340,"activeCount":152,"soonestReadout":1250},[2341],{"nctId":1247,"briefTitle":1248,"status":216,"phases":2342,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":1253,"conditions":2343,"interventions":2344},[88],[1255],[50,1234,627,490,493,1257,498,1258,1259],{"trials":2346,"activeCount":96},[],{"trials":2348,"activeCount":96},[],{"intervention":1258,"totalTrials":152,"cells":2350},{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2357,"PHASE4":2363,"NA":2365},{"trials":2352,"activeCount":96},[],{"trials":2354,"activeCount":96},[],{"trials":2356,"activeCount":96},[],{"trials":2358,"activeCount":152,"soonestReadout":1250},[2359],{"nctId":1247,"briefTitle":1248,"status":216,"phases":2360,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":1253,"conditions":2361,"interventions":2362},[88],[1255],[50,1234,627,490,493,1257,498,1258,1259],{"trials":2364,"activeCount":96},[],{"trials":2366,"activeCount":96},[],{"intervention":1259,"totalTrials":152,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2375,"PHASE4":2381,"NA":2383},{"trials":2370,"activeCount":96},[],{"trials":2372,"activeCount":96},[],{"trials":2374,"activeCount":96},[],{"trials":2376,"activeCount":152,"soonestReadout":1250},[2377],{"nctId":1247,"briefTitle":1248,"status":216,"phases":2378,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":1253,"conditions":2379,"interventions":2380},[88],[1255],[50,1234,627,490,493,1257,498,1258,1259],{"trials":2382,"activeCount":96},[],{"trials":2384,"activeCount":96},[],{"intervention":682,"totalTrials":152,"cells":2386},{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2399,"NA":2401},{"trials":2388,"activeCount":96},[],{"trials":2390,"activeCount":96},[],{"trials":2392,"activeCount":96},[],{"trials":2394,"activeCount":152,"soonestReadout":677},[2395],{"nctId":674,"briefTitle":675,"status":122,"phases":2396,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":2397,"interventions":2398},[88],[476],[682,496,129,490,624],{"trials":2400,"activeCount":96},[],{"trials":2402,"activeCount":96},[],{"intervention":2404,"totalTrials":268,"cells":2405},"INCB099280",{"EARLY_PHASE1":2406,"PHASE1":2408,"PHASE2":2449,"PHASE3":2476,"PHASE4":2478,"NA":2480},{"trials":2407,"activeCount":96},[],{"trials":2409,"activeCount":96},[2410,2418,2439],{"nctId":2411,"briefTitle":2412,"status":102,"phases":2413,"primaryCompletion":2414,"completion":2414,"start":2415,"enrollment":1123,"conditions":2416,"interventions":2417},"NCT06309394","A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants",[86],"2024-06-04","2024-05-15",[18],[2404],{"nctId":2419,"briefTitle":2420,"status":102,"phases":2421,"primaryCompletion":2422,"completion":2423,"start":2424,"enrollment":2425,"conditions":2426,"interventions":2438},"NCT04242199","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors",[86],"2024-08-29","2024-11-21","2020-09-04",182,[2427,2428,2429,1491,2430,2431,2432,2433,2434,2435,2436,2437],"Advanced Solid Tumor","MSI-H\u002FdMMR Tumors","Cutaneous Squamous Cell Carcinoma","Cervical Cancer","HepatoCellular Carcinoma","Esophageal Squamous Cell Carcinoma","Merkel Cell Carcinoma","Small-cell Lung Cancer","Mesothelioma","PD-L1 Amplified Tumor (9p24.1)","Nasopharyngeal Carcinoma",[2404],{"nctId":2440,"briefTitle":2441,"status":283,"phases":2442,"primaryCompletion":2443,"completion":2444,"start":2445,"enrollment":268,"conditions":2446,"interventions":2447},"NCT06039384","A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation",[86],"2025-04-11","2025-07-11","2023-12-28",[1449],[2404,2448],"adagrasib",{"trials":2450,"activeCount":194,"soonestReadout":2455},[2451,2459,2468],{"nctId":2452,"briefTitle":2453,"status":216,"phases":2454,"primaryCompletion":2455,"completion":2455,"start":2456,"enrollment":563,"conditions":2457,"interventions":2458},"NCT05879822","A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive",[87],"2026-07-22","2023-10-30",[2427],[2404],{"nctId":2460,"briefTitle":2461,"status":283,"phases":2462,"primaryCompletion":2463,"completion":2463,"start":2464,"enrollment":1123,"conditions":2465,"interventions":2466},"NCT05949632","A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors",[86,87],"2025-06-06","2024-04-16",[1449],[2404,2467],"axitinib",{"nctId":2469,"briefTitle":2470,"status":216,"phases":2471,"primaryCompletion":2472,"completion":2472,"start":2473,"enrollment":1901,"conditions":2474,"interventions":2475},"NCT05888844","A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma",[87],"2026-09-28","2023-10-09",[2429],[2404],{"trials":2477,"activeCount":96},[],{"trials":2479,"activeCount":96},[],{"trials":2481,"activeCount":96},[],{"intervention":55,"totalTrials":12,"cells":2483},{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2499,"PHASE3":2525,"PHASE4":2527,"NA":2529},{"trials":2485,"activeCount":96},[],{"trials":2487,"activeCount":96},[2488],{"nctId":2489,"briefTitle":2490,"status":102,"phases":2491,"primaryCompletion":2492,"completion":2493,"start":2494,"enrollment":2495,"conditions":2496,"interventions":2498},"NCT05099445","Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis",[86],"2023-02-19","2023-02-27","2021-12-14",48,[1142,2497],"Hemodialysis",[55],{"trials":2500,"activeCount":194,"soonestReadout":54},[2501,2505,2516],{"nctId":52,"briefTitle":53,"status":216,"phases":2502,"primaryCompletion":54,"completion":348,"start":349,"enrollment":350,"conditions":2503,"interventions":2504},[86,87],[352,353,354],[55,292],{"nctId":2506,"briefTitle":2507,"status":122,"phases":2508,"primaryCompletion":2509,"completion":2510,"start":2511,"enrollment":2512,"conditions":2513,"interventions":2515},"NCT05090891","To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva",[87],"2027-07-30","2033-01-20","2022-05-05",98,[2514],"Fibrodysplasia Ossificans Progressiva (FOP)",[55],{"nctId":2517,"briefTitle":2518,"status":283,"phases":2519,"primaryCompletion":2520,"completion":2520,"start":2521,"enrollment":516,"conditions":2522,"interventions":2524},"NCT04582539","To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma",[86,87],"2024-08-15","2021-08-19",[2523,1553,352],"Myelodysplastic Syndromes",[55],{"trials":2526,"activeCount":96},[],{"trials":2528,"activeCount":96},[],{"trials":2530,"activeCount":96},[],{"intervention":399,"totalTrials":2532,"cells":2533},20,{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2579,"PHASE3":2667,"PHASE4":2685,"NA":2687},{"trials":2535,"activeCount":96},[],{"trials":2537,"activeCount":96},[2538,2549,2558,2562,2570],{"nctId":2539,"briefTitle":2540,"status":102,"phases":2541,"primaryCompletion":2542,"completion":2542,"start":2543,"enrollment":2544,"conditions":2545,"interventions":2546},"NCT03039114","Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)",[86],"2021-03-30","2017-02-15",26,[32],[399,2547,2548],"Hexal","Gazyvaro",{"nctId":2550,"briefTitle":2551,"status":102,"phases":2552,"primaryCompletion":2553,"completion":2554,"start":2555,"enrollment":1398,"conditions":2556,"interventions":2557},"NCT03314922","A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)",[86],"2020-05-05","2023-03-09","2018-08-02",[32],[399],{"nctId":1788,"briefTitle":1789,"status":102,"phases":2559,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":1793,"conditions":2560,"interventions":2561},[86],[1795],[399,627,1269,630],{"nctId":2563,"briefTitle":2564,"status":102,"phases":2565,"primaryCompletion":2566,"completion":2566,"start":2567,"enrollment":2495,"conditions":2568,"interventions":2569},"NCT04831996","To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.",[86],"2022-07-08","2021-05-04",[1310],[653],{"nctId":2571,"briefTitle":2572,"status":102,"phases":2573,"primaryCompletion":2574,"completion":1846,"start":2575,"enrollment":2576,"conditions":2577,"interventions":2578},"NCT04831944","To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.",[86],"2022-03-10","2021-03-29",21,[1310],[653],{"trials":2580,"activeCount":152,"soonestReadout":550},[2581,2591,2601,2605,2614,2618,2628,2637,2646,2654,2663],{"nctId":2582,"briefTitle":2583,"status":216,"phases":2584,"primaryCompletion":550,"completion":550,"start":582,"enrollment":2585,"conditions":2586,"interventions":2587},"NCT04509700","Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)",[87],112,[1807],[399,2588,2589,2590],"parsaclisib + itacitinib","parsaclisib + ruxolitinib","parsaclisib + ibrutinib",{"nctId":2592,"briefTitle":2593,"status":102,"phases":2594,"primaryCompletion":2595,"completion":2596,"start":2597,"enrollment":373,"conditions":2598,"interventions":2600},"NCT03538041","A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia",[87],"2021-08-05","2024-04-02","2018-11-21",[2599],"Autoimmune Hemolytic Anemia",[399],{"nctId":390,"briefTitle":391,"status":283,"phases":2602,"primaryCompletion":393,"completion":394,"start":395,"enrollment":396,"conditions":2603,"interventions":2604},[87],[30],[399,399,129,399,399],{"nctId":2606,"briefTitle":2607,"status":934,"phases":2608,"primaryCompletion":2609,"completion":2609,"start":2610,"enrollment":96,"conditions":2611,"interventions":2613},"NCT03780166","A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris",[87],"2020-11","2019-03",[2612],"Pemphigus Vulgaris",[399],{"nctId":1207,"briefTitle":1208,"status":283,"phases":2615,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":1212,"conditions":2616,"interventions":2617},[86,87],[1214,1215],[45,653],{"nctId":2619,"briefTitle":2620,"status":102,"phases":2621,"primaryCompletion":2622,"completion":2623,"start":2624,"enrollment":552,"conditions":2625,"interventions":2627},"NCT03627065","A Study of INCB050465 in Primary Sjögren's Syndrome",[87],"2019-12-07","2020-01-02","2019-02-28",[2626],"Primary Sjögren's Syndrome",[399],{"nctId":2629,"briefTitle":2630,"status":102,"phases":2631,"primaryCompletion":2632,"completion":2633,"start":2634,"enrollment":9,"conditions":2635,"interventions":2636},"NCT02998476","A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)",[87],"2019-02-22","2021-02-05","2017-03-02",[32],[399],{"nctId":2638,"briefTitle":2639,"status":102,"phases":2640,"primaryCompletion":2641,"completion":2642,"start":2643,"enrollment":606,"conditions":2644,"interventions":2645},"NCT03144674","A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)",[87],"2021-01-15","2024-05-29","2017-12-18",[32],[399],{"nctId":2647,"briefTitle":2648,"status":102,"phases":2649,"primaryCompletion":698,"completion":104,"start":2650,"enrollment":2651,"conditions":2652,"interventions":2653},"NCT03126019","A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma",[87],"2018-03-14",126,[32],[399],{"nctId":2655,"briefTitle":2656,"status":102,"phases":2657,"primaryCompletion":2658,"completion":2658,"start":2659,"enrollment":2660,"conditions":2661,"interventions":2662},"NCT03235544","A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor",[87],"2024-04-30","2017-11-20",162,[32],[399],{"nctId":1800,"briefTitle":1801,"status":102,"phases":2664,"primaryCompletion":1803,"completion":1803,"start":1804,"enrollment":1805,"conditions":2665,"interventions":2666},[86,87],[1807],[399,422,627,1809,1466,1595],{"trials":2668,"activeCount":96},[2669,2673,2677,2681],{"nctId":1813,"briefTitle":1814,"status":934,"phases":2670,"primaryCompletion":1816,"completion":1817,"start":1818,"enrollment":96,"conditions":2671,"interventions":2672},[88],[1820,1821],[653,1279,1823],{"nctId":642,"briefTitle":643,"status":283,"phases":2674,"primaryCompletion":645,"completion":646,"start":647,"enrollment":648,"conditions":2675,"interventions":2676},[88],[303,385,650,651],[653,292],{"nctId":1841,"briefTitle":1842,"status":934,"phases":2678,"primaryCompletion":1844,"completion":1845,"start":1846,"enrollment":96,"conditions":2679,"interventions":2680},[88],[1848],[653,1279,1850],{"nctId":722,"briefTitle":723,"status":283,"phases":2682,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":2683,"interventions":2684},[88],[303,385,650,651],[653,292],{"trials":2686,"activeCount":96},[],{"trials":2688,"activeCount":96},[],{"intervention":1440,"totalTrials":2532,"cells":2690},{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2719,"PHASE3":2811,"PHASE4":2856,"NA":2858},{"trials":2692,"activeCount":96},[],{"trials":2694,"activeCount":96},[2695,2705,2715],{"nctId":2696,"briefTitle":2697,"status":283,"phases":2698,"primaryCompletion":2699,"completion":2700,"start":2701,"enrollment":2702,"conditions":2703,"interventions":2704},"NCT02559492","Itacitinib Combined With INCB024360 and\u002For Itacitinib Combined With INCB050465 in Advanced Solid Tumors",[86],"2018-09-10","2019-08-18","2015-11",142,[15],[422,1440,422,1319],{"nctId":2706,"briefTitle":2707,"status":283,"phases":2708,"primaryCompletion":2709,"completion":2709,"start":2710,"enrollment":757,"conditions":2711,"interventions":2713},"NCT02298153","A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma",[86],"2017-11-08","2015-01-27",[542,2712],"UC (Urothelial Cancer)",[1440,2714],"Atezolizumab",{"nctId":1432,"briefTitle":1433,"status":102,"phases":2716,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":1308,"conditions":2717,"interventions":2718},[86],[1438],[40,1440,1319],{"trials":2720,"activeCount":152,"soonestReadout":72},[2721,2732,2740,2750,2757,2761,2765,2775,2779,2791,2801],{"nctId":2722,"briefTitle":2723,"status":102,"phases":2724,"primaryCompletion":2725,"completion":2726,"start":2727,"enrollment":2728,"conditions":2729,"interventions":2730},"NCT03322566","A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06\u002FECHO-306-06)",[87],"2018-12-13","2020-10-16","2018-01-09",233,[24],[1525,1440,2731],"Platinum-based chemotherapy",{"nctId":2733,"briefTitle":2734,"status":283,"phases":2735,"primaryCompletion":2736,"completion":2736,"start":2737,"enrollment":1123,"conditions":2738,"interventions":2739},"NCT03361228","A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors",[86,87],"2019-03-30","2018-03-01",[15],[1735,1440,1525],{"nctId":2741,"briefTitle":2742,"status":283,"phases":2743,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":1793,"conditions":2747,"interventions":2748},"NCT01604889","A Phase 1\u002F2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma",[86,87],"2016-12-27","2017-01-20","2012-03-29",[27],[1440,2749],"ipilimumab",{"nctId":2751,"briefTitle":2752,"status":102,"phases":2753,"primaryCompletion":2754,"completion":1010,"start":2043,"enrollment":407,"conditions":2755,"interventions":2756},"NCT03322540","Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05\u002FECHO-305-05)",[87],"2019-01-10",[24],[1525,1440],{"nctId":1485,"briefTitle":1486,"status":283,"phases":2758,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1359,"conditions":2759,"interventions":2760},[87],[1491],[73,1493,1494,1495],{"nctId":70,"briefTitle":71,"status":216,"phases":2762,"primaryCompletion":72,"completion":1498,"start":1499,"enrollment":1500,"conditions":2763,"interventions":2764},[87],[1502],[73,1493,1504,1494,1495],{"nctId":2766,"briefTitle":2767,"status":283,"phases":2768,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":25,"conditions":2771,"interventions":2772},"NCT03347123","A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)",[86,87],"2021-01-29","2018-03-21",[15],[1440,1776,2773,2774],"Ipilimumab","Lirilumab",{"nctId":1744,"briefTitle":1745,"status":102,"phases":2776,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":2777,"interventions":2778},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"nctId":2780,"briefTitle":2781,"status":102,"phases":2782,"primaryCompletion":2783,"completion":2783,"start":2784,"enrollment":2785,"conditions":2786,"interventions":2789},"NCT02327078","A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)",[86,87],"2020-06-16","2014-11-26",307,[2787,554,2017,24,32,27,34,2788],"B-cell Malignancies","Glioblastoma",[1776,1440,2790],"Chemotherapy",{"nctId":2792,"briefTitle":2793,"status":283,"phases":2794,"primaryCompletion":2795,"completion":2796,"start":2797,"enrollment":1750,"conditions":2798,"interventions":2799},"NCT02959437","Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)",[86,87],"2019-02-15","2020-03-02","2017-02-27",[15,1310,1311],[467,1525,1440,320,1525,1440,2800],"INCB059872",{"nctId":2802,"briefTitle":2803,"status":283,"phases":2804,"primaryCompletion":2805,"completion":2805,"start":2806,"enrollment":1308,"conditions":2807,"interventions":2809},"NCT01685255","A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy",[87],"2014-10-23","2012-08",[34,2808],"Genitourinary (GU) Tumors",[1440,2810],"tamoxifen",{"trials":2812,"activeCount":96},[2813,2822,2826,2838,2848,2852],{"nctId":2814,"briefTitle":2815,"status":102,"phases":2816,"primaryCompletion":2817,"completion":2818,"start":2819,"enrollment":350,"conditions":2820,"interventions":2821},"NCT03374488","Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma",[88],"2018-07-27","2020-07-23","2017-12-22",[2712],[1525,1440],{"nctId":2009,"briefTitle":2010,"status":102,"phases":2823,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":2015,"conditions":2824,"interventions":2825},[88],[2017],[1525,1440,1414,545,1466,1738],{"nctId":2827,"briefTitle":2828,"status":102,"phases":2829,"primaryCompletion":2830,"completion":1380,"start":2831,"enrollment":2832,"conditions":2833,"interventions":2835},"NCT03260894","Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679\u002FECHO-302)",[88],"2018-08-22","2017-12-07",129,[2834],"Renal Cell Carcinoma (RCC)",[1525,1440,2836,2837],"Sunitinib","Pazopanib",{"nctId":2839,"briefTitle":2840,"status":102,"phases":2841,"primaryCompletion":2842,"completion":2843,"start":2844,"enrollment":2845,"conditions":2846,"interventions":2847},"NCT03361865","Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672\u002FECHO-307)",[88],"2018-08-09","2020-08-04","2017-12-04",93,[2712],[1525,1440],{"nctId":2039,"briefTitle":2040,"status":934,"phases":2849,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":96,"conditions":2850,"interventions":2851},[88],[2017],[1776,1440,1466,545,1414,1738],{"nctId":1769,"briefTitle":1770,"status":283,"phases":2853,"primaryCompletion":1772,"completion":1772,"start":1773,"enrollment":194,"conditions":2854,"interventions":2855},[88],[24],[1776,1440,1466,545,463,464,544],{"trials":2857,"activeCount":96},[],{"trials":2859,"activeCount":96},[],{"intervention":365,"totalTrials":1123,"cells":2861},{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2866,"PHASE3":2880,"PHASE4":2890,"NA":2892},{"trials":2863,"activeCount":96},[],{"trials":2865,"activeCount":96},[],{"trials":2867,"activeCount":152,"soonestReadout":550},[2868,2872,2876],{"nctId":357,"briefTitle":358,"status":102,"phases":2869,"primaryCompletion":360,"completion":361,"start":362,"enrollment":162,"conditions":2870,"interventions":2871},[87],[290],[365,129],{"nctId":436,"briefTitle":437,"status":283,"phases":2873,"primaryCompletion":427,"completion":439,"start":440,"enrollment":441,"conditions":2874,"interventions":2875},[87],[443],[129,365],{"nctId":547,"briefTitle":548,"status":216,"phases":2877,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":2878,"interventions":2879},[87],[290,554,443,24],[129,365,434],{"trials":2881,"activeCount":96},[2882,2886],{"nctId":592,"briefTitle":593,"status":283,"phases":2883,"primaryCompletion":427,"completion":595,"start":596,"enrollment":597,"conditions":2884,"interventions":2885},[88],[290],[129,365],{"nctId":705,"briefTitle":706,"status":283,"phases":2887,"primaryCompletion":427,"completion":428,"start":429,"enrollment":708,"conditions":2888,"interventions":2889},[88],[290],[129,365],{"trials":2891,"activeCount":96},[],{"trials":2893,"activeCount":96},[],{"intervention":1495,"totalTrials":12,"cells":2895},{"EARLY_PHASE1":2896,"PHASE1":2898,"PHASE2":2921,"PHASE3":2940,"PHASE4":2942,"NA":2944},{"trials":2897,"activeCount":96},[],{"trials":2899,"activeCount":96},[2900],{"nctId":2901,"briefTitle":2902,"status":102,"phases":2903,"primaryCompletion":2904,"completion":2904,"start":2905,"enrollment":190,"conditions":2906,"interventions":2920},"NCT03652077","A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies",[86],"2021-08-18","2018-09-24",[2430,1551,2907,2908,2909,2910,27,2911,2433,2435,2912,1593,2913,34,2914,2915,2916,2917,2918,1491,2919],"Stomach Cancer","Gastroesophageal Junction Cancer","Esophageal Cancer","Hepatocellular Carcinoma","Uveal Melanoma","MSI","NSCLC","Squamous Cell Carcinoma of the Head and Neck","Small Cell Lung Cancer","Renal Cell Carcinoma","RCC","Triple-negative Breast Cancer","Mismatch Repair Deficiency",[1495],{"trials":2922,"activeCount":152,"soonestReadout":72},[2923,2932,2936],{"nctId":2924,"briefTitle":2925,"status":102,"phases":2926,"primaryCompletion":2927,"completion":2927,"start":2928,"enrollment":798,"conditions":2929,"interventions":2930},"NCT04370704","Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies",[86,87],"2025-08-25","2020-07-27",[27],[1494,1495,2931],"INCMGA00012.",{"nctId":1485,"briefTitle":1486,"status":283,"phases":2933,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1359,"conditions":2934,"interventions":2935},[87],[1491],[73,1493,1494,1495],{"nctId":70,"briefTitle":71,"status":216,"phases":2937,"primaryCompletion":72,"completion":1498,"start":1499,"enrollment":1500,"conditions":2938,"interventions":2939},[87],[1502],[73,1493,1504,1494,1495],{"trials":2941,"activeCount":96},[],{"trials":2943,"activeCount":96},[],{"trials":2945,"activeCount":96},[],{"intervention":1494,"totalTrials":588,"cells":2947},{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2952,"PHASE3":2966,"PHASE4":2968,"NA":2970},{"trials":2949,"activeCount":96},[],{"trials":2951,"activeCount":96},[],{"trials":2953,"activeCount":152,"soonestReadout":72},[2954,2958,2962],{"nctId":2924,"briefTitle":2925,"status":102,"phases":2955,"primaryCompletion":2927,"completion":2927,"start":2928,"enrollment":798,"conditions":2956,"interventions":2957},[86,87],[27],[1494,1495,2931],{"nctId":1485,"briefTitle":1486,"status":283,"phases":2959,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1359,"conditions":2960,"interventions":2961},[87],[1491],[73,1493,1494,1495],{"nctId":70,"briefTitle":71,"status":216,"phases":2963,"primaryCompletion":72,"completion":1498,"start":1499,"enrollment":1500,"conditions":2964,"interventions":2965},[87],[1502],[73,1493,1504,1494,1495],{"trials":2967,"activeCount":96},[],{"trials":2969,"activeCount":96},[],{"trials":2971,"activeCount":96},[],{"intervention":434,"totalTrials":194,"cells":2973},{"EARLY_PHASE1":2974,"PHASE1":2976,"PHASE2":2978,"PHASE3":2988,"PHASE4":2990,"NA":2992},{"trials":2975,"activeCount":96},[],{"trials":2977,"activeCount":96},[],{"trials":2979,"activeCount":152,"soonestReadout":550},[2980,2984],{"nctId":424,"briefTitle":425,"status":283,"phases":2981,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":2982,"interventions":2983},[87],[432],[129,434],{"nctId":547,"briefTitle":548,"status":216,"phases":2985,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":2986,"interventions":2987},[87],[290,554,443,24],[129,365,434],{"trials":2989,"activeCount":96},[],{"trials":2991,"activeCount":96},[],{"trials":2993,"activeCount":96},[],{"intervention":2588,"totalTrials":152,"cells":2995},{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3000,"PHASE3":3006,"PHASE4":3008,"NA":3010},{"trials":2997,"activeCount":96},[],{"trials":2999,"activeCount":96},[],{"trials":3001,"activeCount":152,"soonestReadout":550},[3002],{"nctId":2582,"briefTitle":2583,"status":216,"phases":3003,"primaryCompletion":550,"completion":550,"start":582,"enrollment":2585,"conditions":3004,"interventions":3005},[87],[1807],[399,2588,2589,2590],{"trials":3007,"activeCount":96},[],{"trials":3009,"activeCount":96},[],{"trials":3011,"activeCount":96},[],{"intervention":2589,"totalTrials":152,"cells":3013},{"EARLY_PHASE1":3014,"PHASE1":3016,"PHASE2":3018,"PHASE3":3024,"PHASE4":3026,"NA":3028},{"trials":3015,"activeCount":96},[],{"trials":3017,"activeCount":96},[],{"trials":3019,"activeCount":152,"soonestReadout":550},[3020],{"nctId":2582,"briefTitle":2583,"status":216,"phases":3021,"primaryCompletion":550,"completion":550,"start":582,"enrollment":2585,"conditions":3022,"interventions":3023},[87],[1807],[399,2588,2589,2590],{"trials":3025,"activeCount":96},[],{"trials":3027,"activeCount":96},[],{"trials":3029,"activeCount":96},[],{"intervention":2590,"totalTrials":152,"cells":3031},{"EARLY_PHASE1":3032,"PHASE1":3034,"PHASE2":3036,"PHASE3":3042,"PHASE4":3044,"NA":3046},{"trials":3033,"activeCount":96},[],{"trials":3035,"activeCount":96},[],{"trials":3037,"activeCount":152,"soonestReadout":550},[3038],{"nctId":2582,"briefTitle":2583,"status":216,"phases":3039,"primaryCompletion":550,"completion":550,"start":582,"enrollment":2585,"conditions":3040,"interventions":3041},[87],[1807],[399,2588,2589,2590],{"trials":3043,"activeCount":96},[],{"trials":3045,"activeCount":96},[],{"trials":3047,"activeCount":96},[],{"intervention":78,"totalTrials":152,"cells":3049},{"EARLY_PHASE1":3050,"PHASE1":3052,"PHASE2":3054,"PHASE3":3060,"PHASE4":3062,"NA":3064},{"trials":3051,"activeCount":96},[],{"trials":3053,"activeCount":96},[],{"trials":3055,"activeCount":152,"soonestReadout":77},[3056],{"nctId":75,"briefTitle":76,"status":216,"phases":3057,"primaryCompletion":77,"completion":77,"start":1481,"enrollment":28,"conditions":3058,"interventions":3059},[86,87],[15,1449,1429],[78,40],{"trials":3061,"activeCount":96},[],{"trials":3063,"activeCount":96},[],{"trials":3065,"activeCount":96},[],{"intervention":183,"totalTrials":152,"cells":3067},{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3072,"PHASE3":3078,"PHASE4":3080,"NA":3082},{"trials":3069,"activeCount":96},[],{"trials":3071,"activeCount":96},[],{"trials":3073,"activeCount":152,"soonestReadout":175},[3074],{"nctId":172,"briefTitle":173,"status":122,"phases":3075,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":3076,"interventions":3077},[87],[180],[182,183],{"trials":3079,"activeCount":96},[],{"trials":3081,"activeCount":96},[],{"trials":3083,"activeCount":96},[],{"intervention":3085,"totalTrials":152,"cells":3086},"INCA000585",{"EARLY_PHASE1":3087,"PHASE1":3089,"PHASE2":3091,"PHASE3":3104,"PHASE4":3106,"NA":3108},{"trials":3088,"activeCount":96},[],{"trials":3090,"activeCount":96},[],{"trials":3092,"activeCount":152,"soonestReadout":3097},[3093],{"nctId":3094,"briefTitle":3095,"status":122,"phases":3096,"primaryCompletion":3097,"completion":3098,"start":3099,"enrollment":3100,"conditions":3101,"interventions":3103},"NCT07104565","Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders",[87],"2027-09-23","2028-03-09","2025-12-29",56,[3102],"Immune Thrombocytopenia",[3085],{"trials":3105,"activeCount":96},[],{"trials":3107,"activeCount":96},[],{"trials":3109,"activeCount":96},[],{"intervention":1371,"totalTrials":152,"cells":3111},{"EARLY_PHASE1":3112,"PHASE1":3114,"PHASE2":3116,"PHASE3":3122,"PHASE4":3124,"NA":3126},{"trials":3113,"activeCount":96},[],{"trials":3115,"activeCount":96},[],{"trials":3117,"activeCount":152,"soonestReadout":1366},[3118],{"nctId":1363,"briefTitle":1364,"status":122,"phases":3119,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":9,"conditions":3120,"interventions":3121},[87],[529],[1344,1371],{"trials":3123,"activeCount":96},[],{"trials":3125,"activeCount":96},[],{"trials":3127,"activeCount":96},[],{"intervention":422,"totalTrials":373,"cells":3129},{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3180,"PHASE3":3327,"PHASE4":3337,"NA":3339},{"trials":3131,"activeCount":96},[],{"trials":3133,"activeCount":96},[3134,3145,3156,3166,3176],{"nctId":3135,"briefTitle":3136,"status":102,"phases":3137,"primaryCompletion":3138,"completion":3139,"start":3140,"enrollment":3141,"conditions":3142,"interventions":3144},"NCT02646748","Pembrolizumab Combined With Itacitinib (INCB039110) and\u002For Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",[86],"2019-11-07","2020-11-20","2016-01-25",159,[554,1502,27,2017,24,3143,443,290,2834,15,2712],"MMR-deficient Tumors",[1525,2148,1319],{"nctId":3146,"briefTitle":3147,"status":102,"phases":3148,"primaryCompletion":3149,"completion":3150,"start":3151,"enrollment":3152,"conditions":3153,"interventions":3154},"NCT02614612","Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD",[86],"2016-06","2018-08","2015-12",31,[476],[422,422,3155],"prednisone or methylprednisolone",{"nctId":3157,"briefTitle":3158,"status":283,"phases":3159,"primaryCompletion":3160,"completion":3161,"start":3162,"enrollment":350,"conditions":3163,"interventions":3164},"NCT03320642","GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease",[86],"2021-02-25","2022-02-17","2018-02-27",[1224],[422,3165],"Calcineurin inhibitor",{"nctId":3167,"briefTitle":3168,"status":102,"phases":3169,"primaryCompletion":3170,"completion":1942,"start":3171,"enrollment":3172,"conditions":3173,"interventions":3174},"NCT03497273","Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects",[86],"2019-11-30","2018-03-20",14,[1944],[422,3175],"Corticosteroid",{"nctId":2696,"briefTitle":2697,"status":283,"phases":3177,"primaryCompletion":2699,"completion":2700,"start":2701,"enrollment":2702,"conditions":3178,"interventions":3179},[86],[15],[422,1440,422,1319],{"trials":3181,"activeCount":152,"soonestReadout":3254},[3182,3186,3190,3199,3211,3223,3232,3241,3250,3260,3270,3279,3289,3298,3307,3319,3323],{"nctId":2141,"briefTitle":2142,"status":102,"phases":3183,"primaryCompletion":427,"completion":2144,"start":360,"enrollment":2145,"conditions":3184,"interventions":3185},[86,87],[15,290],[2148,463,294,295],{"nctId":413,"briefTitle":414,"status":102,"phases":3187,"primaryCompletion":416,"completion":417,"start":418,"enrollment":419,"conditions":3188,"interventions":3189},[87],[30],[422,129],{"nctId":3191,"briefTitle":3192,"status":102,"phases":3193,"primaryCompletion":3194,"completion":3195,"start":605,"enrollment":1793,"conditions":3196,"interventions":3198},"NCT01634087","A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis",[87],"2013-01","2013-02",[3197],"Plaque Psoriasis",[422],{"nctId":3200,"briefTitle":3201,"status":102,"phases":3202,"primaryCompletion":3203,"completion":3204,"start":3205,"enrollment":2585,"conditions":3206,"interventions":3208},"NCT04071366","A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy",[87],"2023-02-23","2023-08-22","2020-02-07",[3207],"Cytokine Release Syndrome",[422,3209,3210],"Immune effector cell therapy","Yescarta",{"nctId":3212,"briefTitle":3213,"status":102,"phases":3214,"primaryCompletion":3215,"completion":3216,"start":3217,"enrollment":3218,"conditions":3219,"interventions":3221},"NCT01626573","A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis",[87],"2013-07","2013-10","2012-03",106,[3220],"Rheumatoid Arthritis",[422,3222],"Itacitinib Placebo",{"nctId":3224,"briefTitle":3225,"status":283,"phases":3226,"primaryCompletion":427,"completion":3227,"start":3228,"enrollment":28,"conditions":3229,"interventions":3230},"NCT02257619","Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer",[87],"2016-04-05","2014-09-24",[542],[422,3231],"docetaxel",{"nctId":3233,"briefTitle":3234,"status":102,"phases":3235,"primaryCompletion":3236,"completion":3236,"start":3237,"enrollment":12,"conditions":3238,"interventions":3240},"NCT04629508","To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and\u002For Fedratinib Monotherapy (LIMBER-213)",[87],"2023-08-24","2021-07-12",[303,409,3239],"Thrombocythemia",[2148],{"nctId":3242,"briefTitle":3243,"status":934,"phases":3244,"primaryCompletion":3245,"completion":3245,"start":3246,"enrollment":96,"conditions":3247,"interventions":3249},"NCT03627052","A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis",[87],"2019-11-13","2018-09-20",[3248],"Moderate to Severe Ulcerative Colitis",[422],{"nctId":3251,"briefTitle":3252,"status":216,"phases":3253,"primaryCompletion":3254,"completion":3254,"start":3255,"enrollment":136,"conditions":3256,"interventions":3259},"NCT04640025","A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib",[87],"2026-06-22","2021-03-10",[303,3257,3258],"Postlung Transplant (Bronchiolitis Obliterans)","Chronic Graft Versus Host Disease",[2148],{"nctId":3261,"briefTitle":3262,"status":102,"phases":3263,"primaryCompletion":3264,"completion":3265,"start":3266,"enrollment":3267,"conditions":3268,"interventions":3269},"NCT01633372","An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis",[87],"2013-12-31","2021-06-29","2012-07-16",87,[30],[2148],{"nctId":3271,"briefTitle":3272,"status":934,"phases":3273,"primaryCompletion":285,"completion":285,"start":3274,"enrollment":96,"conditions":3275,"interventions":3277},"NCT02355431","Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations",[87],"2014-12",[3276,542],"Solid Tumors and Hematologic Malignancy",[422,3278],"erlotinib",{"nctId":3280,"briefTitle":3281,"status":102,"phases":3282,"primaryCompletion":3283,"completion":3283,"start":3284,"enrollment":3285,"conditions":3286,"interventions":3287},"NCT02760485","A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[86,87],"2022-06-06","2016-12-29",33,[32],[2148,3288],"ibrutinib",{"nctId":3290,"briefTitle":3291,"status":283,"phases":3292,"primaryCompletion":3293,"completion":3293,"start":3294,"enrollment":419,"conditions":3295,"interventions":3297},"NCT03978637","Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation",[86,87],"2023-10-13","2020-02-04",[3296],"Bronchiolitis Obliterans Syndrome",[422],{"nctId":3299,"briefTitle":3300,"status":102,"phases":3301,"primaryCompletion":3302,"completion":3302,"start":3303,"enrollment":8,"conditions":3304,"interventions":3305},"NCT02917993","An Open-Label Phase 1\u002F2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer",[86,87],"2025-12-24","2016-12-20",[24],[422,3306],"Osimertinib",{"nctId":3308,"briefTitle":3309,"status":283,"phases":3310,"primaryCompletion":3311,"completion":3311,"start":3312,"enrollment":1198,"conditions":3313,"interventions":3316},"NCT02456675","INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed\u002FRefractory Hodgkin Lymphoma",[87],"2016-12-16","2015-06",[3314,3315],"Refractory Hodgkin Lymphoma","Recurrent Adult Hodgkin's Lymphoma",[3317,3318,2148],"INCB040093 Monotherapy","INCB040093",{"nctId":1939,"briefTitle":1940,"status":283,"phases":3320,"primaryCompletion":1942,"completion":1942,"start":300,"enrollment":194,"conditions":3321,"interventions":3322},[86,87],[1944],[422,532],{"nctId":1800,"briefTitle":1801,"status":102,"phases":3324,"primaryCompletion":1803,"completion":1803,"start":1804,"enrollment":1805,"conditions":3325,"interventions":3326},[86,87],[1807],[399,422,627,1809,1466,1595],{"trials":3328,"activeCount":96},[3329,3333],{"nctId":2220,"briefTitle":2221,"status":283,"phases":3330,"primaryCompletion":2223,"completion":2223,"start":2224,"enrollment":2225,"conditions":3331,"interventions":3332},[87,88],[2227],[422,2229,498],{"nctId":2235,"briefTitle":2236,"status":102,"phases":3334,"primaryCompletion":2238,"completion":1748,"start":2239,"enrollment":2240,"conditions":3335,"interventions":3336},[88],[476],[422,498,2229],{"trials":3338,"activeCount":96},[],{"trials":3340,"activeCount":96},[3341],{"nctId":3342,"briefTitle":3343,"status":1603,"phases":3344,"conditions":3345,"interventions":3347},"NCT05561985","Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease",[],[3346],"STAT1 Gain-of-Function Disease",[422],{"intervention":1524,"totalTrials":3172,"cells":3349},{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3363,"PHASE3":3443,"PHASE4":3449,"NA":3451},{"trials":3351,"activeCount":96},[],{"trials":3353,"activeCount":96},[3354],{"nctId":3355,"briefTitle":3356,"status":102,"phases":3357,"primaryCompletion":3358,"completion":3358,"start":3359,"enrollment":3360,"conditions":3361,"interventions":3362},"NCT03235570","A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)",[86],"2020-03-04","2017-08-01",44,[15],[1524],{"trials":3364,"activeCount":152,"soonestReadout":72},[3365,3372,3380,3384,3388,3399,3408,3418,3422,3430,3434],{"nctId":3366,"briefTitle":3367,"status":102,"phases":3368,"primaryCompletion":645,"completion":645,"start":394,"enrollment":1198,"conditions":3369,"interventions":3371},"NCT05253807","Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration",[87],[3370],"Non-Small Cell Lung Cancer (NSCLC)",[1524],{"nctId":3373,"briefTitle":3374,"status":102,"phases":3375,"primaryCompletion":3376,"completion":3376,"start":3377,"enrollment":1022,"conditions":3378,"interventions":3379},"NCT03011372","A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid\u002FLymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)",[87],"2024-10-30","2017-04-25",[30],[1524],{"nctId":70,"briefTitle":71,"status":216,"phases":3381,"primaryCompletion":72,"completion":1498,"start":1499,"enrollment":1500,"conditions":3382,"interventions":3383},[87],[1502],[73,1493,1504,1494,1495],{"nctId":2071,"briefTitle":2072,"status":283,"phases":3385,"primaryCompletion":2074,"completion":2074,"start":2075,"enrollment":2076,"conditions":3386,"interventions":3387},[87],[2078,2079],[1524,1525,463,1466],{"nctId":3389,"briefTitle":3390,"status":283,"phases":3391,"primaryCompletion":3392,"completion":3392,"start":3393,"enrollment":152,"conditions":3394,"interventions":3398},"NCT04003623","Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)",[87],"2020-06-12","2019-10-31",[3395,3396,3397],"Advanced or Metastatic Solid Tumors","FGFR Mutations","FGFR Translocations",[1524],{"nctId":3400,"briefTitle":3401,"status":102,"phases":3402,"primaryCompletion":3403,"completion":3403,"start":3404,"enrollment":3405,"conditions":3406,"interventions":3407},"NCT02924376","Efficacy and Safety of Pemigatinib in Subjects With Advanced\u002FMetastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)",[87],"2022-02-01","2017-01-16",147,[1554],[1524],{"nctId":3409,"briefTitle":3410,"status":283,"phases":3411,"primaryCompletion":3412,"completion":3412,"start":3413,"enrollment":3414,"conditions":3415,"interventions":3417},"NCT03822117","Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced\u002FMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)",[87],"2022-03-29","2019-10-17",111,[3416],"Solid Tumor Malignancy",[1524],{"nctId":1517,"briefTitle":1518,"status":283,"phases":3419,"primaryCompletion":1520,"completion":1520,"start":1521,"enrollment":552,"conditions":3420,"interventions":3421},[87],[1310],[1524,40,1525],{"nctId":3423,"briefTitle":3424,"status":102,"phases":3425,"primaryCompletion":3403,"completion":3403,"start":3426,"enrollment":3427,"conditions":3428,"interventions":3429},"NCT02872714","A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)",[87],"2017-01-12",263,[2712],[1504,1504],{"nctId":1543,"briefTitle":1544,"status":283,"phases":3431,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":3432,"interventions":3433},[86,87],[24,1550,1551,1552,1502,1553,329,443,1554,1555,1556],[1524,463,1525,1558,1559,40,545],{"nctId":3435,"briefTitle":3436,"status":283,"phases":3437,"primaryCompletion":3438,"completion":3438,"start":3439,"enrollment":1308,"conditions":3440,"interventions":3442},"NCT05267106","Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations",[87],"2024-12-17","2022-05-20",[2788,3441],"Adult-type Diffuse Gliomas",[1524],{"trials":3444,"activeCount":96},[3445],{"nctId":2020,"briefTitle":2021,"status":283,"phases":3446,"primaryCompletion":2023,"completion":2023,"start":2024,"enrollment":2025,"conditions":3447,"interventions":3448},[88],[2027,2028],[1524,463,545],{"trials":3450,"activeCount":96},[],{"trials":3452,"activeCount":96},[3453],{"nctId":3454,"briefTitle":3455,"status":751,"phases":3456,"conditions":3457,"interventions":3458},"NCT03906357","Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer",[],[],[1524],{"intervention":531,"totalTrials":588,"cells":3460},{"EARLY_PHASE1":3461,"PHASE1":3463,"PHASE2":3474,"PHASE3":3480,"PHASE4":3482,"NA":3484},{"trials":3462,"activeCount":96},[],{"trials":3464,"activeCount":96},[3465],{"nctId":3466,"briefTitle":3467,"status":102,"phases":3468,"primaryCompletion":2463,"completion":3469,"start":3470,"enrollment":3471,"conditions":3472,"interventions":3473},"NCT06713590","A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants",[86],"2025-06-10","2025-01-14",72,[18],[531],{"trials":3475,"activeCount":152,"soonestReadout":524},[3476],{"nctId":521,"briefTitle":522,"status":216,"phases":3477,"primaryCompletion":524,"completion":525,"start":526,"enrollment":527,"conditions":3478,"interventions":3479},[87],[529],[531,129,532],{"trials":3481,"activeCount":96},[],{"trials":3483,"activeCount":96},[],{"trials":3485,"activeCount":96},[3486],{"nctId":3487,"briefTitle":3488,"status":1603,"phases":3489,"conditions":3490,"interventions":3492},"NCT05544032","Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)",[],[3491],"Chronic Graft Vs. Host Disease",[3493],"axatilimab",{"intervention":1414,"totalTrials":1123,"cells":3495},{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3517,"PHASE3":3519,"PHASE4":3529,"NA":3531},{"trials":3497,"activeCount":96},[],{"trials":3499,"activeCount":588,"soonestReadout":1408},[3500,3509,3513],{"nctId":3501,"briefTitle":3502,"status":216,"phases":3503,"primaryCompletion":3504,"completion":3504,"start":3505,"enrollment":1359,"conditions":3506,"interventions":3507},"NCT06818812","A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",[86],"2027-03-27","2025-03-27",[15],[3508,1414,1415,1416],"INCB186748",{"nctId":1405,"briefTitle":1406,"status":122,"phases":3510,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":3511,"interventions":3512},[86],[15],[1413,1414,40,1415,1416,1417,1418,1419],{"nctId":1618,"briefTitle":1619,"status":122,"phases":3514,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":3515,"interventions":3516},[86],[15,1449,1429],[1419,1626,1418,1417,1414],{"trials":3518,"activeCount":96},[],{"trials":3520,"activeCount":96},[3521,3525],{"nctId":2009,"briefTitle":2010,"status":102,"phases":3522,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":2015,"conditions":3523,"interventions":3524},[88],[2017],[1525,1440,1414,545,1466,1738],{"nctId":2039,"briefTitle":2040,"status":934,"phases":3526,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":96,"conditions":3527,"interventions":3528},[88],[2017],[1776,1440,1466,545,1414,1738],{"trials":3530,"activeCount":96},[],{"trials":3532,"activeCount":96},[],{"intervention":331,"totalTrials":588,"cells":3534},{"EARLY_PHASE1":3535,"PHASE1":3537,"PHASE2":3555,"PHASE3":3557,"PHASE4":3559,"NA":3561},{"trials":3536,"activeCount":96},[],{"trials":3538,"activeCount":588,"soonestReadout":3543},[3539,3547,3551],{"nctId":3540,"briefTitle":3541,"status":216,"phases":3542,"primaryCompletion":3543,"completion":3543,"start":3544,"enrollment":3471,"conditions":3545,"interventions":3546},"NCT07448155","A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants",[86],"2026-05-23","2026-03-19",[18],[331],{"nctId":322,"briefTitle":323,"status":122,"phases":3548,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":3549,"interventions":3550},[86],[329],[331,129],{"nctId":337,"briefTitle":323,"status":122,"phases":3552,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":3553,"interventions":3554},[86],[329],[331,129],{"trials":3556,"activeCount":96},[],{"trials":3558,"activeCount":96},[],{"trials":3560,"activeCount":96},[],{"trials":3562,"activeCount":96},[],{"intervention":3564,"totalTrials":194,"cells":3565},"Standard disease-directed therapy",{"EARLY_PHASE1":3566,"PHASE1":3568,"PHASE2":3589,"PHASE3":3591,"PHASE4":3593,"NA":3595},{"trials":3567,"activeCount":96},[],{"trials":3569,"activeCount":194,"soonestReadout":3574},[3570,3579],{"nctId":3571,"briefTitle":3572,"status":122,"phases":3573,"primaryCompletion":3574,"completion":3574,"start":3575,"enrollment":809,"conditions":3576,"interventions":3577},"NCT06313593","A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms",[86],"2028-10-09","2024-08-08",[329],[3578,3564],"INCB160058",{"nctId":3580,"briefTitle":3581,"status":122,"phases":3582,"primaryCompletion":3583,"completion":3583,"start":3584,"enrollment":3585,"conditions":3586,"interventions":3587},"NCT07441694","Study of INCA036978 in Participants With Myeloproliferative Neoplasms",[86],"2030-05-24","2026-05-11",218,[329],[3588,3564],"INCA036978",{"trials":3590,"activeCount":96},[],{"trials":3592,"activeCount":96},[],{"trials":3594,"activeCount":96},[],{"trials":3596,"activeCount":96},[],{"intervention":1415,"totalTrials":194,"cells":3598},{"EARLY_PHASE1":3599,"PHASE1":3601,"PHASE2":3611,"PHASE3":3613,"PHASE4":3615,"NA":3617},{"trials":3600,"activeCount":96},[],{"trials":3602,"activeCount":194,"soonestReadout":1408},[3603,3607],{"nctId":3501,"briefTitle":3502,"status":216,"phases":3604,"primaryCompletion":3504,"completion":3504,"start":3505,"enrollment":1359,"conditions":3605,"interventions":3606},[86],[15],[3508,1414,1415,1416],{"nctId":1405,"briefTitle":1406,"status":122,"phases":3608,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":3609,"interventions":3610},[86],[15],[1413,1414,40,1415,1416,1417,1418,1419],{"trials":3612,"activeCount":96},[],{"trials":3614,"activeCount":96},[],{"trials":3616,"activeCount":96},[],{"trials":3618,"activeCount":96},[],{"intervention":1416,"totalTrials":194,"cells":3620},{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3633,"PHASE3":3635,"PHASE4":3637,"NA":3639},{"trials":3622,"activeCount":96},[],{"trials":3624,"activeCount":194,"soonestReadout":1408},[3625,3629],{"nctId":3501,"briefTitle":3502,"status":216,"phases":3626,"primaryCompletion":3504,"completion":3504,"start":3505,"enrollment":1359,"conditions":3627,"interventions":3628},[86],[15],[3508,1414,1415,1416],{"nctId":1405,"briefTitle":1406,"status":122,"phases":3630,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":3631,"interventions":3632},[86],[15],[1413,1414,40,1415,1416,1417,1418,1419],{"trials":3634,"activeCount":96},[],{"trials":3636,"activeCount":96},[],{"trials":3638,"activeCount":96},[],{"trials":3640,"activeCount":96},[],{"intervention":1418,"totalTrials":194,"cells":3642},{"EARLY_PHASE1":3643,"PHASE1":3645,"PHASE2":3655,"PHASE3":3657,"PHASE4":3659,"NA":3661},{"trials":3644,"activeCount":96},[],{"trials":3646,"activeCount":194,"soonestReadout":1408},[3647,3651],{"nctId":1405,"briefTitle":1406,"status":122,"phases":3648,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":3649,"interventions":3650},[86],[15],[1413,1414,40,1415,1416,1417,1418,1419],{"nctId":1618,"briefTitle":1619,"status":122,"phases":3652,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":3653,"interventions":3654},[86],[15,1449,1429],[1419,1626,1418,1417,1414],{"trials":3656,"activeCount":96},[],{"trials":3658,"activeCount":96},[],{"trials":3660,"activeCount":96},[],{"trials":3662,"activeCount":96},[],{"intervention":320,"totalTrials":12,"cells":3664},{"EARLY_PHASE1":3665,"PHASE1":3667,"PHASE2":3682,"PHASE3":3692,"PHASE4":3694,"NA":3696},{"trials":3666,"activeCount":96},[],{"trials":3668,"activeCount":152,"soonestReadout":309},[3669,3673],{"nctId":306,"briefTitle":307,"status":216,"phases":3670,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":3671,"interventions":3672},[86],[303,313,314,315,316,317,318],[320,129],{"nctId":3674,"briefTitle":3675,"status":102,"phases":3676,"primaryCompletion":3677,"completion":3677,"start":3678,"enrollment":2495,"conditions":3679,"interventions":3681},"NCT06941077","A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants",[86],"2025-06-03","2025-05-12",[3680],"Healthy Volunteers",[320],{"trials":3683,"activeCount":96},[3684,3688],{"nctId":455,"briefTitle":456,"status":283,"phases":3685,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":3686,"interventions":3687},[86,87],[15],[320,463,464,465,466,129,467],{"nctId":2792,"briefTitle":2793,"status":283,"phases":3689,"primaryCompletion":2795,"completion":2796,"start":2797,"enrollment":1750,"conditions":3690,"interventions":3691},[86,87],[15,1310,1311],[467,1525,1440,320,1525,1440,2800],{"trials":3693,"activeCount":96},[],{"trials":3695,"activeCount":96},[],{"trials":3697,"activeCount":96},[],{"intervention":3578,"totalTrials":194,"cells":3699},{"EARLY_PHASE1":3700,"PHASE1":3702,"PHASE2":3715,"PHASE3":3717,"PHASE4":3719,"NA":3721},{"trials":3701,"activeCount":96},[],{"trials":3703,"activeCount":152,"soonestReadout":3574},[3704,3708],{"nctId":3571,"briefTitle":3572,"status":122,"phases":3705,"primaryCompletion":3574,"completion":3574,"start":3575,"enrollment":809,"conditions":3706,"interventions":3707},[86],[329],[3578,3564],{"nctId":3709,"briefTitle":3710,"status":102,"phases":3711,"primaryCompletion":3712,"completion":3712,"start":818,"enrollment":460,"conditions":3713,"interventions":3714},"NCT06213818","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant",[86],"2025-08-19",[18],[3578,1906,1907],{"trials":3716,"activeCount":96},[],{"trials":3718,"activeCount":96},[],{"trials":3720,"activeCount":96},[],{"trials":3722,"activeCount":96},[],{"intervention":1904,"totalTrials":194,"cells":3724},{"EARLY_PHASE1":3725,"PHASE1":3727,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3743},{"trials":3726,"activeCount":96},[],{"trials":3728,"activeCount":152,"soonestReadout":82},[3729,3733],{"nctId":1896,"briefTitle":1897,"status":102,"phases":3730,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":1901,"conditions":3731,"interventions":3732},[86],[18],[1413,1904,1905,1906,1907],{"nctId":80,"briefTitle":81,"status":122,"phases":3734,"primaryCompletion":82,"completion":82,"start":1146,"enrollment":1147,"conditions":3735,"interventions":3736},[86],[18],[83,1150,1151],{"trials":3738,"activeCount":96},[],{"trials":3740,"activeCount":96},[],{"trials":3742,"activeCount":96},[],{"trials":3744,"activeCount":96},[],{"intervention":3746,"totalTrials":152,"cells":3747},"INCA036873",{"EARLY_PHASE1":3748,"PHASE1":3750,"PHASE2":3761,"PHASE3":3763,"PHASE4":3765,"NA":3767},{"trials":3749,"activeCount":96},[],{"trials":3751,"activeCount":152,"soonestReadout":3756},[3752],{"nctId":3753,"briefTitle":3754,"status":122,"phases":3755,"primaryCompletion":3756,"completion":3756,"start":3757,"enrollment":3758,"conditions":3759,"interventions":3760},"NCT07195916","A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies",[86],"2028-08-18","2026-01-08",280,[15,1224],[3746],{"trials":3762,"activeCount":96},[],{"trials":3764,"activeCount":96},[],{"trials":3766,"activeCount":96},[],{"trials":3768,"activeCount":96},[],{"intervention":3508,"totalTrials":152,"cells":3770},{"EARLY_PHASE1":3771,"PHASE1":3773,"PHASE2":3779,"PHASE3":3781,"PHASE4":3783,"NA":3785},{"trials":3772,"activeCount":96},[],{"trials":3774,"activeCount":152,"soonestReadout":3504},[3775],{"nctId":3501,"briefTitle":3502,"status":216,"phases":3776,"primaryCompletion":3504,"completion":3504,"start":3505,"enrollment":1359,"conditions":3777,"interventions":3778},[86],[15],[3508,1414,1415,1416],{"trials":3780,"activeCount":96},[],{"trials":3782,"activeCount":96},[],{"trials":3784,"activeCount":96},[],{"trials":3786,"activeCount":96},[],{"intervention":1662,"totalTrials":152,"cells":3788},{"EARLY_PHASE1":3789,"PHASE1":3791,"PHASE2":3797,"PHASE3":3799,"PHASE4":3801,"NA":3803},{"trials":3790,"activeCount":96},[],{"trials":3792,"activeCount":152,"soonestReadout":1656},[3793],{"nctId":1653,"briefTitle":1654,"status":122,"phases":3794,"primaryCompletion":1656,"completion":1657,"start":1658,"enrollment":1659,"conditions":3795,"interventions":3796},[86],[15],[1662,1663,1641,1664,464,1665,1666],{"trials":3798,"activeCount":96},[],{"trials":3800,"activeCount":96},[],{"trials":3802,"activeCount":96},[],{"trials":3804,"activeCount":96},[],{"intervention":1663,"totalTrials":152,"cells":3806},{"EARLY_PHASE1":3807,"PHASE1":3809,"PHASE2":3815,"PHASE3":3817,"PHASE4":3819,"NA":3821},{"trials":3808,"activeCount":96},[],{"trials":3810,"activeCount":152,"soonestReadout":1656},[3811],{"nctId":1653,"briefTitle":1654,"status":122,"phases":3812,"primaryCompletion":1656,"completion":1657,"start":1658,"enrollment":1659,"conditions":3813,"interventions":3814},[86],[15],[1662,1663,1641,1664,464,1665,1666],{"trials":3816,"activeCount":96},[],{"trials":3818,"activeCount":96},[],{"trials":3820,"activeCount":96},[],{"trials":3822,"activeCount":96},[],{"intervention":1664,"totalTrials":152,"cells":3824},{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3833,"PHASE3":3835,"PHASE4":3837,"NA":3839},{"trials":3826,"activeCount":96},[],{"trials":3828,"activeCount":152,"soonestReadout":1656},[3829],{"nctId":1653,"briefTitle":1654,"status":122,"phases":3830,"primaryCompletion":1656,"completion":1657,"start":1658,"enrollment":1659,"conditions":3831,"interventions":3832},[86],[15],[1662,1663,1641,1664,464,1665,1666],{"trials":3834,"activeCount":96},[],{"trials":3836,"activeCount":96},[],{"trials":3838,"activeCount":96},[],{"trials":3840,"activeCount":96},[],{"intervention":1665,"totalTrials":152,"cells":3842},{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3851,"PHASE3":3853,"PHASE4":3855,"NA":3857},{"trials":3844,"activeCount":96},[],{"trials":3846,"activeCount":152,"soonestReadout":1656},[3847],{"nctId":1653,"briefTitle":1654,"status":122,"phases":3848,"primaryCompletion":1656,"completion":1657,"start":1658,"enrollment":1659,"conditions":3849,"interventions":3850},[86],[15],[1662,1663,1641,1664,464,1665,1666],{"trials":3852,"activeCount":96},[],{"trials":3854,"activeCount":96},[],{"trials":3856,"activeCount":96},[],{"trials":3858,"activeCount":96},[],{"intervention":1666,"totalTrials":152,"cells":3860},{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3869,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3862,"activeCount":96},[],{"trials":3864,"activeCount":152,"soonestReadout":1656},[3865],{"nctId":1653,"briefTitle":1654,"status":122,"phases":3866,"primaryCompletion":1656,"completion":1657,"start":1658,"enrollment":1659,"conditions":3867,"interventions":3868},[86],[15],[1662,1663,1641,1664,464,1665,1666],{"trials":3870,"activeCount":96},[],{"trials":3872,"activeCount":96},[],{"trials":3874,"activeCount":96},[],{"trials":3876,"activeCount":96},[],{"intervention":3878,"totalTrials":152,"cells":3879},"INCA035784",{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3894,"PHASE3":3896,"PHASE4":3898,"NA":3900},{"trials":3881,"activeCount":96},[],{"trials":3883,"activeCount":152,"soonestReadout":3888},[3884],{"nctId":3885,"briefTitle":3886,"status":122,"phases":3887,"primaryCompletion":3888,"completion":3889,"start":3890,"enrollment":3891,"conditions":3892,"interventions":3893},"NCT07008118","A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms",[86],"2028-03-14","2029-12-14","2025-10-01",120,[329],[3878],{"trials":3895,"activeCount":96},[],{"trials":3897,"activeCount":96},[],{"trials":3899,"activeCount":96},[],{"trials":3901,"activeCount":96},[],{"intervention":1151,"totalTrials":152,"cells":3903},{"EARLY_PHASE1":3904,"PHASE1":3906,"PHASE2":3912,"PHASE3":3914,"PHASE4":3916,"NA":3918},{"trials":3905,"activeCount":96},[],{"trials":3907,"activeCount":152,"soonestReadout":82},[3908],{"nctId":80,"briefTitle":81,"status":122,"phases":3909,"primaryCompletion":82,"completion":82,"start":1146,"enrollment":1147,"conditions":3910,"interventions":3911},[86],[18],[83,1150,1151],{"trials":3913,"activeCount":96},[],{"trials":3915,"activeCount":96},[],{"trials":3917,"activeCount":96},[],{"trials":3919,"activeCount":96},[],{"intervention":3588,"totalTrials":152,"cells":3921},{"EARLY_PHASE1":3922,"PHASE1":3924,"PHASE2":3930,"PHASE3":3932,"PHASE4":3934,"NA":3936},{"trials":3923,"activeCount":96},[],{"trials":3925,"activeCount":152,"soonestReadout":3583},[3926],{"nctId":3580,"briefTitle":3581,"status":122,"phases":3927,"primaryCompletion":3583,"completion":3583,"start":3584,"enrollment":3585,"conditions":3928,"interventions":3929},[86],[329],[3588,3564],{"trials":3931,"activeCount":96},[],{"trials":3933,"activeCount":96},[],{"trials":3935,"activeCount":96},[],{"trials":3937,"activeCount":96},[],{"intervention":1038,"totalTrials":152,"cells":3939},{"EARLY_PHASE1":3940,"PHASE1":3942,"PHASE2":3944,"PHASE3":3946,"PHASE4":3948,"NA":3950},{"trials":3941,"activeCount":96},[],{"trials":3943,"activeCount":96},[],{"trials":3945,"activeCount":96},[],{"trials":3947,"activeCount":96},[],{"trials":3949,"activeCount":96},[],{"trials":3951,"activeCount":152,"soonestReadout":1031},[3952],{"nctId":1028,"briefTitle":1029,"status":122,"phases":3953,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":3954,"interventions":3955},[],[1036,21],[780,1038],{"intervention":1525,"totalTrials":3172,"cells":3957},{"EARLY_PHASE1":3958,"PHASE1":3960,"PHASE2":3977,"PHASE3":4011,"PHASE4":4029,"NA":4031},{"trials":3959,"activeCount":96},[],{"trials":3961,"activeCount":96},[3962,3966],{"nctId":3135,"briefTitle":3136,"status":102,"phases":3963,"primaryCompletion":3138,"completion":3139,"start":3140,"enrollment":3141,"conditions":3964,"interventions":3965},[86],[554,1502,27,2017,24,3143,443,290,2834,15,2712],[1525,2148,1319],{"nctId":3967,"briefTitle":3968,"status":102,"phases":3969,"primaryCompletion":3970,"completion":3971,"start":3972,"enrollment":3973,"conditions":3974,"interventions":3976},"NCT02903914","Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced\u002FMetastatic Solid Tumors",[86],"2020-04-30","2022-08-15","2016-09-14",260,[1311,15,554,1551,2017,24,2834,3975,2712,2435],"Bladder Cancer",[1735,1525],{"trials":3978,"activeCount":96},[3979,3983,3987,3991,3995,3999,4003,4007],{"nctId":2722,"briefTitle":2723,"status":102,"phases":3980,"primaryCompletion":2725,"completion":2726,"start":2727,"enrollment":2728,"conditions":3981,"interventions":3982},[87],[24],[1525,1440,2731],{"nctId":2733,"briefTitle":2734,"status":283,"phases":3984,"primaryCompletion":2736,"completion":2736,"start":2737,"enrollment":1123,"conditions":3985,"interventions":3986},[86,87],[15],[1735,1440,1525],{"nctId":2751,"briefTitle":2752,"status":102,"phases":3988,"primaryCompletion":2754,"completion":1010,"start":2043,"enrollment":407,"conditions":3989,"interventions":3990},[87],[24],[1525,1440],{"nctId":1744,"briefTitle":1745,"status":102,"phases":3992,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":3993,"interventions":3994},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"nctId":2071,"briefTitle":2072,"status":283,"phases":3996,"primaryCompletion":2074,"completion":2074,"start":2075,"enrollment":2076,"conditions":3997,"interventions":3998},[87],[2078,2079],[1524,1525,463,1466],{"nctId":2792,"briefTitle":2793,"status":283,"phases":4000,"primaryCompletion":2795,"completion":2796,"start":2797,"enrollment":1750,"conditions":4001,"interventions":4002},[86,87],[15,1310,1311],[467,1525,1440,320,1525,1440,2800],{"nctId":1517,"briefTitle":1518,"status":283,"phases":4004,"primaryCompletion":1520,"completion":1520,"start":1521,"enrollment":552,"conditions":4005,"interventions":4006},[87],[1310],[1524,40,1525],{"nctId":1543,"briefTitle":1544,"status":283,"phases":4008,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":4009,"interventions":4010},[86,87],[24,1550,1551,1552,1502,1553,329,443,1554,1555,1556],[1524,463,1525,1558,1559,40,545],{"trials":4012,"activeCount":96},[4013,4017,4021,4025],{"nctId":2814,"briefTitle":2815,"status":102,"phases":4014,"primaryCompletion":2817,"completion":2818,"start":2819,"enrollment":350,"conditions":4015,"interventions":4016},[88],[2712],[1525,1440],{"nctId":2009,"briefTitle":2010,"status":102,"phases":4018,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":2015,"conditions":4019,"interventions":4020},[88],[2017],[1525,1440,1414,545,1466,1738],{"nctId":2827,"briefTitle":2828,"status":102,"phases":4022,"primaryCompletion":2830,"completion":1380,"start":2831,"enrollment":2832,"conditions":4023,"interventions":4024},[88],[2834],[1525,1440,2836,2837],{"nctId":2839,"briefTitle":2840,"status":102,"phases":4026,"primaryCompletion":2842,"completion":2843,"start":2844,"enrollment":2845,"conditions":4027,"interventions":4028},[88],[2712],[1525,1440],{"trials":4030,"activeCount":96},[],{"trials":4032,"activeCount":96},[],{"intervention":463,"totalTrials":584,"cells":4034},{"EARLY_PHASE1":4035,"PHASE1":4037,"PHASE2":4051,"PHASE3":4081,"PHASE4":4091,"NA":4093},{"trials":4036,"activeCount":96},[],{"trials":4038,"activeCount":96},[4039,4043,4047],{"nctId":281,"briefTitle":282,"status":283,"phases":4040,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":4041,"interventions":4042},[86],[15,290],[292,293,294,295],{"nctId":2126,"briefTitle":2127,"status":283,"phases":4044,"primaryCompletion":2129,"completion":2129,"start":2130,"enrollment":1123,"conditions":4045,"interventions":4046},[86],[1550,2132,2133,290,443,2134,2135,1311],[2137,2137,463,294],{"nctId":1456,"briefTitle":1457,"status":934,"phases":4048,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":96,"conditions":4049,"interventions":4050},[86],[1462,1463,1464],[40,463,545,544,1466,464],{"trials":4052,"activeCount":96},[4053,4057,4061,4065,4069,4073,4077],{"nctId":2141,"briefTitle":2142,"status":102,"phases":4054,"primaryCompletion":427,"completion":2144,"start":360,"enrollment":2145,"conditions":4055,"interventions":4056},[86,87],[15,290],[2148,463,294,295],{"nctId":1303,"briefTitle":1304,"status":283,"phases":4058,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":4059,"interventions":4060},[86,87],[15,1310,1311],[1313,293,294,1314,1315,1316,1280,1317,1313,1318,1319,1320],{"nctId":1726,"briefTitle":1727,"status":102,"phases":4062,"primaryCompletion":1729,"completion":1729,"start":1730,"enrollment":441,"conditions":4063,"interventions":4064},[86,87],[1732,554,1502,1733,34,15],[1735,1736,1737,1738,463,545,464],{"nctId":455,"briefTitle":456,"status":283,"phases":4066,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":4067,"interventions":4068},[86,87],[15],[320,463,464,465,466,129,467],{"nctId":1744,"briefTitle":1745,"status":102,"phases":4070,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":4071,"interventions":4072},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"nctId":2071,"briefTitle":2072,"status":283,"phases":4074,"primaryCompletion":2074,"completion":2074,"start":2075,"enrollment":2076,"conditions":4075,"interventions":4076},[87],[2078,2079],[1524,1525,463,1466],{"nctId":1543,"briefTitle":1544,"status":283,"phases":4078,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":4079,"interventions":4080},[86,87],[24,1550,1551,1552,1502,1553,329,443,1554,1555,1556],[1524,463,1525,1558,1559,40,545],{"trials":4082,"activeCount":96},[4083,4087],{"nctId":2020,"briefTitle":2021,"status":283,"phases":4084,"primaryCompletion":2023,"completion":2023,"start":2024,"enrollment":2025,"conditions":4085,"interventions":4086},[88],[2027,2028],[1524,463,545],{"nctId":1769,"briefTitle":1770,"status":283,"phases":4088,"primaryCompletion":1772,"completion":1772,"start":1773,"enrollment":194,"conditions":4089,"interventions":4090},[88],[24],[1776,1440,1466,545,463,464,544],{"trials":4092,"activeCount":96},[],{"trials":4094,"activeCount":96},[],{"intervention":693,"totalTrials":2076,"cells":4096},{"EARLY_PHASE1":4097,"PHASE1":4099,"PHASE2":4101,"PHASE3":4111,"PHASE4":4133,"NA":4135},{"trials":4098,"activeCount":96},[],{"trials":4100,"activeCount":96},[],{"trials":4102,"activeCount":96},[4103,4107],{"nctId":804,"briefTitle":805,"status":102,"phases":4104,"primaryCompletion":807,"completion":808,"start":161,"enrollment":809,"conditions":4105,"interventions":4106},[87],[811],[756,693],{"nctId":860,"briefTitle":861,"status":102,"phases":4108,"primaryCompletion":725,"completion":863,"start":864,"enrollment":865,"conditions":4109,"interventions":4110},[87],[21],[756,693],{"trials":4112,"activeCount":96},[4113,4117,4121,4125,4129],{"nctId":893,"briefTitle":894,"status":102,"phases":4114,"primaryCompletion":896,"completion":897,"start":898,"enrollment":619,"conditions":4115,"interventions":4116},[88],[900],[756,693],{"nctId":912,"briefTitle":913,"status":102,"phases":4118,"primaryCompletion":915,"completion":916,"start":917,"enrollment":918,"conditions":4119,"interventions":4120},[88],[900],[756,693],{"nctId":932,"briefTitle":933,"status":934,"phases":4122,"primaryCompletion":936,"completion":937,"start":938,"enrollment":96,"conditions":4123,"interventions":4124},[88],[811],[756,693],{"nctId":684,"briefTitle":685,"status":102,"phases":4126,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":4127,"interventions":4128},[88],[691],[292,693],{"nctId":992,"briefTitle":993,"status":934,"phases":4130,"primaryCompletion":936,"completion":937,"start":938,"enrollment":96,"conditions":4131,"interventions":4132},[88],[996],[756,693],{"trials":4134,"activeCount":96},[],{"trials":4136,"activeCount":96},[],{"intervention":1776,"totalTrials":1123,"cells":4138},{"EARLY_PHASE1":4139,"PHASE1":4141,"PHASE2":4143,"PHASE3":4164,"PHASE4":4174,"NA":4176},{"trials":4140,"activeCount":96},[],{"trials":4142,"activeCount":96},[],{"trials":4144,"activeCount":96},[4145,4149,4160],{"nctId":2766,"briefTitle":2767,"status":283,"phases":4146,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":25,"conditions":4147,"interventions":4148},[86,87],[15],[1440,1776,2773,2774],{"nctId":4150,"briefTitle":4151,"status":283,"phases":4152,"primaryCompletion":4153,"completion":4153,"start":4154,"enrollment":4155,"conditions":4156,"interventions":4157},"NCT02712905","An Open-Label, Dose-Escalation\u002FDose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies",[86,87],"2022-04-14","2016-05-05",116,[3276],[2800,4158,1317,4159],"all-trans retinoic acid","nivolumab",{"nctId":2780,"briefTitle":2781,"status":102,"phases":4161,"primaryCompletion":2783,"completion":2783,"start":2784,"enrollment":2785,"conditions":4162,"interventions":4163},[86,87],[2787,554,2017,24,32,27,34,2788],[1776,1440,2790],{"trials":4165,"activeCount":96},[4166,4170],{"nctId":2039,"briefTitle":2040,"status":934,"phases":4167,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":96,"conditions":4168,"interventions":4169},[88],[2017],[1776,1440,1466,545,1414,1738],{"nctId":1769,"briefTitle":1770,"status":283,"phases":4171,"primaryCompletion":1772,"completion":1772,"start":1773,"enrollment":194,"conditions":4172,"interventions":4173},[88],[24],[1776,1440,1466,545,463,464,544],{"trials":4175,"activeCount":96},[],{"trials":4177,"activeCount":96},[],{"intervention":1738,"totalTrials":12,"cells":4179},{"EARLY_PHASE1":4180,"PHASE1":4182,"PHASE2":4184,"PHASE3":4194,"PHASE4":4204,"NA":4206},{"trials":4181,"activeCount":96},[],{"trials":4183,"activeCount":96},[],{"trials":4185,"activeCount":96},[4186,4190],{"nctId":1726,"briefTitle":1727,"status":102,"phases":4187,"primaryCompletion":1729,"completion":1729,"start":1730,"enrollment":441,"conditions":4188,"interventions":4189},[86,87],[1732,554,1502,1733,34,15],[1735,1736,1737,1738,463,545,464],{"nctId":1744,"briefTitle":1745,"status":102,"phases":4191,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":4192,"interventions":4193},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"trials":4195,"activeCount":96},[4196,4200],{"nctId":2009,"briefTitle":2010,"status":102,"phases":4197,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":2015,"conditions":4198,"interventions":4199},[88],[2017],[1525,1440,1414,545,1466,1738],{"nctId":2039,"briefTitle":2040,"status":934,"phases":4201,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":96,"conditions":4202,"interventions":4203},[88],[2017],[1776,1440,1466,545,1414,1738],{"trials":4205,"activeCount":96},[],{"trials":4207,"activeCount":96},[],{"intervention":1269,"totalTrials":588,"cells":4209},{"EARLY_PHASE1":4210,"PHASE1":4212,"PHASE2":4218,"PHASE3":4220,"PHASE4":4230,"NA":4232},{"trials":4211,"activeCount":96},[],{"trials":4213,"activeCount":96},[4214],{"nctId":1788,"briefTitle":1789,"status":102,"phases":4215,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":1793,"conditions":4216,"interventions":4217},[86],[1795],[399,627,1269,630],{"trials":4219,"activeCount":96},[],{"trials":4221,"activeCount":96},[4222,4226],{"nctId":1261,"briefTitle":1262,"status":102,"phases":4223,"primaryCompletion":1264,"completion":1264,"start":1265,"enrollment":1266,"conditions":4224,"interventions":4225},[87,88],[1255],[627,50,1269],{"nctId":1841,"briefTitle":1842,"status":934,"phases":4227,"primaryCompletion":1844,"completion":1845,"start":1846,"enrollment":96,"conditions":4228,"interventions":4229},[88],[1848],[653,1279,1850],{"trials":4231,"activeCount":96},[],{"trials":4233,"activeCount":96},[],{"intervention":630,"totalTrials":588,"cells":4235},{"EARLY_PHASE1":4236,"PHASE1":4238,"PHASE2":4244,"PHASE3":4250,"PHASE4":4256,"NA":4258},{"trials":4237,"activeCount":96},[],{"trials":4239,"activeCount":96},[4240],{"nctId":1788,"briefTitle":1789,"status":102,"phases":4241,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":1793,"conditions":4242,"interventions":4243},[86],[1795],[399,627,1269,630],{"trials":4245,"activeCount":96},[4246],{"nctId":3280,"briefTitle":3281,"status":102,"phases":4247,"primaryCompletion":3283,"completion":3283,"start":3284,"enrollment":3285,"conditions":4248,"interventions":4249},[86,87],[32],[2148,3288],{"trials":4251,"activeCount":96},[4252],{"nctId":613,"briefTitle":614,"status":102,"phases":4253,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":4254,"interventions":4255},[88],[476],[129,622,623,624,625,626,627,628,629,630],{"trials":4257,"activeCount":96},[],{"trials":4259,"activeCount":96},[],{"intervention":2229,"totalTrials":194,"cells":4261},{"EARLY_PHASE1":4262,"PHASE1":4264,"PHASE2":4266,"PHASE3":4268,"PHASE4":4278,"NA":4280},{"trials":4263,"activeCount":96},[],{"trials":4265,"activeCount":96},[],{"trials":4267,"activeCount":96},[],{"trials":4269,"activeCount":96},[4270,4274],{"nctId":2220,"briefTitle":2221,"status":283,"phases":4271,"primaryCompletion":2223,"completion":2223,"start":2224,"enrollment":2225,"conditions":4272,"interventions":4273},[87,88],[2227],[422,2229,498],{"nctId":2235,"briefTitle":2236,"status":102,"phases":4275,"primaryCompletion":2238,"completion":1748,"start":2239,"enrollment":2240,"conditions":4276,"interventions":4277},[88],[476],[422,498,2229],{"trials":4279,"activeCount":96},[],{"trials":4281,"activeCount":96},[],{"intervention":1595,"totalTrials":194,"cells":4283},{"EARLY_PHASE1":4284,"PHASE1":4286,"PHASE2":4288,"PHASE3":4294,"PHASE4":4300,"NA":4302},{"trials":4285,"activeCount":96},[],{"trials":4287,"activeCount":96},[],{"trials":4289,"activeCount":96},[4290],{"nctId":1800,"briefTitle":1801,"status":102,"phases":4291,"primaryCompletion":1803,"completion":1803,"start":1804,"enrollment":1805,"conditions":4292,"interventions":4293},[86,87],[1807],[399,422,627,1809,1466,1595],{"trials":4295,"activeCount":96},[4296],{"nctId":1586,"briefTitle":1587,"status":934,"phases":4297,"primaryCompletion":1589,"completion":1590,"start":1591,"enrollment":96,"conditions":4298,"interventions":4299},[88],[1593],[40,544,545,1466,464,1595],{"trials":4301,"activeCount":96},[],{"trials":4303,"activeCount":96},[],{"intervention":1823,"totalTrials":152,"cells":4305},{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4310,"PHASE3":4312,"PHASE4":4318,"NA":4320},{"trials":4307,"activeCount":96},[],{"trials":4309,"activeCount":96},[],{"trials":4311,"activeCount":96},[],{"trials":4313,"activeCount":96},[4314],{"nctId":1813,"briefTitle":1814,"status":934,"phases":4315,"primaryCompletion":1816,"completion":1817,"start":1818,"enrollment":96,"conditions":4316,"interventions":4317},[88],[1820,1821],[653,1279,1823],{"trials":4319,"activeCount":96},[],{"trials":4321,"activeCount":96},[],{"intervention":609,"totalTrials":152,"cells":4323},{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4328,"PHASE3":4330,"PHASE4":4336,"NA":4338},{"trials":4325,"activeCount":96},[],{"trials":4327,"activeCount":96},[],{"trials":4329,"activeCount":96},[],{"trials":4331,"activeCount":96},[4332],{"nctId":601,"briefTitle":602,"status":102,"phases":4333,"primaryCompletion":429,"completion":604,"start":605,"enrollment":606,"conditions":4334,"interventions":4335},[88],[409],[129,609,610,611],{"trials":4337,"activeCount":96},[],{"trials":4339,"activeCount":96},[],{"intervention":610,"totalTrials":152,"cells":4341},{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4346,"PHASE3":4348,"PHASE4":4354,"NA":4356},{"trials":4343,"activeCount":96},[],{"trials":4345,"activeCount":96},[],{"trials":4347,"activeCount":96},[],{"trials":4349,"activeCount":96},[4350],{"nctId":601,"briefTitle":602,"status":102,"phases":4351,"primaryCompletion":429,"completion":604,"start":605,"enrollment":606,"conditions":4352,"interventions":4353},[88],[409],[129,609,610,611],{"trials":4355,"activeCount":96},[],{"trials":4357,"activeCount":96},[],{"intervention":611,"totalTrials":152,"cells":4359},{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4364,"PHASE3":4366,"PHASE4":4372,"NA":4374},{"trials":4361,"activeCount":96},[],{"trials":4363,"activeCount":96},[],{"trials":4365,"activeCount":96},[],{"trials":4367,"activeCount":96},[4368],{"nctId":601,"briefTitle":602,"status":102,"phases":4369,"primaryCompletion":429,"completion":604,"start":605,"enrollment":606,"conditions":4370,"interventions":4371},[88],[409],[129,609,610,611],{"trials":4373,"activeCount":96},[],{"trials":4375,"activeCount":96},[],{"intervention":622,"totalTrials":152,"cells":4377},{"EARLY_PHASE1":4378,"PHASE1":4380,"PHASE2":4382,"PHASE3":4384,"PHASE4":4390,"NA":4392},{"trials":4379,"activeCount":96},[],{"trials":4381,"activeCount":96},[],{"trials":4383,"activeCount":96},[],{"trials":4385,"activeCount":96},[4386],{"nctId":613,"briefTitle":614,"status":102,"phases":4387,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":4388,"interventions":4389},[88],[476],[129,622,623,624,625,626,627,628,629,630],{"trials":4391,"activeCount":96},[],{"trials":4393,"activeCount":96},[],{"intervention":623,"totalTrials":152,"cells":4395},{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4400,"PHASE3":4402,"PHASE4":4408,"NA":4410},{"trials":4397,"activeCount":96},[],{"trials":4399,"activeCount":96},[],{"trials":4401,"activeCount":96},[],{"trials":4403,"activeCount":96},[4404],{"nctId":613,"briefTitle":614,"status":102,"phases":4405,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":4406,"interventions":4407},[88],[476],[129,622,623,624,625,626,627,628,629,630],{"trials":4409,"activeCount":96},[],{"trials":4411,"activeCount":96},[],{"intervention":625,"totalTrials":152,"cells":4413},{"EARLY_PHASE1":4414,"PHASE1":4416,"PHASE2":4418,"PHASE3":4420,"PHASE4":4426,"NA":4428},{"trials":4415,"activeCount":96},[],{"trials":4417,"activeCount":96},[],{"trials":4419,"activeCount":96},[],{"trials":4421,"activeCount":96},[4422],{"nctId":613,"briefTitle":614,"status":102,"phases":4423,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":4424,"interventions":4425},[88],[476],[129,622,623,624,625,626,627,628,629,630],{"trials":4427,"activeCount":96},[],{"trials":4429,"activeCount":96},[],{"intervention":626,"totalTrials":152,"cells":4431},{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4436,"PHASE3":4438,"PHASE4":4444,"NA":4446},{"trials":4433,"activeCount":96},[],{"trials":4435,"activeCount":96},[],{"trials":4437,"activeCount":96},[],{"trials":4439,"activeCount":96},[4440],{"nctId":613,"briefTitle":614,"status":102,"phases":4441,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":4442,"interventions":4443},[88],[476],[129,622,623,624,625,626,627,628,629,630],{"trials":4445,"activeCount":96},[],{"trials":4447,"activeCount":96},[],{"intervention":628,"totalTrials":152,"cells":4449},{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4454,"PHASE3":4456,"PHASE4":4462,"NA":4464},{"trials":4451,"activeCount":96},[],{"trials":4453,"activeCount":96},[],{"trials":4455,"activeCount":96},[],{"trials":4457,"activeCount":96},[4458],{"nctId":613,"briefTitle":614,"status":102,"phases":4459,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":4460,"interventions":4461},[88],[476],[129,622,623,624,625,626,627,628,629,630],{"trials":4463,"activeCount":96},[],{"trials":4465,"activeCount":96},[],{"intervention":629,"totalTrials":152,"cells":4467},{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4472,"PHASE3":4474,"PHASE4":4480,"NA":4482},{"trials":4469,"activeCount":96},[],{"trials":4471,"activeCount":96},[],{"trials":4473,"activeCount":96},[],{"trials":4475,"activeCount":96},[4476],{"nctId":613,"briefTitle":614,"status":102,"phases":4477,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":4478,"interventions":4479},[88],[476],[129,622,623,624,625,626,627,628,629,630],{"trials":4481,"activeCount":96},[],{"trials":4483,"activeCount":96},[],{"intervention":4485,"totalTrials":152,"cells":4486},"pembrolizumab + epacadostat",{"EARLY_PHASE1":4487,"PHASE1":4489,"PHASE2":4491,"PHASE3":4493,"PHASE4":4505,"NA":4507},{"trials":4488,"activeCount":96},[],{"trials":4490,"activeCount":96},[],{"trials":4492,"activeCount":96},[],{"trials":4494,"activeCount":96},[4495],{"nctId":4496,"briefTitle":4497,"status":102,"phases":4498,"primaryCompletion":4499,"completion":4500,"start":538,"enrollment":4501,"conditions":4502,"interventions":4503},"NCT02752074","A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 \u002F ECHO-301)",[88],"2018-01-08","2019-08-16",706,[27],[4485,4504],"pembrolizumab + placebo",{"trials":4506,"activeCount":96},[],{"trials":4508,"activeCount":96},[],{"intervention":4504,"totalTrials":152,"cells":4510},{"EARLY_PHASE1":4511,"PHASE1":4513,"PHASE2":4515,"PHASE3":4517,"PHASE4":4523,"NA":4525},{"trials":4512,"activeCount":96},[],{"trials":4514,"activeCount":96},[],{"trials":4516,"activeCount":96},[],{"trials":4518,"activeCount":96},[4519],{"nctId":4496,"briefTitle":4497,"status":102,"phases":4520,"primaryCompletion":4499,"completion":4500,"start":538,"enrollment":4501,"conditions":4521,"interventions":4522},[88],[27],[4485,4504],{"trials":4524,"activeCount":96},[],{"trials":4526,"activeCount":96},[],{"intervention":2836,"totalTrials":152,"cells":4528},{"EARLY_PHASE1":4529,"PHASE1":4531,"PHASE2":4533,"PHASE3":4535,"PHASE4":4541,"NA":4543},{"trials":4530,"activeCount":96},[],{"trials":4532,"activeCount":96},[],{"trials":4534,"activeCount":96},[],{"trials":4536,"activeCount":96},[4537],{"nctId":2827,"briefTitle":2828,"status":102,"phases":4538,"primaryCompletion":2830,"completion":1380,"start":2831,"enrollment":2832,"conditions":4539,"interventions":4540},[88],[2834],[1525,1440,2836,2837],{"trials":4542,"activeCount":96},[],{"trials":4544,"activeCount":96},[],{"intervention":2837,"totalTrials":152,"cells":4546},{"EARLY_PHASE1":4547,"PHASE1":4549,"PHASE2":4551,"PHASE3":4553,"PHASE4":4559,"NA":4561},{"trials":4548,"activeCount":96},[],{"trials":4550,"activeCount":96},[],{"trials":4552,"activeCount":96},[],{"trials":4554,"activeCount":96},[4555],{"nctId":2827,"briefTitle":2828,"status":102,"phases":4556,"primaryCompletion":2830,"completion":1380,"start":2831,"enrollment":2832,"conditions":4557,"interventions":4558},[88],[2834],[1525,1440,2836,2837],{"trials":4560,"activeCount":96},[],{"trials":4562,"activeCount":96},[],{"intervention":4564,"totalTrials":152,"cells":4565},"parsaclisinib",{"EARLY_PHASE1":4566,"PHASE1":4568,"PHASE2":4570,"PHASE3":4572,"PHASE4":4585,"NA":4587},{"trials":4567,"activeCount":96},[],{"trials":4569,"activeCount":96},[],{"trials":4571,"activeCount":96},[],{"trials":4573,"activeCount":96},[4574],{"nctId":4575,"briefTitle":4576,"status":283,"phases":4577,"primaryCompletion":4578,"completion":4579,"start":4580,"enrollment":4581,"conditions":4582,"interventions":4584},"NCT05073458","Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia",[88],"2023-10-17","2024-04-29","2022-03-15",13,[4583],"Warm Autoimmune Hemolytic Anemia (wAIHA)",[4564],{"trials":4586,"activeCount":96},[],{"trials":4588,"activeCount":96},[],{"intervention":4590,"totalTrials":2076,"cells":4591},"INCB054707",{"EARLY_PHASE1":4592,"PHASE1":4594,"PHASE2":4614,"PHASE3":4662,"PHASE4":4664,"NA":4666},{"trials":4593,"activeCount":96},[],{"trials":4595,"activeCount":96},[4596,4606],{"nctId":4597,"briefTitle":4598,"status":102,"phases":4599,"primaryCompletion":4600,"completion":4600,"start":4601,"enrollment":274,"conditions":4602,"interventions":4605},"NCT05624723","Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis",[86],"2024-02-07","2023-01-12",[4603,4604],"Renal Insufficiency","Kidney Diseases",[4590],{"nctId":4607,"briefTitle":4608,"status":102,"phases":4609,"primaryCompletion":4610,"completion":4610,"start":4611,"enrollment":373,"conditions":4612,"interventions":4613},"NCT05624710","A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment",[86],"2023-06-30","2022-12-08",[4603,4604],[4590],{"trials":4615,"activeCount":96},[4616,4625,4633,4642,4652],{"nctId":4617,"briefTitle":4618,"status":102,"phases":4619,"primaryCompletion":4620,"completion":4620,"start":4621,"enrollment":4622,"conditions":4623,"interventions":4624},"NCT03607487","A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa",[87],"2019-08-13","2018-10-15",35,[778],[4590],{"nctId":4626,"briefTitle":4627,"status":102,"phases":4628,"primaryCompletion":4629,"completion":4629,"start":4630,"enrollment":552,"conditions":4631,"interventions":4632},"NCT03569371","A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa",[87],"2019-04-22","2018-07-17",[778],[4590],{"nctId":4634,"briefTitle":4635,"status":102,"phases":4636,"primaryCompletion":4637,"completion":4638,"start":4639,"enrollment":485,"conditions":4640,"interventions":4641},"NCT04818346","A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo",[87],"2022-05-24","2023-05-24","2021-05-06",[222],[4590],{"nctId":4643,"briefTitle":4644,"status":102,"phases":4645,"primaryCompletion":4646,"completion":645,"start":4647,"enrollment":4648,"conditions":4649,"interventions":4651},"NCT04476043","To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa",[87],"2021-12-15","2020-08-25",209,[778,4650],"Acne Inversa",[4590],{"nctId":4653,"briefTitle":4654,"status":102,"phases":4655,"primaryCompletion":4656,"completion":4657,"start":4658,"enrollment":4659,"conditions":4660,"interventions":4661},"NCT05061693","A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis",[87],"2023-08-11","2024-02-28","2021-11-04",146,[250],[4590],{"trials":4663,"activeCount":96},[],{"trials":4665,"activeCount":96},[],{"trials":4667,"activeCount":96},[],{"intervention":1319,"totalTrials":1123,"cells":4669},{"EARLY_PHASE1":4670,"PHASE1":4672,"PHASE2":4696,"PHASE3":4702,"PHASE4":4704,"NA":4706},{"trials":4671,"activeCount":96},[],{"trials":4673,"activeCount":96},[4674,4678,4682,4686],{"nctId":3135,"briefTitle":3136,"status":102,"phases":4675,"primaryCompletion":3138,"completion":3139,"start":3140,"enrollment":3141,"conditions":4676,"interventions":4677},[86],[554,1502,27,2017,24,3143,443,290,2834,15,2712],[1525,2148,1319],{"nctId":2696,"briefTitle":2697,"status":283,"phases":4679,"primaryCompletion":2699,"completion":2700,"start":2701,"enrollment":2702,"conditions":4680,"interventions":4681},[86],[15],[422,1440,422,1319],{"nctId":1432,"briefTitle":1433,"status":102,"phases":4683,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":1308,"conditions":4684,"interventions":4685},[86],[1438],[40,1440,1319],{"nctId":4687,"briefTitle":4688,"status":102,"phases":4689,"primaryCompletion":4690,"completion":4690,"start":4691,"enrollment":28,"conditions":4692,"interventions":4695},"NCT03688152","A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma",[86],"2020-09-01","2018-12-03",[4693,4694],"Relapsed Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma",[576,1319],{"trials":4697,"activeCount":96},[4698],{"nctId":1303,"briefTitle":1304,"status":283,"phases":4699,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":4700,"interventions":4701},[86,87],[15,1310,1311],[1313,293,294,1314,1315,1316,1280,1317,1313,1318,1319,1320],{"trials":4703,"activeCount":96},[],{"trials":4705,"activeCount":96},[],{"trials":4707,"activeCount":96},[],{"intervention":467,"totalTrials":1123,"cells":4709},{"EARLY_PHASE1":4710,"PHASE1":4712,"PHASE2":4714,"PHASE3":4736,"PHASE4":4738,"NA":4740},{"trials":4711,"activeCount":96},[],{"trials":4713,"activeCount":96},[],{"trials":4715,"activeCount":96},[4716,4720,4724,4728,4732],{"nctId":1303,"briefTitle":1304,"status":283,"phases":4717,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":4718,"interventions":4719},[86,87],[15,1310,1311],[1313,293,294,1314,1315,1316,1280,1317,1313,1318,1319,1320],{"nctId":455,"briefTitle":456,"status":283,"phases":4721,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":4722,"interventions":4723},[86,87],[15],[320,463,464,465,466,129,467],{"nctId":4150,"briefTitle":4151,"status":283,"phases":4725,"primaryCompletion":4153,"completion":4153,"start":4154,"enrollment":4155,"conditions":4726,"interventions":4727},[86,87],[3276],[2800,4158,1317,4159],{"nctId":2792,"briefTitle":2793,"status":283,"phases":4729,"primaryCompletion":2795,"completion":2796,"start":2797,"enrollment":1750,"conditions":4730,"interventions":4731},[86,87],[15,1310,1311],[467,1525,1440,320,1525,1440,2800],{"nctId":568,"briefTitle":569,"status":283,"phases":4733,"primaryCompletion":571,"completion":571,"start":572,"enrollment":573,"conditions":4734,"interventions":4735},[86,87],[15],[576,577,467,129],{"trials":4737,"activeCount":96},[],{"trials":4739,"activeCount":96},[],{"trials":4741,"activeCount":96},[],{"intervention":2800,"totalTrials":12,"cells":4743},{"EARLY_PHASE1":4744,"PHASE1":4746,"PHASE2":4766,"PHASE3":4776,"PHASE4":4778,"NA":4780},{"trials":4745,"activeCount":96},[],{"trials":4747,"activeCount":96},[4748,4757],{"nctId":4749,"briefTitle":4750,"status":283,"phases":4751,"primaryCompletion":4752,"completion":4752,"start":4753,"enrollment":584,"conditions":4754,"interventions":4756},"NCT03132324","A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease",[86],"2018-10-03","2017-04-20",[4755],"Sickle Cell Disease",[2800],{"nctId":4758,"briefTitle":4759,"status":283,"phases":4760,"primaryCompletion":4761,"completion":4761,"start":4762,"enrollment":373,"conditions":4763,"interventions":4765},"NCT03514407","A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma",[86],"2020-06-25","2018-06-27",[4764],"Relapsed Ewing Sarcoma",[2800],{"trials":4767,"activeCount":96},[4768,4772],{"nctId":4150,"briefTitle":4151,"status":283,"phases":4769,"primaryCompletion":4153,"completion":4153,"start":4154,"enrollment":4155,"conditions":4770,"interventions":4771},[86,87],[3276],[2800,4158,1317,4159],{"nctId":2792,"briefTitle":2793,"status":283,"phases":4773,"primaryCompletion":2795,"completion":2796,"start":2797,"enrollment":1750,"conditions":4774,"interventions":4775},[86,87],[15,1310,1311],[467,1525,1440,320,1525,1440,2800],{"trials":4777,"activeCount":96},[],{"trials":4779,"activeCount":96},[],{"trials":4781,"activeCount":96},[],{"intervention":1735,"totalTrials":12,"cells":4783},{"EARLY_PHASE1":4784,"PHASE1":4786,"PHASE2":4792,"PHASE3":4812,"PHASE4":4814,"NA":4816},{"trials":4785,"activeCount":96},[],{"trials":4787,"activeCount":96},[4788],{"nctId":3967,"briefTitle":3968,"status":102,"phases":4789,"primaryCompletion":3970,"completion":3971,"start":3972,"enrollment":3973,"conditions":4790,"interventions":4791},[86],[1311,15,554,1551,2017,24,2834,3975,2712,2435],[1735,1525],{"trials":4793,"activeCount":96},[4794,4804,4808],{"nctId":4795,"briefTitle":4796,"status":283,"phases":4797,"primaryCompletion":4798,"completion":4798,"start":4799,"enrollment":22,"conditions":4800,"interventions":4802},"NCT03837509","INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma",[86,87],"2022-04-05","2019-09-25",[4801],"Relapsed or Refractory Multiple Myeloma",[1735,4803],"Daratumumab SC",{"nctId":2733,"briefTitle":2734,"status":283,"phases":4805,"primaryCompletion":2736,"completion":2736,"start":2737,"enrollment":1123,"conditions":4806,"interventions":4807},[86,87],[15],[1735,1440,1525],{"nctId":1726,"briefTitle":1727,"status":102,"phases":4809,"primaryCompletion":1729,"completion":1729,"start":1730,"enrollment":441,"conditions":4810,"interventions":4811},[86,87],[1732,554,1502,1733,34,15],[1735,1736,1737,1738,463,545,464],{"trials":4813,"activeCount":96},[],{"trials":4815,"activeCount":96},[],{"trials":4817,"activeCount":96},[],{"intervention":1559,"totalTrials":588,"cells":4819},{"EARLY_PHASE1":4820,"PHASE1":4822,"PHASE2":4824,"PHASE3":4851,"PHASE4":4853,"NA":4855},{"trials":4821,"activeCount":96},[],{"trials":4823,"activeCount":96},[],{"trials":4825,"activeCount":96},[4826,4836,4847],{"nctId":4827,"briefTitle":4828,"status":283,"phases":4829,"primaryCompletion":382,"completion":4830,"start":4831,"enrollment":2532,"conditions":4832,"interventions":4833},"NCT01254136","Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer",[86,87],"2011-10","2010-10",[443],[4834,1559,4835],"INCB007839 300mg BID","Vinorelbine",{"nctId":4837,"briefTitle":4838,"status":283,"phases":4839,"primaryCompletion":4840,"completion":4830,"start":4841,"enrollment":4842,"conditions":4843,"interventions":4844},"NCT00864175","Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer",[86,87],"2011-06","2007-07",68,[443],[4845,4845,4845,4845,4846,1558],"INCB007839","trastuzumab",{"nctId":1543,"briefTitle":1544,"status":283,"phases":4848,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":4849,"interventions":4850},[86,87],[24,1550,1551,1552,1502,1553,329,443,1554,1555,1556],[1524,463,1525,1558,1559,40,545],{"trials":4852,"activeCount":96},[],{"trials":4854,"activeCount":96},[],{"trials":4856,"activeCount":96},[],{"intervention":4858,"totalTrials":588,"cells":4859},"INCB086550",{"EARLY_PHASE1":4860,"PHASE1":4862,"PHASE2":4880,"PHASE3":4891,"PHASE4":4893,"NA":4895},{"trials":4861,"activeCount":96},[],{"trials":4863,"activeCount":96},[4864,4871],{"nctId":4865,"briefTitle":4866,"status":102,"phases":4867,"primaryCompletion":4868,"completion":4868,"start":1509,"enrollment":2076,"conditions":4869,"interventions":4870},"NCT05101369","A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550",[86],"2022-03-25",[3680],[4858],{"nctId":4872,"briefTitle":4873,"status":102,"phases":4874,"primaryCompletion":4875,"completion":4875,"start":4876,"enrollment":4877,"conditions":4878,"interventions":4879},"NCT03762447","A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors",[86],"2023-11-17","2018-12-10",138,[15],[4858],{"trials":4881,"activeCount":96},[4882],{"nctId":4883,"briefTitle":4884,"status":283,"phases":4885,"primaryCompletion":4886,"completion":4886,"start":4887,"enrollment":19,"conditions":4888,"interventions":4890},"NCT04629339","Study of INCB086550 in Select Solid Tumors",[87],"2024-03-26","2021-09-02",[4889,1552,2916,2910,27],"Non Small Cell Lung Cancer",[4858],{"trials":4892,"activeCount":96},[],{"trials":4894,"activeCount":96},[],{"trials":4896,"activeCount":96},[],{"intervention":4898,"totalTrials":588,"cells":4899},"INCB024360",{"EARLY_PHASE1":4900,"PHASE1":4902,"PHASE2":4913,"PHASE3":4939,"PHASE4":4941,"NA":4943},{"trials":4901,"activeCount":96},[],{"trials":4903,"activeCount":96},[4904],{"nctId":4905,"briefTitle":4906,"status":102,"phases":4907,"primaryCompletion":4908,"completion":3215,"start":4909,"enrollment":4910,"conditions":4911,"interventions":4912},"NCT01195311","A Dose-escalation Study in Subjects With Advanced Malignancies",[86],"2013-05","2010-07",52,[3276],[4898],{"trials":4914,"activeCount":96},[4915,4929],{"nctId":4916,"briefTitle":4917,"status":102,"phases":4918,"primaryCompletion":4919,"completion":4920,"start":4921,"enrollment":4922,"conditions":4923,"interventions":4927},"NCT02178722","Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers",[86,87],"2018-11-26","2020-11-06","2014-07-17",444,[4924,1502,2017,4925,1551,24,32,2834,34,15,2712,27,3975,4926],"Microsatellite-instability (MSI) High Colorectal Cancer (CRC)","Hepatocellular Carcinoma (HCC)","Triple Negative Breast Cancer (TNBC)",[4928,4898],"MK-3475",{"nctId":4930,"briefTitle":4931,"status":102,"phases":4932,"primaryCompletion":4933,"completion":2726,"start":4934,"enrollment":4935,"conditions":4936,"interventions":4937},"NCT02318277","A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)",[86,87],"2019-08-28","2015-01-05",176,[15,2017,24,2712],[4938,4898],"MEDI4736",{"trials":4940,"activeCount":96},[],{"trials":4942,"activeCount":96},[],{"trials":4944,"activeCount":96},[],{"intervention":2137,"totalTrials":588,"cells":4946},{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4955,"PHASE3":4972,"PHASE4":4974,"NA":4976},{"trials":4948,"activeCount":96},[],{"trials":4950,"activeCount":96},[4951],{"nctId":2126,"briefTitle":2127,"status":283,"phases":4952,"primaryCompletion":2129,"completion":2129,"start":2130,"enrollment":1123,"conditions":4953,"interventions":4954},[86],[1550,2132,2133,290,443,2134,2135,1311],[2137,2137,463,294],{"trials":4956,"activeCount":96},[4957,4963],{"nctId":4958,"briefTitle":4959,"status":283,"phases":4960,"primaryCompletion":2129,"completion":2129,"start":440,"enrollment":588,"conditions":4961,"interventions":4962},"NCT02151474","INCB047986 in Rheumatoid Arthritis",[87],[3220],[2137],{"nctId":4964,"briefTitle":4965,"status":283,"phases":4966,"primaryCompletion":4967,"completion":4967,"start":4968,"enrollment":268,"conditions":4969,"interventions":4971},"NCT02093429","Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)",[86,87],"2014-09","2014-01",[4970],"MDS (Myelodysplastic Syndrome)",[2137],{"trials":4973,"activeCount":96},[],{"trials":4975,"activeCount":96},[],{"trials":4977,"activeCount":96},[],{"intervention":150,"totalTrials":588,"cells":4979},{"EARLY_PHASE1":4980,"PHASE1":4982,"PHASE2":4988,"PHASE3":5011,"PHASE4":5013,"NA":5015},{"trials":4981,"activeCount":96},[],{"trials":4983,"activeCount":96},[4984],{"nctId":140,"briefTitle":141,"status":102,"phases":4985,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":4986,"interventions":4987},[86],[18],[148,149,150,60,151],{"trials":4989,"activeCount":96},[4990,5001],{"nctId":4991,"briefTitle":4992,"status":283,"phases":4993,"primaryCompletion":4994,"completion":4995,"start":4996,"enrollment":2495,"conditions":4997,"interventions":4999},"NCT00698789","Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes",[87],"2009-02","2009-06","2008-05",[4998],"Type 2 Diabetes",[5000,5000,5000,5000,5000,150],"INCB019602",{"nctId":5002,"briefTitle":5003,"status":102,"phases":5004,"primaryCompletion":5005,"completion":5006,"start":4996,"enrollment":5007,"conditions":5008,"interventions":5009},"NCT00698230","Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics",[87],"2009-04","2009-05",302,[4998],[5010,5010,5010,5010,5010,150],"INCB013739",{"trials":5012,"activeCount":96},[],{"trials":5014,"activeCount":96},[],{"trials":5016,"activeCount":96},[],{"intervention":1558,"totalTrials":588,"cells":5018},{"EARLY_PHASE1":5019,"PHASE1":5021,"PHASE2":5023,"PHASE3":5037,"PHASE4":5039,"NA":5041},{"trials":5020,"activeCount":96},[],{"trials":5022,"activeCount":96},[],{"trials":5024,"activeCount":96},[5025,5029,5033],{"nctId":3224,"briefTitle":3225,"status":283,"phases":5026,"primaryCompletion":427,"completion":3227,"start":3228,"enrollment":28,"conditions":5027,"interventions":5028},[87],[542],[422,3231],{"nctId":4837,"briefTitle":4838,"status":283,"phases":5030,"primaryCompletion":4840,"completion":4830,"start":4841,"enrollment":4842,"conditions":5031,"interventions":5032},[86,87],[443],[4845,4845,4845,4845,4846,1558],{"nctId":1543,"briefTitle":1544,"status":283,"phases":5034,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":5035,"interventions":5036},[86,87],[24,1550,1551,1552,1502,1553,329,443,1554,1555,1556],[1524,463,1525,1558,1559,40,545],{"trials":5038,"activeCount":96},[],{"trials":5040,"activeCount":96},[],{"trials":5042,"activeCount":96},[],{"intervention":5044,"totalTrials":588,"cells":5045},"Ruxolitinib phosphate cream",{"EARLY_PHASE1":5046,"PHASE1":5048,"PHASE2":5058,"PHASE3":5081,"PHASE4":5083,"NA":5085},{"trials":5047,"activeCount":96},[],{"trials":5049,"activeCount":96},[5050],{"nctId":5051,"briefTitle":5052,"status":102,"phases":5053,"primaryCompletion":5054,"completion":5054,"start":5055,"enrollment":1750,"conditions":5056,"interventions":5057},"NCT03257644","A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis",[86],"2020-10-07","2017-09-21",[21],[5044],{"trials":5059,"activeCount":96},[5060,5071],{"nctId":5061,"briefTitle":5062,"status":283,"phases":5063,"primaryCompletion":5064,"completion":5064,"start":5065,"enrollment":5066,"conditions":5067,"interventions":5069},"NCT02553330","A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)",[87],"2017-10-03","2015-11-18",90,[5068],"Alopecia Areata",[5070],"Ruxolitinib Phosphate Cream",{"nctId":5072,"briefTitle":5073,"status":102,"phases":5074,"primaryCompletion":5075,"completion":370,"start":5076,"enrollment":757,"conditions":5077,"interventions":5078},"NCT00820950","A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis",[87],"2009-01-31","2007-05-31",[375],[5044,5079,5080,5044,5044],"Dovonex® calcipotriene 0.005%","Diprolene® AF betamethasone dipropionate 0.05% cream.",{"trials":5082,"activeCount":96},[],{"trials":5084,"activeCount":96},[],{"trials":5086,"activeCount":96},[],{"intervention":295,"totalTrials":194,"cells":5088},{"EARLY_PHASE1":5089,"PHASE1":5091,"PHASE2":5097,"PHASE3":5103,"PHASE4":5105,"NA":5107},{"trials":5090,"activeCount":96},[],{"trials":5092,"activeCount":96},[5093],{"nctId":281,"briefTitle":282,"status":283,"phases":5094,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":5095,"interventions":5096},[86],[15,290],[292,293,294,295],{"trials":5098,"activeCount":96},[5099],{"nctId":2141,"briefTitle":2142,"status":102,"phases":5100,"primaryCompletion":427,"completion":2144,"start":360,"enrollment":2145,"conditions":5101,"interventions":5102},[86,87],[15,290],[2148,463,294,295],{"trials":5104,"activeCount":96},[],{"trials":5106,"activeCount":96},[],{"trials":5108,"activeCount":96},[],{"intervention":1314,"totalTrials":194,"cells":5110},{"EARLY_PHASE1":5111,"PHASE1":5113,"PHASE2":5115,"PHASE3":5125,"PHASE4":5127,"NA":5129},{"trials":5112,"activeCount":96},[],{"trials":5114,"activeCount":96},[],{"trials":5116,"activeCount":96},[5117,5121],{"nctId":1303,"briefTitle":1304,"status":283,"phases":5118,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":5119,"interventions":5120},[86,87],[15,1310,1311],[1313,293,294,1314,1315,1316,1280,1317,1313,1318,1319,1320],{"nctId":480,"briefTitle":481,"status":102,"phases":5122,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":5123,"interventions":5124},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"trials":5126,"activeCount":96},[],{"trials":5128,"activeCount":96},[],{"trials":5130,"activeCount":96},[],{"intervention":3155,"totalTrials":194,"cells":5132},{"EARLY_PHASE1":5133,"PHASE1":5135,"PHASE2":5141,"PHASE3":5147,"PHASE4":5149,"NA":5151},{"trials":5134,"activeCount":96},[],{"trials":5136,"activeCount":96},[5137],{"nctId":3146,"briefTitle":3147,"status":102,"phases":5138,"primaryCompletion":3149,"completion":3150,"start":3151,"enrollment":3152,"conditions":5139,"interventions":5140},[86],[476],[422,422,3155],{"trials":5142,"activeCount":96},[5143],{"nctId":469,"briefTitle":470,"status":102,"phases":5144,"primaryCompletion":472,"completion":473,"start":474,"enrollment":145,"conditions":5145,"interventions":5146},[87],[476],[129,478],{"trials":5148,"activeCount":96},[],{"trials":5150,"activeCount":96},[],{"trials":5152,"activeCount":96},[],{"intervention":3318,"totalTrials":194,"cells":5154},{"EARLY_PHASE1":5155,"PHASE1":5157,"PHASE2":5168,"PHASE3":5174,"PHASE4":5176,"NA":5178},{"trials":5156,"activeCount":96},[],{"trials":5158,"activeCount":96},[5159],{"nctId":5160,"briefTitle":5161,"status":102,"phases":5162,"primaryCompletion":5163,"completion":5163,"start":5164,"enrollment":1532,"conditions":5165,"interventions":5166},"NCT01905813","Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies",[86],"2026-02-26","2013-06-30",[2787],[3318,5167],"INCB040093 + itacitinib",{"trials":5169,"activeCount":96},[5170],{"nctId":3308,"briefTitle":3309,"status":283,"phases":5171,"primaryCompletion":3311,"completion":3311,"start":3312,"enrollment":1198,"conditions":5172,"interventions":5173},[87],[3314,3315],[3317,3318,2148],{"trials":5175,"activeCount":96},[],{"trials":5177,"activeCount":96},[],{"trials":5179,"activeCount":96},[],{"intervention":1736,"totalTrials":194,"cells":5181},{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5186,"PHASE3":5196,"PHASE4":5198,"NA":5200},{"trials":5183,"activeCount":96},[],{"trials":5185,"activeCount":96},[],{"trials":5187,"activeCount":96},[5188,5192],{"nctId":1726,"briefTitle":1727,"status":102,"phases":5189,"primaryCompletion":1729,"completion":1729,"start":1730,"enrollment":441,"conditions":5190,"interventions":5191},[86,87],[1732,554,1502,1733,34,15],[1735,1736,1737,1738,463,545,464],{"nctId":1744,"briefTitle":1745,"status":102,"phases":5193,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":5194,"interventions":5195},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"trials":5197,"activeCount":96},[],{"trials":5199,"activeCount":96},[],{"trials":5201,"activeCount":96},[],{"intervention":1737,"totalTrials":194,"cells":5203},{"EARLY_PHASE1":5204,"PHASE1":5206,"PHASE2":5208,"PHASE3":5218,"PHASE4":5220,"NA":5222},{"trials":5205,"activeCount":96},[],{"trials":5207,"activeCount":96},[],{"trials":5209,"activeCount":96},[5210,5214],{"nctId":1726,"briefTitle":1727,"status":102,"phases":5211,"primaryCompletion":1729,"completion":1729,"start":1730,"enrollment":441,"conditions":5212,"interventions":5213},[86,87],[1732,554,1502,1733,34,15],[1735,1736,1737,1738,463,545,464],{"nctId":1744,"briefTitle":1745,"status":102,"phases":5215,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":5216,"interventions":5217},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"trials":5219,"activeCount":96},[],{"trials":5221,"activeCount":96},[],{"trials":5223,"activeCount":96},[],{"intervention":4845,"totalTrials":194,"cells":5225},{"EARLY_PHASE1":5226,"PHASE1":5228,"PHASE2":5237,"PHASE3":5243,"PHASE4":5245,"NA":5247},{"trials":5227,"activeCount":96},[],{"trials":5229,"activeCount":96},[5230],{"nctId":5231,"briefTitle":5232,"status":102,"phases":5233,"primaryCompletion":514,"completion":514,"start":5234,"enrollment":507,"conditions":5235,"interventions":5236},"NCT00820560","Open-Label Study to Assess the Safety\u002FTolerability in Patients With Solid Tumors",[86],"2005-01",[3276],[4845],{"trials":5238,"activeCount":96},[5239],{"nctId":4837,"briefTitle":4838,"status":283,"phases":5240,"primaryCompletion":4840,"completion":4830,"start":4841,"enrollment":4842,"conditions":5241,"interventions":5242},[86,87],[443],[4845,4845,4845,4845,4846,1558],{"trials":5244,"activeCount":96},[],{"trials":5246,"activeCount":96},[],{"trials":5248,"activeCount":96},[],{"intervention":2749,"totalTrials":194,"cells":5250},{"EARLY_PHASE1":5251,"PHASE1":5253,"PHASE2":5255,"PHASE3":5265,"PHASE4":5267,"NA":5269},{"trials":5252,"activeCount":96},[],{"trials":5254,"activeCount":96},[],{"trials":5256,"activeCount":96},[5257,5261],{"nctId":2741,"briefTitle":2742,"status":283,"phases":5258,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":1793,"conditions":5259,"interventions":5260},[86,87],[27],[1440,2749],{"nctId":2766,"briefTitle":2767,"status":283,"phases":5262,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":25,"conditions":5263,"interventions":5264},[86,87],[15],[1440,1776,2773,2774],{"trials":5266,"activeCount":96},[],{"trials":5268,"activeCount":96},[],{"trials":5270,"activeCount":96},[],{"intervention":5010,"totalTrials":194,"cells":5272},{"EARLY_PHASE1":5273,"PHASE1":5275,"PHASE2":5277,"PHASE3":5293,"PHASE4":5295,"NA":5297},{"trials":5274,"activeCount":96},[],{"trials":5276,"activeCount":96},[],{"trials":5278,"activeCount":96},[5279,5289],{"nctId":5280,"briefTitle":5281,"status":102,"phases":5282,"primaryCompletion":5283,"completion":515,"start":5284,"enrollment":16,"conditions":5285,"interventions":5288},"NCT00478322","Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects",[87],"2007-11","2007-04",[5286,5287],"Diabetes Mellitus, Type 2","Obesity",[5010],{"nctId":5002,"briefTitle":5003,"status":102,"phases":5290,"primaryCompletion":5005,"completion":5006,"start":4996,"enrollment":5007,"conditions":5291,"interventions":5292},[87],[4998],[5010,5010,5010,5010,5010,150],{"trials":5294,"activeCount":96},[],{"trials":5296,"activeCount":96},[],{"trials":5298,"activeCount":96},[],{"intervention":576,"totalTrials":194,"cells":5300},{"EARLY_PHASE1":5301,"PHASE1":5303,"PHASE2":5309,"PHASE3":5315,"PHASE4":5317,"NA":5319},{"trials":5302,"activeCount":96},[],{"trials":5304,"activeCount":96},[5305],{"nctId":4687,"briefTitle":4688,"status":102,"phases":5306,"primaryCompletion":4690,"completion":4690,"start":4691,"enrollment":28,"conditions":5307,"interventions":5308},[86],[4693,4694],[576,1319],{"trials":5310,"activeCount":96},[5311],{"nctId":568,"briefTitle":569,"status":283,"phases":5312,"primaryCompletion":571,"completion":571,"start":572,"enrollment":573,"conditions":5313,"interventions":5314},[86,87],[15],[576,577,467,129],{"trials":5316,"activeCount":96},[],{"trials":5318,"activeCount":96},[],{"trials":5320,"activeCount":96},[],{"intervention":5322,"totalTrials":152,"cells":5323},"Ponatinib",{"EARLY_PHASE1":5324,"PHASE1":5326,"PHASE2":5328,"PHASE3":5342,"PHASE4":5344,"NA":5346},{"trials":5325,"activeCount":96},[],{"trials":5327,"activeCount":96},[],{"trials":5329,"activeCount":96},[5330],{"nctId":5331,"briefTitle":5332,"status":102,"phases":5333,"primaryCompletion":5334,"completion":5335,"start":5336,"enrollment":3360,"conditions":5337,"interventions":5341},"NCT01641107","Phase II Front-line Ponatinib in Adult Philadelphia+\u002FBCR-ABL+ Acute Lymphoblastic Leukemia.",[87],"2020-04-24","2021-09-30","2014-12-04",[5338,5339,5340],"Philadelphia Positive","BCR-ABL Positive","Acute Lymphoblastic Leukemia",[5322],{"trials":5343,"activeCount":96},[],{"trials":5345,"activeCount":96},[],{"trials":5347,"activeCount":96},[],{"intervention":4834,"totalTrials":152,"cells":5349},{"EARLY_PHASE1":5350,"PHASE1":5352,"PHASE2":5354,"PHASE3":5360,"PHASE4":5362,"NA":5364},{"trials":5351,"activeCount":96},[],{"trials":5353,"activeCount":96},[],{"trials":5355,"activeCount":96},[5356],{"nctId":4827,"briefTitle":4828,"status":283,"phases":5357,"primaryCompletion":382,"completion":4830,"start":4831,"enrollment":2532,"conditions":5358,"interventions":5359},[86,87],[443],[4834,1559,4835],{"trials":5361,"activeCount":96},[],{"trials":5363,"activeCount":96},[],{"trials":5365,"activeCount":96},[],{"intervention":4835,"totalTrials":152,"cells":5367},{"EARLY_PHASE1":5368,"PHASE1":5370,"PHASE2":5372,"PHASE3":5378,"PHASE4":5380,"NA":5382},{"trials":5369,"activeCount":96},[],{"trials":5371,"activeCount":96},[],{"trials":5373,"activeCount":96},[5374],{"nctId":4827,"briefTitle":4828,"status":283,"phases":5375,"primaryCompletion":382,"completion":4830,"start":4831,"enrollment":2532,"conditions":5376,"interventions":5377},[86,87],[443],[4834,1559,4835],{"trials":5379,"activeCount":96},[],{"trials":5381,"activeCount":96},[],{"trials":5383,"activeCount":96},[],{"intervention":1315,"totalTrials":152,"cells":5385},{"EARLY_PHASE1":5386,"PHASE1":5388,"PHASE2":5390,"PHASE3":5396,"PHASE4":5398,"NA":5400},{"trials":5387,"activeCount":96},[],{"trials":5389,"activeCount":96},[],{"trials":5391,"activeCount":96},[5392],{"nctId":1303,"briefTitle":1304,"status":283,"phases":5393,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":5394,"interventions":5395},[86,87],[15,1310,1311],[1313,293,294,1314,1315,1316,1280,1317,1313,1318,1319,1320],{"trials":5397,"activeCount":96},[],{"trials":5399,"activeCount":96},[],{"trials":5401,"activeCount":96},[],{"intervention":1316,"totalTrials":152,"cells":5403},{"EARLY_PHASE1":5404,"PHASE1":5406,"PHASE2":5408,"PHASE3":5414,"PHASE4":5416,"NA":5418},{"trials":5405,"activeCount":96},[],{"trials":5407,"activeCount":96},[],{"trials":5409,"activeCount":96},[5410],{"nctId":1303,"briefTitle":1304,"status":283,"phases":5411,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":5412,"interventions":5413},[86,87],[15,1310,1311],[1313,293,294,1314,1315,1316,1280,1317,1313,1318,1319,1320],{"trials":5415,"activeCount":96},[],{"trials":5417,"activeCount":96},[],{"trials":5419,"activeCount":96},[],{"intervention":1318,"totalTrials":152,"cells":5421},{"EARLY_PHASE1":5422,"PHASE1":5424,"PHASE2":5426,"PHASE3":5432,"PHASE4":5434,"NA":5436},{"trials":5423,"activeCount":96},[],{"trials":5425,"activeCount":96},[],{"trials":5427,"activeCount":96},[5428],{"nctId":1303,"briefTitle":1304,"status":283,"phases":5429,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":5430,"interventions":5431},[86,87],[15,1310,1311],[1313,293,294,1314,1315,1316,1280,1317,1313,1318,1319,1320],{"trials":5433,"activeCount":96},[],{"trials":5435,"activeCount":96},[],{"trials":5437,"activeCount":96},[],{"intervention":1320,"totalTrials":152,"cells":5439},{"EARLY_PHASE1":5440,"PHASE1":5442,"PHASE2":5444,"PHASE3":5450,"PHASE4":5452,"NA":5454},{"trials":5441,"activeCount":96},[],{"trials":5443,"activeCount":96},[],{"trials":5445,"activeCount":96},[5446],{"nctId":1303,"briefTitle":1304,"status":283,"phases":5447,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":5448,"interventions":5449},[86,87],[15,1310,1311],[1313,293,294,1314,1315,1316,1280,1317,1313,1318,1319,1320],{"trials":5451,"activeCount":96},[],{"trials":5453,"activeCount":96},[],{"trials":5455,"activeCount":96},[],{"intervention":4803,"totalTrials":152,"cells":5457},{"EARLY_PHASE1":5458,"PHASE1":5460,"PHASE2":5462,"PHASE3":5468,"PHASE4":5470,"NA":5472},{"trials":5459,"activeCount":96},[],{"trials":5461,"activeCount":96},[],{"trials":5463,"activeCount":96},[5464],{"nctId":4795,"briefTitle":4796,"status":283,"phases":5465,"primaryCompletion":4798,"completion":4798,"start":4799,"enrollment":22,"conditions":5466,"interventions":5467},[86,87],[4801],[1735,4803],{"trials":5469,"activeCount":96},[],{"trials":5471,"activeCount":96},[],{"trials":5473,"activeCount":96},[],{"intervention":2731,"totalTrials":152,"cells":5475},{"EARLY_PHASE1":5476,"PHASE1":5478,"PHASE2":5480,"PHASE3":5486,"PHASE4":5488,"NA":5490},{"trials":5477,"activeCount":96},[],{"trials":5479,"activeCount":96},[],{"trials":5481,"activeCount":96},[5482],{"nctId":2722,"briefTitle":2723,"status":102,"phases":5483,"primaryCompletion":2725,"completion":2726,"start":2727,"enrollment":2728,"conditions":5484,"interventions":5485},[87],[24],[1525,1440,2731],{"trials":5487,"activeCount":96},[],{"trials":5489,"activeCount":96},[],{"trials":5491,"activeCount":96},[],{"intervention":3209,"totalTrials":152,"cells":5493},{"EARLY_PHASE1":5494,"PHASE1":5496,"PHASE2":5498,"PHASE3":5504,"PHASE4":5506,"NA":5508},{"trials":5495,"activeCount":96},[],{"trials":5497,"activeCount":96},[],{"trials":5499,"activeCount":96},[5500],{"nctId":3200,"briefTitle":3201,"status":102,"phases":5501,"primaryCompletion":3203,"completion":3204,"start":3205,"enrollment":2585,"conditions":5502,"interventions":5503},[87],[3207],[422,3209,3210],{"trials":5505,"activeCount":96},[],{"trials":5507,"activeCount":96},[],{"trials":5509,"activeCount":96},[],{"intervention":3210,"totalTrials":152,"cells":5511},{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5516,"PHASE3":5522,"PHASE4":5524,"NA":5526},{"trials":5513,"activeCount":96},[],{"trials":5515,"activeCount":96},[],{"trials":5517,"activeCount":96},[5518],{"nctId":3200,"briefTitle":3201,"status":102,"phases":5519,"primaryCompletion":3203,"completion":3204,"start":3205,"enrollment":2585,"conditions":5520,"interventions":5521},[87],[3207],[422,3209,3210],{"trials":5523,"activeCount":96},[],{"trials":5525,"activeCount":96},[],{"trials":5527,"activeCount":96},[],{"intervention":3222,"totalTrials":152,"cells":5529},{"EARLY_PHASE1":5530,"PHASE1":5532,"PHASE2":5534,"PHASE3":5540,"PHASE4":5542,"NA":5544},{"trials":5531,"activeCount":96},[],{"trials":5533,"activeCount":96},[],{"trials":5535,"activeCount":96},[5536],{"nctId":3212,"briefTitle":3213,"status":102,"phases":5537,"primaryCompletion":3215,"completion":3216,"start":3217,"enrollment":3218,"conditions":5538,"interventions":5539},[87],[3220],[422,3222],{"trials":5541,"activeCount":96},[],{"trials":5543,"activeCount":96},[],{"trials":5545,"activeCount":96},[],{"intervention":5547,"totalTrials":152,"cells":5548},"Ruxolitinib 25 mg",{"EARLY_PHASE1":5549,"PHASE1":5551,"PHASE2":5553,"PHASE3":5563,"PHASE4":5565,"NA":5567},{"trials":5550,"activeCount":96},[],{"trials":5552,"activeCount":96},[],{"trials":5554,"activeCount":96},[5555],{"nctId":5556,"briefTitle":5557,"status":102,"phases":5558,"primaryCompletion":4909,"completion":4909,"start":5559,"enrollment":4581,"conditions":5560,"interventions":5561},"NCT00639002","A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma",[87],"2008-03",[1553],[5547,5562],"Dexamethasone 40 mg",{"trials":5564,"activeCount":96},[],{"trials":5566,"activeCount":96},[],{"trials":5568,"activeCount":96},[],{"intervention":5562,"totalTrials":152,"cells":5570},{"EARLY_PHASE1":5571,"PHASE1":5573,"PHASE2":5575,"PHASE3":5581,"PHASE4":5583,"NA":5585},{"trials":5572,"activeCount":96},[],{"trials":5574,"activeCount":96},[],{"trials":5576,"activeCount":96},[5577],{"nctId":5556,"briefTitle":5557,"status":102,"phases":5578,"primaryCompletion":4909,"completion":4909,"start":5559,"enrollment":4581,"conditions":5579,"interventions":5580},[87],[1553],[5547,5562],{"trials":5582,"activeCount":96},[],{"trials":5584,"activeCount":96},[],{"trials":5586,"activeCount":96},[],{"intervention":4928,"totalTrials":152,"cells":5588},{"EARLY_PHASE1":5589,"PHASE1":5591,"PHASE2":5593,"PHASE3":5599,"PHASE4":5601,"NA":5603},{"trials":5590,"activeCount":96},[],{"trials":5592,"activeCount":96},[],{"trials":5594,"activeCount":96},[5595],{"nctId":4916,"briefTitle":4917,"status":102,"phases":5596,"primaryCompletion":4919,"completion":4920,"start":4921,"enrollment":4922,"conditions":5597,"interventions":5598},[86,87],[4924,1502,2017,4925,1551,24,32,2834,34,15,2712,27,3975,4926],[4928,4898],{"trials":5600,"activeCount":96},[],{"trials":5602,"activeCount":96},[],{"trials":5604,"activeCount":96},[],{"intervention":465,"totalTrials":152,"cells":5606},{"EARLY_PHASE1":5607,"PHASE1":5609,"PHASE2":5611,"PHASE3":5617,"PHASE4":5619,"NA":5621},{"trials":5608,"activeCount":96},[],{"trials":5610,"activeCount":96},[],{"trials":5612,"activeCount":96},[5613],{"nctId":455,"briefTitle":456,"status":283,"phases":5614,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":5615,"interventions":5616},[86,87],[15],[320,463,464,465,466,129,467],{"trials":5618,"activeCount":96},[],{"trials":5620,"activeCount":96},[],{"trials":5622,"activeCount":96},[],{"intervention":466,"totalTrials":152,"cells":5624},{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5629,"PHASE3":5635,"PHASE4":5637,"NA":5639},{"trials":5626,"activeCount":96},[],{"trials":5628,"activeCount":96},[],{"trials":5630,"activeCount":96},[5631],{"nctId":455,"briefTitle":456,"status":283,"phases":5632,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":5633,"interventions":5634},[86,87],[15],[320,463,464,465,466,129,467],{"trials":5636,"activeCount":96},[],{"trials":5638,"activeCount":96},[],{"trials":5640,"activeCount":96},[],{"intervention":5000,"totalTrials":152,"cells":5642},{"EARLY_PHASE1":5643,"PHASE1":5645,"PHASE2":5647,"PHASE3":5653,"PHASE4":5655,"NA":5657},{"trials":5644,"activeCount":96},[],{"trials":5646,"activeCount":96},[],{"trials":5648,"activeCount":96},[5649],{"nctId":4991,"briefTitle":4992,"status":283,"phases":5650,"primaryCompletion":4994,"completion":4995,"start":4996,"enrollment":2495,"conditions":5651,"interventions":5652},[87],[4998],[5000,5000,5000,5000,5000,150],{"trials":5654,"activeCount":96},[],{"trials":5656,"activeCount":96},[],{"trials":5658,"activeCount":96},[],{"intervention":489,"totalTrials":152,"cells":5660},{"EARLY_PHASE1":5661,"PHASE1":5663,"PHASE2":5665,"PHASE3":5671,"PHASE4":5673,"NA":5675},{"trials":5662,"activeCount":96},[],{"trials":5664,"activeCount":96},[],{"trials":5666,"activeCount":96},[5667],{"nctId":480,"briefTitle":481,"status":102,"phases":5668,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":5669,"interventions":5670},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"trials":5672,"activeCount":96},[],{"trials":5674,"activeCount":96},[],{"trials":5676,"activeCount":96},[],{"intervention":491,"totalTrials":152,"cells":5678},{"EARLY_PHASE1":5679,"PHASE1":5681,"PHASE2":5683,"PHASE3":5689,"PHASE4":5691,"NA":5693},{"trials":5680,"activeCount":96},[],{"trials":5682,"activeCount":96},[],{"trials":5684,"activeCount":96},[5685],{"nctId":480,"briefTitle":481,"status":102,"phases":5686,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":5687,"interventions":5688},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"trials":5690,"activeCount":96},[],{"trials":5692,"activeCount":96},[],{"trials":5694,"activeCount":96},[],{"intervention":494,"totalTrials":152,"cells":5696},{"EARLY_PHASE1":5697,"PHASE1":5699,"PHASE2":5701,"PHASE3":5707,"PHASE4":5709,"NA":5711},{"trials":5698,"activeCount":96},[],{"trials":5700,"activeCount":96},[],{"trials":5702,"activeCount":96},[5703],{"nctId":480,"briefTitle":481,"status":102,"phases":5704,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":5705,"interventions":5706},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"trials":5708,"activeCount":96},[],{"trials":5710,"activeCount":96},[],{"trials":5712,"activeCount":96},[],{"intervention":495,"totalTrials":152,"cells":5714},{"EARLY_PHASE1":5715,"PHASE1":5717,"PHASE2":5719,"PHASE3":5725,"PHASE4":5727,"NA":5729},{"trials":5716,"activeCount":96},[],{"trials":5718,"activeCount":96},[],{"trials":5720,"activeCount":96},[5721],{"nctId":480,"briefTitle":481,"status":102,"phases":5722,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":5723,"interventions":5724},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"trials":5726,"activeCount":96},[],{"trials":5728,"activeCount":96},[],{"trials":5730,"activeCount":96},[],{"intervention":497,"totalTrials":152,"cells":5732},{"EARLY_PHASE1":5733,"PHASE1":5735,"PHASE2":5737,"PHASE3":5743,"PHASE4":5745,"NA":5747},{"trials":5734,"activeCount":96},[],{"trials":5736,"activeCount":96},[],{"trials":5738,"activeCount":96},[5739],{"nctId":480,"briefTitle":481,"status":102,"phases":5740,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":5741,"interventions":5742},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"trials":5744,"activeCount":96},[],{"trials":5746,"activeCount":96},[],{"trials":5748,"activeCount":96},[],{"intervention":499,"totalTrials":152,"cells":5750},{"EARLY_PHASE1":5751,"PHASE1":5753,"PHASE2":5755,"PHASE3":5761,"PHASE4":5763,"NA":5765},{"trials":5752,"activeCount":96},[],{"trials":5754,"activeCount":96},[],{"trials":5756,"activeCount":96},[5757],{"nctId":480,"briefTitle":481,"status":102,"phases":5758,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":5759,"interventions":5760},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"trials":5762,"activeCount":96},[],{"trials":5764,"activeCount":96},[],{"trials":5766,"activeCount":96},[],{"intervention":500,"totalTrials":152,"cells":5768},{"EARLY_PHASE1":5769,"PHASE1":5771,"PHASE2":5773,"PHASE3":5779,"PHASE4":5781,"NA":5783},{"trials":5770,"activeCount":96},[],{"trials":5772,"activeCount":96},[],{"trials":5774,"activeCount":96},[5775],{"nctId":480,"briefTitle":481,"status":102,"phases":5776,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":5777,"interventions":5778},[87],[487],[129,489,490,491,492,493,494,495,496,497,498,499,500],{"trials":5780,"activeCount":96},[],{"trials":5782,"activeCount":96},[],{"trials":5784,"activeCount":96},[],{"intervention":5786,"totalTrials":152,"cells":5787},"Ruxolitinib 1.5% cream",{"EARLY_PHASE1":5788,"PHASE1":5790,"PHASE2":5792,"PHASE3":5801,"PHASE4":5803,"NA":5805},{"trials":5789,"activeCount":96},[],{"trials":5791,"activeCount":96},[],{"trials":5793,"activeCount":96},[5794],{"nctId":5795,"briefTitle":5796,"status":102,"phases":5797,"primaryCompletion":5798,"completion":5798,"start":2511,"enrollment":2145,"conditions":5799,"interventions":5800},"NCT05247489","A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo",[87],"2023-12-19",[691],[5786],{"trials":5802,"activeCount":96},[],{"trials":5804,"activeCount":96},[],{"trials":5806,"activeCount":96},[],{"intervention":5808,"totalTrials":152,"cells":5809},"INCB018424",{"EARLY_PHASE1":5810,"PHASE1":5812,"PHASE2":5814,"PHASE3":5824,"PHASE4":5826,"NA":5828},{"trials":5811,"activeCount":96},[],{"trials":5813,"activeCount":96},[],{"trials":5815,"activeCount":96},[5816],{"nctId":5817,"briefTitle":5818,"status":102,"phases":5819,"primaryCompletion":5820,"completion":5820,"start":5821,"enrollment":1793,"conditions":5822,"interventions":5823},"NCT00550043","A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis",[87],"2008-09","2007-10",[3220],[5808],{"trials":5825,"activeCount":96},[],{"trials":5827,"activeCount":96},[],{"trials":5829,"activeCount":96},[],{"intervention":2931,"totalTrials":152,"cells":5831},{"EARLY_PHASE1":5832,"PHASE1":5834,"PHASE2":5836,"PHASE3":5842,"PHASE4":5844,"NA":5846},{"trials":5833,"activeCount":96},[],{"trials":5835,"activeCount":96},[],{"trials":5837,"activeCount":96},[5838],{"nctId":2924,"briefTitle":2925,"status":102,"phases":5839,"primaryCompletion":2927,"completion":2927,"start":2928,"enrollment":798,"conditions":5840,"interventions":5841},[86,87],[27],[1494,1495,2931],{"trials":5843,"activeCount":96},[],{"trials":5845,"activeCount":96},[],{"trials":5847,"activeCount":96},[],{"intervention":5849,"totalTrials":152,"cells":5850},"INCB009471",{"EARLY_PHASE1":5851,"PHASE1":5853,"PHASE2":5855,"PHASE3":5866,"PHASE4":5868,"NA":5870},{"trials":5852,"activeCount":96},[],{"trials":5854,"activeCount":96},[],{"trials":5856,"activeCount":96},[5857],{"nctId":5858,"briefTitle":5859,"status":102,"phases":5860,"primaryCompletion":5861,"completion":5861,"start":5862,"enrollment":383,"conditions":5863,"interventions":5865},"NCT00393120","Safety\u002FEffectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients",[87],"2007-09","2006-10",[5864],"HIV Infections",[5849,5849],{"trials":5867,"activeCount":96},[],{"trials":5869,"activeCount":96},[],{"trials":5871,"activeCount":96},[],{"intervention":2774,"totalTrials":152,"cells":5873},{"EARLY_PHASE1":5874,"PHASE1":5876,"PHASE2":5878,"PHASE3":5884,"PHASE4":5886,"NA":5888},{"trials":5875,"activeCount":96},[],{"trials":5877,"activeCount":96},[],{"trials":5879,"activeCount":96},[5880],{"nctId":2766,"briefTitle":2767,"status":283,"phases":5881,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":25,"conditions":5882,"interventions":5883},[86,87],[15],[1440,1776,2773,2774],{"trials":5885,"activeCount":96},[],{"trials":5887,"activeCount":96},[],{"trials":5889,"activeCount":96},[],{"intervention":1753,"totalTrials":152,"cells":5891},{"EARLY_PHASE1":5892,"PHASE1":5894,"PHASE2":5896,"PHASE3":5902,"PHASE4":5904,"NA":5906},{"trials":5893,"activeCount":96},[],{"trials":5895,"activeCount":96},[],{"trials":5897,"activeCount":96},[5898],{"nctId":1744,"briefTitle":1745,"status":102,"phases":5899,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":5900,"interventions":5901},[86,87],[1550],[1440,1525,1736,1737,1738,463,1584,1466,464,544,490,1466,545,1738,1753],{"trials":5903,"activeCount":96},[],{"trials":5905,"activeCount":96},[],{"trials":5907,"activeCount":96},[],{"intervention":5909,"totalTrials":152,"cells":5910},"INCB028050",{"EARLY_PHASE1":5911,"PHASE1":5913,"PHASE2":5915,"PHASE3":5925,"PHASE4":5927,"NA":5929},{"trials":5912,"activeCount":96},[],{"trials":5914,"activeCount":96},[],{"trials":5916,"activeCount":96},[5917],{"nctId":5918,"briefTitle":5919,"status":102,"phases":5920,"primaryCompletion":5921,"completion":4909,"start":5006,"enrollment":5922,"conditions":5923,"interventions":5924},"NCT00902486","INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs",[87],"2010-06",127,[3220],[5909,5909,5909],{"trials":5926,"activeCount":96},[],{"trials":5928,"activeCount":96},[],{"trials":5930,"activeCount":96},[],{"intervention":4158,"totalTrials":152,"cells":5932},{"EARLY_PHASE1":5933,"PHASE1":5935,"PHASE2":5937,"PHASE3":5943,"PHASE4":5945,"NA":5947},{"trials":5934,"activeCount":96},[],{"trials":5936,"activeCount":96},[],{"trials":5938,"activeCount":96},[5939],{"nctId":4150,"briefTitle":4151,"status":283,"phases":5940,"primaryCompletion":4153,"completion":4153,"start":4154,"enrollment":4155,"conditions":5941,"interventions":5942},[86,87],[3276],[2800,4158,1317,4159],{"trials":5944,"activeCount":96},[],{"trials":5946,"activeCount":96},[],{"trials":5948,"activeCount":96},[],{"intervention":3278,"totalTrials":152,"cells":5950},{"EARLY_PHASE1":5951,"PHASE1":5953,"PHASE2":5955,"PHASE3":5961,"PHASE4":5963,"NA":5965},{"trials":5952,"activeCount":96},[],{"trials":5954,"activeCount":96},[],{"trials":5956,"activeCount":96},[5957],{"nctId":3271,"briefTitle":3272,"status":934,"phases":5958,"primaryCompletion":285,"completion":285,"start":3274,"enrollment":96,"conditions":5959,"interventions":5960},[87],[3276,542],[422,3278],{"trials":5962,"activeCount":96},[],{"trials":5964,"activeCount":96},[],{"trials":5966,"activeCount":96},[],{"intervention":2790,"totalTrials":152,"cells":5968},{"EARLY_PHASE1":5969,"PHASE1":5971,"PHASE2":5973,"PHASE3":5979,"PHASE4":5981,"NA":5983},{"trials":5970,"activeCount":96},[],{"trials":5972,"activeCount":96},[],{"trials":5974,"activeCount":96},[5975],{"nctId":2780,"briefTitle":2781,"status":102,"phases":5976,"primaryCompletion":2783,"completion":2783,"start":2784,"enrollment":2785,"conditions":5977,"interventions":5978},[86,87],[2787,554,2017,24,32,27,34,2788],[1776,1440,2790],{"trials":5980,"activeCount":96},[],{"trials":5982,"activeCount":96},[],{"trials":5984,"activeCount":96},[],{"intervention":3306,"totalTrials":152,"cells":5986},{"EARLY_PHASE1":5987,"PHASE1":5989,"PHASE2":5991,"PHASE3":5997,"PHASE4":5999,"NA":6001},{"trials":5988,"activeCount":96},[],{"trials":5990,"activeCount":96},[],{"trials":5992,"activeCount":96},[5993],{"nctId":3299,"briefTitle":3300,"status":102,"phases":5994,"primaryCompletion":3302,"completion":3302,"start":3303,"enrollment":8,"conditions":5995,"interventions":5996},[86,87],[24],[422,3306],{"trials":5998,"activeCount":96},[],{"trials":6000,"activeCount":96},[],{"trials":6002,"activeCount":96},[],{"intervention":4938,"totalTrials":152,"cells":6004},{"EARLY_PHASE1":6005,"PHASE1":6007,"PHASE2":6009,"PHASE3":6015,"PHASE4":6017,"NA":6019},{"trials":6006,"activeCount":96},[],{"trials":6008,"activeCount":96},[],{"trials":6010,"activeCount":96},[6011],{"nctId":4930,"briefTitle":4931,"status":102,"phases":6012,"primaryCompletion":4933,"completion":2726,"start":4934,"enrollment":4935,"conditions":6013,"interventions":6014},[86,87],[15,2017,24,2712],[4938,4898],{"trials":6016,"activeCount":96},[],{"trials":6018,"activeCount":96},[],{"trials":6020,"activeCount":96},[],{"intervention":6022,"totalTrials":152,"cells":6023},"Ruxolitinib 0.15% Cream QD",{"EARLY_PHASE1":6024,"PHASE1":6026,"PHASE2":6028,"PHASE3":6044,"PHASE4":6046,"NA":6048},{"trials":6025,"activeCount":96},[],{"trials":6027,"activeCount":96},[],{"trials":6029,"activeCount":96},[6030],{"nctId":6031,"briefTitle":6032,"status":102,"phases":6033,"primaryCompletion":6034,"completion":6035,"start":6036,"enrollment":2785,"conditions":6037,"interventions":6038},"NCT03011892","A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis",[87],"2018-01-10","2018-03-12","2017-01-09",[21],[6022,6039,6040,6041,6042,6043],"Ruxolitinib 0.5% Cream QD","Ruxolitinib 1.5% Cream QD","Ruxolitinib 1.5% Cream BID","Triamcinolone 0.1% Cream BID","Vehicle Cream BID",{"trials":6045,"activeCount":96},[],{"trials":6047,"activeCount":96},[],{"trials":6049,"activeCount":96},[],{"intervention":6039,"totalTrials":152,"cells":6051},{"EARLY_PHASE1":6052,"PHASE1":6054,"PHASE2":6056,"PHASE3":6062,"PHASE4":6064,"NA":6066},{"trials":6053,"activeCount":96},[],{"trials":6055,"activeCount":96},[],{"trials":6057,"activeCount":96},[6058],{"nctId":6031,"briefTitle":6032,"status":102,"phases":6059,"primaryCompletion":6034,"completion":6035,"start":6036,"enrollment":2785,"conditions":6060,"interventions":6061},[87],[21],[6022,6039,6040,6041,6042,6043],{"trials":6063,"activeCount":96},[],{"trials":6065,"activeCount":96},[],{"trials":6067,"activeCount":96},[],{"intervention":6040,"totalTrials":152,"cells":6069},{"EARLY_PHASE1":6070,"PHASE1":6072,"PHASE2":6074,"PHASE3":6080,"PHASE4":6082,"NA":6084},{"trials":6071,"activeCount":96},[],{"trials":6073,"activeCount":96},[],{"trials":6075,"activeCount":96},[6076],{"nctId":6031,"briefTitle":6032,"status":102,"phases":6077,"primaryCompletion":6034,"completion":6035,"start":6036,"enrollment":2785,"conditions":6078,"interventions":6079},[87],[21],[6022,6039,6040,6041,6042,6043],{"trials":6081,"activeCount":96},[],{"trials":6083,"activeCount":96},[],{"trials":6085,"activeCount":96},[],{"intervention":6041,"totalTrials":152,"cells":6087},{"EARLY_PHASE1":6088,"PHASE1":6090,"PHASE2":6092,"PHASE3":6098,"PHASE4":6100,"NA":6102},{"trials":6089,"activeCount":96},[],{"trials":6091,"activeCount":96},[],{"trials":6093,"activeCount":96},[6094],{"nctId":6031,"briefTitle":6032,"status":102,"phases":6095,"primaryCompletion":6034,"completion":6035,"start":6036,"enrollment":2785,"conditions":6096,"interventions":6097},[87],[21],[6022,6039,6040,6041,6042,6043],{"trials":6099,"activeCount":96},[],{"trials":6101,"activeCount":96},[],{"trials":6103,"activeCount":96},[],{"intervention":6042,"totalTrials":152,"cells":6105},{"EARLY_PHASE1":6106,"PHASE1":6108,"PHASE2":6110,"PHASE3":6116,"PHASE4":6118,"NA":6120},{"trials":6107,"activeCount":96},[],{"trials":6109,"activeCount":96},[],{"trials":6111,"activeCount":96},[6112],{"nctId":6031,"briefTitle":6032,"status":102,"phases":6113,"primaryCompletion":6034,"completion":6035,"start":6036,"enrollment":2785,"conditions":6114,"interventions":6115},[87],[21],[6022,6039,6040,6041,6042,6043],{"trials":6117,"activeCount":96},[],{"trials":6119,"activeCount":96},[],{"trials":6121,"activeCount":96},[],{"intervention":6043,"totalTrials":152,"cells":6123},{"EARLY_PHASE1":6124,"PHASE1":6126,"PHASE2":6128,"PHASE3":6134,"PHASE4":6136,"NA":6138},{"trials":6125,"activeCount":96},[],{"trials":6127,"activeCount":96},[],{"trials":6129,"activeCount":96},[6130],{"nctId":6031,"briefTitle":6032,"status":102,"phases":6131,"primaryCompletion":6034,"completion":6035,"start":6036,"enrollment":2785,"conditions":6132,"interventions":6133},[87],[21],[6022,6039,6040,6041,6042,6043],{"trials":6135,"activeCount":96},[],{"trials":6137,"activeCount":96},[],{"trials":6139,"activeCount":96},[],{"intervention":6141,"totalTrials":152,"cells":6142},"Ruxolitinib Phosphate",{"EARLY_PHASE1":6143,"PHASE1":6145,"PHASE2":6147,"PHASE3":6158,"PHASE4":6160,"NA":6162},{"trials":6144,"activeCount":96},[],{"trials":6146,"activeCount":96},[],{"trials":6148,"activeCount":96},[6149],{"nctId":6150,"briefTitle":6151,"status":102,"phases":6152,"primaryCompletion":6153,"completion":6153,"start":6154,"enrollment":6155,"conditions":6156,"interventions":6157},"NCT00778700","A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis",[87],"2009-06-26","2008-10-28",199,[375],[6141],{"trials":6159,"activeCount":96},[],{"trials":6161,"activeCount":96},[],{"trials":6163,"activeCount":96},[],{"intervention":577,"totalTrials":152,"cells":6165},{"EARLY_PHASE1":6166,"PHASE1":6168,"PHASE2":6170,"PHASE3":6176,"PHASE4":6178,"NA":6180},{"trials":6167,"activeCount":96},[],{"trials":6169,"activeCount":96},[],{"trials":6171,"activeCount":96},[6172],{"nctId":568,"briefTitle":569,"status":283,"phases":6173,"primaryCompletion":571,"completion":571,"start":572,"enrollment":573,"conditions":6174,"interventions":6175},[86,87],[15],[576,577,467,129],{"trials":6177,"activeCount":96},[],{"trials":6179,"activeCount":96},[],{"trials":6181,"activeCount":96},[],{"intervention":5079,"totalTrials":152,"cells":6183},{"EARLY_PHASE1":6184,"PHASE1":6186,"PHASE2":6188,"PHASE3":6194,"PHASE4":6196,"NA":6198},{"trials":6185,"activeCount":96},[],{"trials":6187,"activeCount":96},[],{"trials":6189,"activeCount":96},[6190],{"nctId":5072,"briefTitle":5073,"status":102,"phases":6191,"primaryCompletion":5075,"completion":370,"start":5076,"enrollment":757,"conditions":6192,"interventions":6193},[87],[375],[5044,5079,5080,5044,5044],{"trials":6195,"activeCount":96},[],{"trials":6197,"activeCount":96},[],{"trials":6199,"activeCount":96},[],{"intervention":5080,"totalTrials":152,"cells":6201},{"EARLY_PHASE1":6202,"PHASE1":6204,"PHASE2":6206,"PHASE3":6212,"PHASE4":6214,"NA":6216},{"trials":6203,"activeCount":96},[],{"trials":6205,"activeCount":96},[],{"trials":6207,"activeCount":96},[6208],{"nctId":5072,"briefTitle":5073,"status":102,"phases":6209,"primaryCompletion":5075,"completion":370,"start":5076,"enrollment":757,"conditions":6210,"interventions":6211},[87],[375],[5044,5079,5080,5044,5044],{"trials":6213,"activeCount":96},[],{"trials":6215,"activeCount":96},[],{"trials":6217,"activeCount":96},[],{"intervention":3317,"totalTrials":152,"cells":6219},{"EARLY_PHASE1":6220,"PHASE1":6222,"PHASE2":6224,"PHASE3":6230,"PHASE4":6232,"NA":6234},{"trials":6221,"activeCount":96},[],{"trials":6223,"activeCount":96},[],{"trials":6225,"activeCount":96},[6226],{"nctId":3308,"briefTitle":3309,"status":283,"phases":6227,"primaryCompletion":3311,"completion":3311,"start":3312,"enrollment":1198,"conditions":6228,"interventions":6229},[87],[3314,3315],[3317,3318,2148],{"trials":6231,"activeCount":96},[],{"trials":6233,"activeCount":96},[],{"trials":6235,"activeCount":96},[],{"intervention":2467,"totalTrials":152,"cells":6237},{"EARLY_PHASE1":6238,"PHASE1":6240,"PHASE2":6242,"PHASE3":6248,"PHASE4":6250,"NA":6252},{"trials":6239,"activeCount":96},[],{"trials":6241,"activeCount":96},[],{"trials":6243,"activeCount":96},[6244],{"nctId":2460,"briefTitle":2461,"status":283,"phases":6245,"primaryCompletion":2463,"completion":2463,"start":2464,"enrollment":1123,"conditions":6246,"interventions":6247},[86,87],[1449],[2404,2467],{"trials":6249,"activeCount":96},[],{"trials":6251,"activeCount":96},[],{"trials":6253,"activeCount":96},[],{"intervention":2810,"totalTrials":152,"cells":6255},{"EARLY_PHASE1":6256,"PHASE1":6258,"PHASE2":6260,"PHASE3":6266,"PHASE4":6268,"NA":6270},{"trials":6257,"activeCount":96},[],{"trials":6259,"activeCount":96},[],{"trials":6261,"activeCount":96},[6262],{"nctId":2802,"briefTitle":2803,"status":283,"phases":6263,"primaryCompletion":2805,"completion":2805,"start":2806,"enrollment":1308,"conditions":6264,"interventions":6265},[87],[34,2808],[1440,2810],{"trials":6267,"activeCount":96},[],{"trials":6269,"activeCount":96},[],{"trials":6271,"activeCount":96},[],{"intervention":6273,"totalTrials":152,"cells":6274},"Dexelvucitabine",{"EARLY_PHASE1":6275,"PHASE1":6277,"PHASE2":6279,"PHASE3":6289,"PHASE4":6291,"NA":6293},{"trials":6276,"activeCount":96},[],{"trials":6278,"activeCount":96},[],{"trials":6280,"activeCount":96},[6281],{"nctId":6282,"briefTitle":6283,"status":283,"phases":6284,"completion":6285,"start":6285,"enrollment":908,"conditions":6286,"interventions":6288},"NCT00300573","Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs",[87],"2006-04",[5864,6287],"Human Immunodeficiency Virus",[6273],{"trials":6290,"activeCount":96},[],{"trials":6292,"activeCount":96},[],{"trials":6294,"activeCount":96},[],{"intervention":587,"totalTrials":152,"cells":6296},{"EARLY_PHASE1":6297,"PHASE1":6299,"PHASE2":6301,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6298,"activeCount":96},[],{"trials":6300,"activeCount":96},[],{"trials":6302,"activeCount":96},[6303],{"nctId":579,"briefTitle":580,"status":283,"phases":6304,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":6305,"interventions":6306},[87],[30],[129,587],{"trials":6308,"activeCount":96},[],{"trials":6310,"activeCount":96},[],{"trials":6312,"activeCount":96},[],{"intervention":6314,"totalTrials":152,"cells":6315},"INCB054329 Monotherapy",{"EARLY_PHASE1":6316,"PHASE1":6318,"PHASE2":6320,"PHASE3":6329,"PHASE4":6331,"NA":6333},{"trials":6317,"activeCount":96},[],{"trials":6319,"activeCount":96},[],{"trials":6321,"activeCount":96},[6322],{"nctId":6323,"briefTitle":6324,"status":283,"phases":6325,"primaryCompletion":472,"completion":472,"start":6326,"enrollment":11,"conditions":6327,"interventions":6328},"NCT02431260","An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies",[86,87],"2015-04-14",[3276],[6314],{"trials":6330,"activeCount":96},[],{"trials":6332,"activeCount":96},[],{"trials":6334,"activeCount":96},[],{"intervention":1809,"totalTrials":152,"cells":6336},{"EARLY_PHASE1":6337,"PHASE1":6339,"PHASE2":6341,"PHASE3":6347,"PHASE4":6349,"NA":6351},{"trials":6338,"activeCount":96},[],{"trials":6340,"activeCount":96},[],{"trials":6342,"activeCount":96},[6343],{"nctId":1800,"briefTitle":1801,"status":102,"phases":6344,"primaryCompletion":1803,"completion":1803,"start":1804,"enrollment":1805,"conditions":6345,"interventions":6346},[86,87],[1807],[399,422,627,1809,1466,1595],{"trials":6348,"activeCount":96},[],{"trials":6350,"activeCount":96},[],{"trials":6352,"activeCount":96},[],{"intervention":6354,"totalTrials":194,"cells":6355},"INCMGA00012",{"EARLY_PHASE1":6356,"PHASE1":6358,"PHASE2":6384,"PHASE3":6386,"PHASE4":6388,"NA":6390},{"trials":6357,"activeCount":96},[],{"trials":6359,"activeCount":96},[6360,6369],{"nctId":6361,"briefTitle":6362,"status":283,"phases":6363,"primaryCompletion":6364,"completion":6364,"start":6365,"enrollment":1308,"conditions":6366,"interventions":6367},"NCT03522142","A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies",[86],"2025-09-10","2018-08-27",[1449],[6368,6354],"INCB081776",{"nctId":6370,"briefTitle":6371,"status":102,"phases":6372,"primaryCompletion":6373,"completion":6373,"start":6374,"enrollment":1212,"conditions":6375,"interventions":6383},"NCT04580485","INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors",[86],"2024-01-22","2021-02-03",[34,3975,4889,6376,6377,6378,6379,6380,2910,6381,6382],"Squamous Cell Carcinoma of Head and Neck","Triple Negative Breast Cancer","Castration Resistant Prostate Cancer","Colorectal Cancer","Gastric\u002F Gastroesophageal Junction","Pancreatic Ductal Adenocarcinoma","Squamous Carcinoma of the Anal Canal",[1454,6354],{"trials":6385,"activeCount":96},[],{"trials":6387,"activeCount":96},[],{"trials":6389,"activeCount":96},[],{"trials":6391,"activeCount":96},[],{"intervention":6393,"totalTrials":194,"cells":6394},"Ruxolitinib IR",{"EARLY_PHASE1":6395,"PHASE1":6397,"PHASE2":6416,"PHASE3":6418,"PHASE4":6420,"NA":6422},{"trials":6396,"activeCount":96},[],{"trials":6398,"activeCount":96},[6399,6406],{"nctId":6400,"briefTitle":6401,"status":102,"phases":6402,"primaryCompletion":2464,"completion":2415,"start":4886,"enrollment":16,"conditions":6403,"interventions":6404},"NCT06310304","A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.",[86],[18],[6393,6405],"Ruxolitinib XR",{"nctId":6407,"briefTitle":6408,"status":102,"phases":6409,"primaryCompletion":6410,"completion":6411,"start":6412,"enrollment":6413,"conditions":6414,"interventions":6415},"NCT06555081","A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants",[86],"2024-10-25","2024-11-07","2024-09-25",168,[18],[6393,6405],{"trials":6417,"activeCount":96},[],{"trials":6419,"activeCount":96},[],{"trials":6421,"activeCount":96},[],{"trials":6423,"activeCount":96},[],{"intervention":6405,"totalTrials":194,"cells":6425},{"EARLY_PHASE1":6426,"PHASE1":6428,"PHASE2":6438,"PHASE3":6440,"PHASE4":6442,"NA":6444},{"trials":6427,"activeCount":96},[],{"trials":6429,"activeCount":96},[6430,6434],{"nctId":6400,"briefTitle":6401,"status":102,"phases":6431,"primaryCompletion":2464,"completion":2415,"start":4886,"enrollment":16,"conditions":6432,"interventions":6433},[86],[18],[6393,6405],{"nctId":6407,"briefTitle":6408,"status":102,"phases":6435,"primaryCompletion":6410,"completion":6411,"start":6412,"enrollment":6413,"conditions":6436,"interventions":6437},[86],[18],[6393,6405],{"trials":6439,"activeCount":96},[],{"trials":6441,"activeCount":96},[],{"trials":6443,"activeCount":96},[],{"trials":6445,"activeCount":96},[],{"intervention":6447,"totalTrials":194,"cells":6448},"INCB000631",{"EARLY_PHASE1":6449,"PHASE1":6451,"PHASE2":6469,"PHASE3":6471,"PHASE4":6473,"NA":6475},{"trials":6450,"activeCount":96},[],{"trials":6452,"activeCount":96},[6453,6461],{"nctId":6454,"briefTitle":6455,"status":102,"phases":6456,"primaryCompletion":6457,"completion":6457,"start":6458,"enrollment":145,"conditions":6459,"interventions":6460},"NCT06775327","Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants",[86],"2025-05-28","2025-02-13",[18],[6447],{"nctId":6462,"briefTitle":6463,"status":283,"phases":6464,"primaryCompletion":6465,"completion":6465,"start":6466,"enrollment":16,"conditions":6467,"interventions":6468},"NCT07039929","Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants",[86],"2025-10-11","2025-07-28",[18],[6447],{"trials":6470,"activeCount":96},[],{"trials":6472,"activeCount":96},[],{"trials":6474,"activeCount":96},[],{"trials":6476,"activeCount":96},[],{"intervention":1906,"totalTrials":194,"cells":6478},{"EARLY_PHASE1":6479,"PHASE1":6481,"PHASE2":6491,"PHASE3":6493,"PHASE4":6495,"NA":6497},{"trials":6480,"activeCount":96},[],{"trials":6482,"activeCount":96},[6483,6487],{"nctId":3709,"briefTitle":3710,"status":102,"phases":6484,"primaryCompletion":3712,"completion":3712,"start":818,"enrollment":460,"conditions":6485,"interventions":6486},[86],[18],[3578,1906,1907],{"nctId":1896,"briefTitle":1897,"status":102,"phases":6488,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":1901,"conditions":6489,"interventions":6490},[86],[18],[1413,1904,1905,1906,1907],{"trials":6492,"activeCount":96},[],{"trials":6494,"activeCount":96},[],{"trials":6496,"activeCount":96},[],{"trials":6498,"activeCount":96},[],{"intervention":1907,"totalTrials":194,"cells":6500},{"EARLY_PHASE1":6501,"PHASE1":6503,"PHASE2":6513,"PHASE3":6515,"PHASE4":6517,"NA":6519},{"trials":6502,"activeCount":96},[],{"trials":6504,"activeCount":96},[6505,6509],{"nctId":3709,"briefTitle":3710,"status":102,"phases":6506,"primaryCompletion":3712,"completion":3712,"start":818,"enrollment":460,"conditions":6507,"interventions":6508},[86],[18],[3578,1906,1907],{"nctId":1896,"briefTitle":1897,"status":102,"phases":6510,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":1901,"conditions":6511,"interventions":6512},[86],[18],[1413,1904,1905,1906,1907],{"trials":6514,"activeCount":96},[],{"trials":6516,"activeCount":96},[],{"trials":6518,"activeCount":96},[],{"trials":6520,"activeCount":96},[],{"intervention":1454,"totalTrials":194,"cells":6522},{"EARLY_PHASE1":6523,"PHASE1":6525,"PHASE2":6535,"PHASE3":6537,"PHASE4":6539,"NA":6541},{"trials":6524,"activeCount":96},[],{"trials":6526,"activeCount":96},[6527,6531],{"nctId":6370,"briefTitle":6371,"status":102,"phases":6528,"primaryCompletion":6373,"completion":6373,"start":6374,"enrollment":1212,"conditions":6529,"interventions":6530},[86],[34,3975,4889,6376,6377,6378,6379,6380,2910,6381,6382],[1454,6354],{"nctId":1442,"briefTitle":1443,"status":283,"phases":6532,"primaryCompletion":1445,"completion":1445,"start":1446,"enrollment":1447,"conditions":6533,"interventions":6534},[86],[1449,1450,1451],[1453,40,1454],{"trials":6536,"activeCount":96},[],{"trials":6538,"activeCount":96},[],{"trials":6540,"activeCount":96},[],{"trials":6542,"activeCount":96},[],{"intervention":6368,"totalTrials":152,"cells":6544},{"EARLY_PHASE1":6545,"PHASE1":6547,"PHASE2":6553,"PHASE3":6555,"PHASE4":6557,"NA":6559},{"trials":6546,"activeCount":96},[],{"trials":6548,"activeCount":96},[6549],{"nctId":6361,"briefTitle":6362,"status":283,"phases":6550,"primaryCompletion":6364,"completion":6364,"start":6365,"enrollment":1308,"conditions":6551,"interventions":6552},[86],[1449],[6368,6354],{"trials":6554,"activeCount":96},[],{"trials":6556,"activeCount":96},[],{"trials":6558,"activeCount":96},[],{"trials":6560,"activeCount":96},[],{"intervention":6562,"totalTrials":152,"cells":6563},"INCB099318",{"EARLY_PHASE1":6564,"PHASE1":6566,"PHASE2":6585,"PHASE3":6587,"PHASE4":6589,"NA":6591},{"trials":6565,"activeCount":96},[],{"trials":6567,"activeCount":96},[6568],{"nctId":6569,"briefTitle":6570,"status":283,"phases":6571,"primaryCompletion":6572,"completion":6572,"start":6573,"enrollment":6574,"conditions":6575,"interventions":6584},"NCT04272034","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors",[86],"2024-08-16","2021-03-26",105,[1449,2428,2429,6576,2430,2432,2433,2434,2435,2436,2437,6577,6578,6579,6580,6581,6582,6583],"Urothelial Carcinoma, HCC","Cyclin-dependent Kinase 12 Mutated Tumors","Basal Cell Carcinoma (Unresectable or Metastatic)","Sarcomatoid Renal Cell Carcinoma","Clear Cell Ovarian or Endometrial Carcinoma","Anal Carcinoma","Squamous Cell Penile Carcinoma","DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)",[6562],{"trials":6586,"activeCount":96},[],{"trials":6588,"activeCount":96},[],{"trials":6590,"activeCount":96},[],{"trials":6592,"activeCount":96},[],{"intervention":5167,"totalTrials":152,"cells":6594},{"EARLY_PHASE1":6595,"PHASE1":6597,"PHASE2":6603,"PHASE3":6605,"PHASE4":6607,"NA":6609},{"trials":6596,"activeCount":96},[],{"trials":6598,"activeCount":96},[6599],{"nctId":5160,"briefTitle":5161,"status":102,"phases":6600,"primaryCompletion":5163,"completion":5163,"start":5164,"enrollment":1532,"conditions":6601,"interventions":6602},[86],[2787],[3318,5167],{"trials":6604,"activeCount":96},[],{"trials":6606,"activeCount":96},[],{"trials":6608,"activeCount":96},[],{"trials":6610,"activeCount":96},[],{"intervention":2547,"totalTrials":152,"cells":6612},{"EARLY_PHASE1":6613,"PHASE1":6615,"PHASE2":6621,"PHASE3":6623,"PHASE4":6625,"NA":6627},{"trials":6614,"activeCount":96},[],{"trials":6616,"activeCount":96},[6617],{"nctId":2539,"briefTitle":2540,"status":102,"phases":6618,"primaryCompletion":2542,"completion":2542,"start":2543,"enrollment":2544,"conditions":6619,"interventions":6620},[86],[32],[399,2547,2548],{"trials":6622,"activeCount":96},[],{"trials":6624,"activeCount":96},[],{"trials":6626,"activeCount":96},[],{"trials":6628,"activeCount":96},[],{"intervention":2548,"totalTrials":152,"cells":6630},{"EARLY_PHASE1":6631,"PHASE1":6633,"PHASE2":6639,"PHASE3":6641,"PHASE4":6643,"NA":6645},{"trials":6632,"activeCount":96},[],{"trials":6634,"activeCount":96},[6635],{"nctId":2539,"briefTitle":2540,"status":102,"phases":6636,"primaryCompletion":2542,"completion":2542,"start":2543,"enrollment":2544,"conditions":6637,"interventions":6638},[86],[32],[399,2547,2548],{"trials":6640,"activeCount":96},[],{"trials":6642,"activeCount":96},[],{"trials":6644,"activeCount":96},[],{"trials":6646,"activeCount":96},[],{"intervention":108,"totalTrials":152,"cells":6648},{"EARLY_PHASE1":6649,"PHASE1":6651,"PHASE2":6657,"PHASE3":6659,"PHASE4":6661,"NA":6663},{"trials":6650,"activeCount":96},[],{"trials":6652,"activeCount":96},[6653],{"nctId":100,"briefTitle":101,"status":102,"phases":6654,"primaryCompletion":104,"completion":104,"start":105,"enrollment":16,"conditions":6655,"interventions":6656},[86],[18],[60,108],{"trials":6658,"activeCount":96},[],{"trials":6660,"activeCount":96},[],{"trials":6662,"activeCount":96},[],{"trials":6664,"activeCount":96},[],{"intervention":3165,"totalTrials":152,"cells":6666},{"EARLY_PHASE1":6667,"PHASE1":6669,"PHASE2":6675,"PHASE3":6677,"PHASE4":6679,"NA":6681},{"trials":6668,"activeCount":96},[],{"trials":6670,"activeCount":96},[6671],{"nctId":3157,"briefTitle":3158,"status":283,"phases":6672,"primaryCompletion":3160,"completion":3161,"start":3162,"enrollment":350,"conditions":6673,"interventions":6674},[86],[1224],[422,3165],{"trials":6676,"activeCount":96},[],{"trials":6678,"activeCount":96},[],{"trials":6680,"activeCount":96},[],{"trials":6682,"activeCount":96},[],{"intervention":3175,"totalTrials":152,"cells":6684},{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6693,"PHASE3":6695,"PHASE4":6697,"NA":6699},{"trials":6686,"activeCount":96},[],{"trials":6688,"activeCount":96},[6689],{"nctId":3167,"briefTitle":3168,"status":102,"phases":6690,"primaryCompletion":3170,"completion":1942,"start":3171,"enrollment":3172,"conditions":6691,"interventions":6692},[86],[1944],[422,3175],{"trials":6694,"activeCount":96},[],{"trials":6696,"activeCount":96},[],{"trials":6698,"activeCount":96},[],{"trials":6700,"activeCount":96},[],{"intervention":6702,"totalTrials":152,"cells":6703},"INCB062079",{"EARLY_PHASE1":6704,"PHASE1":6706,"PHASE2":6717,"PHASE3":6719,"PHASE4":6721,"NA":6723},{"trials":6705,"activeCount":96},[],{"trials":6707,"activeCount":96},[6708],{"nctId":6709,"briefTitle":6710,"status":283,"phases":6711,"primaryCompletion":6712,"completion":6712,"start":6713,"enrollment":373,"conditions":6714,"interventions":6716},"NCT03144661","An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies",[86],"2020-06-10","2017-05-25",[4925,1554,2909,6715,34,15],"Nasopharyngeal Cancer",[6702],{"trials":6718,"activeCount":96},[],{"trials":6720,"activeCount":96},[],{"trials":6722,"activeCount":96},[],{"trials":6724,"activeCount":96},[],{"intervention":118,"totalTrials":152,"cells":6726},{"EARLY_PHASE1":6727,"PHASE1":6729,"PHASE2":6735,"PHASE3":6737,"PHASE4":6739,"NA":6741},{"trials":6728,"activeCount":96},[],{"trials":6730,"activeCount":96},[6731],{"nctId":110,"briefTitle":111,"status":102,"phases":6732,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":6733,"interventions":6734},[86],[18],[60,118],{"trials":6736,"activeCount":96},[],{"trials":6738,"activeCount":96},[],{"trials":6740,"activeCount":96},[],{"trials":6742,"activeCount":96},[],{"intervention":2714,"totalTrials":152,"cells":6744},{"EARLY_PHASE1":6745,"PHASE1":6747,"PHASE2":6753,"PHASE3":6755,"PHASE4":6757,"NA":6759},{"trials":6746,"activeCount":96},[],{"trials":6748,"activeCount":96},[6749],{"nctId":2706,"briefTitle":2707,"status":283,"phases":6750,"primaryCompletion":2709,"completion":2709,"start":2710,"enrollment":757,"conditions":6751,"interventions":6752},[86],[542,2712],[1440,2714],{"trials":6754,"activeCount":96},[],{"trials":6756,"activeCount":96},[],{"trials":6758,"activeCount":96},[],{"trials":6760,"activeCount":96},[],{"intervention":6762,"totalTrials":152,"cells":6763},"INCA32459-101",{"EARLY_PHASE1":6764,"PHASE1":6766,"PHASE2":6777,"PHASE3":6779,"PHASE4":6781,"NA":6783},{"trials":6765,"activeCount":96},[],{"trials":6767,"activeCount":96},[6768],{"nctId":6769,"briefTitle":6770,"status":102,"phases":6771,"primaryCompletion":6772,"completion":6772,"start":6773,"enrollment":6774,"conditions":6775,"interventions":6776},"NCT05577182","Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies",[86],"2025-10-13","2023-01-05",46,[1310],[6762],{"trials":6778,"activeCount":96},[],{"trials":6780,"activeCount":96},[],{"trials":6782,"activeCount":96},[],{"trials":6784,"activeCount":96},[],{"intervention":1905,"totalTrials":152,"cells":6786},{"EARLY_PHASE1":6787,"PHASE1":6789,"PHASE2":6795,"PHASE3":6797,"PHASE4":6799,"NA":6801},{"trials":6788,"activeCount":96},[],{"trials":6790,"activeCount":96},[6791],{"nctId":1896,"briefTitle":1897,"status":102,"phases":6792,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":1901,"conditions":6793,"interventions":6794},[86],[18],[1413,1904,1905,1906,1907],{"trials":6796,"activeCount":96},[],{"trials":6798,"activeCount":96},[],{"trials":6800,"activeCount":96},[],{"trials":6802,"activeCount":96},[],{"intervention":148,"totalTrials":152,"cells":6804},{"EARLY_PHASE1":6805,"PHASE1":6807,"PHASE2":6813,"PHASE3":6815,"PHASE4":6817,"NA":6819},{"trials":6806,"activeCount":96},[],{"trials":6808,"activeCount":96},[6809],{"nctId":140,"briefTitle":141,"status":102,"phases":6810,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":6811,"interventions":6812},[86],[18],[148,149,150,60,151],{"trials":6814,"activeCount":96},[],{"trials":6816,"activeCount":96},[],{"trials":6818,"activeCount":96},[],{"trials":6820,"activeCount":96},[],{"intervention":149,"totalTrials":152,"cells":6822},{"EARLY_PHASE1":6823,"PHASE1":6825,"PHASE2":6831,"PHASE3":6833,"PHASE4":6835,"NA":6837},{"trials":6824,"activeCount":96},[],{"trials":6826,"activeCount":96},[6827],{"nctId":140,"briefTitle":141,"status":102,"phases":6828,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":6829,"interventions":6830},[86],[18],[148,149,150,60,151],{"trials":6832,"activeCount":96},[],{"trials":6834,"activeCount":96},[],{"trials":6836,"activeCount":96},[],{"trials":6838,"activeCount":96},[],{"intervention":151,"totalTrials":152,"cells":6840},{"EARLY_PHASE1":6841,"PHASE1":6843,"PHASE2":6849,"PHASE3":6851,"PHASE4":6853,"NA":6855},{"trials":6842,"activeCount":96},[],{"trials":6844,"activeCount":96},[6845],{"nctId":140,"briefTitle":141,"status":102,"phases":6846,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":6847,"interventions":6848},[86],[18],[148,149,150,60,151],{"trials":6850,"activeCount":96},[],{"trials":6852,"activeCount":96},[],{"trials":6854,"activeCount":96},[],{"trials":6856,"activeCount":96},[],{"intervention":6858,"totalTrials":152,"cells":6859},"Ruxolitinib Cream 1.5%",{"EARLY_PHASE1":6860,"PHASE1":6862,"PHASE2":6872,"PHASE3":6874,"PHASE4":6876,"NA":6878},{"trials":6861,"activeCount":96},[],{"trials":6863,"activeCount":96},[6864],{"nctId":6865,"briefTitle":6866,"status":102,"phases":6867,"primaryCompletion":6868,"completion":6868,"start":6869,"enrollment":419,"conditions":6870,"interventions":6871},"NCT06213831","A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream",[86],"2025-07-17","2024-02-27",[250],[6858],{"trials":6873,"activeCount":96},[],{"trials":6875,"activeCount":96},[],{"trials":6877,"activeCount":96},[],{"trials":6879,"activeCount":96},[],{"intervention":1453,"totalTrials":152,"cells":6881},{"EARLY_PHASE1":6882,"PHASE1":6884,"PHASE2":6890,"PHASE3":6892,"PHASE4":6894,"NA":6896},{"trials":6883,"activeCount":96},[],{"trials":6885,"activeCount":96},[6886],{"nctId":1442,"briefTitle":1443,"status":283,"phases":6887,"primaryCompletion":1445,"completion":1445,"start":1446,"enrollment":1447,"conditions":6888,"interventions":6889},[86],[1449,1450,1451],[1453,40,1454],{"trials":6891,"activeCount":96},[],{"trials":6893,"activeCount":96},[],{"trials":6895,"activeCount":96},[],{"trials":6897,"activeCount":96},[],{"intervention":6899,"totalTrials":152,"cells":6900},"INCB028060",{"EARLY_PHASE1":6901,"PHASE1":6903,"PHASE2":6911,"PHASE3":6913,"PHASE4":6915,"NA":6917},{"trials":6902,"activeCount":96},[],{"trials":6904,"activeCount":96},[6905],{"nctId":6906,"briefTitle":4906,"status":102,"phases":6907,"primaryCompletion":505,"completion":3194,"start":6908,"enrollment":383,"conditions":6909,"interventions":6910},"NCT01072266",[86],"2010-01",[1550,2135,1311],[6899],{"trials":6912,"activeCount":96},[],{"trials":6914,"activeCount":96},[],{"trials":6916,"activeCount":96},[],{"trials":6918,"activeCount":96},[],{"intervention":2448,"totalTrials":152,"cells":6920},{"EARLY_PHASE1":6921,"PHASE1":6923,"PHASE2":6929,"PHASE3":6931,"PHASE4":6933,"NA":6935},{"trials":6922,"activeCount":96},[],{"trials":6924,"activeCount":96},[6925],{"nctId":2440,"briefTitle":2441,"status":283,"phases":6926,"primaryCompletion":2443,"completion":2444,"start":2445,"enrollment":268,"conditions":6927,"interventions":6928},[86],[1449],[2404,2448],{"trials":6930,"activeCount":96},[],{"trials":6932,"activeCount":96},[],{"trials":6934,"activeCount":96},[],{"trials":6936,"activeCount":96},[],{"intervention":6938,"totalTrials":152,"cells":6939},"INCB 99280 with Ipilimumab",{"EARLY_PHASE1":6940,"PHASE1":6942,"PHASE2":6955,"PHASE3":6957,"PHASE4":6959,"NA":6961},{"trials":6941,"activeCount":96},[],{"trials":6943,"activeCount":96},[6944],{"nctId":6945,"briefTitle":6946,"status":283,"phases":6947,"primaryCompletion":1445,"completion":6948,"start":6949,"enrollment":1198,"conditions":6950,"interventions":6954},"NCT05909995","Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors",[86],"2024-11-11","2023-08-29",[27,4925,2834,6951,6952,6953],"Microsatellite Instability - High (MSI-H)","Mismatch Repair Deficient (dMMR)","Colorectal Carcinoma (CRC)",[6938],{"trials":6956,"activeCount":96},[],{"trials":6958,"activeCount":96},[],{"trials":6960,"activeCount":96},[],{"trials":6962,"activeCount":96},[],{"intervention":6964,"totalTrials":152,"cells":6965},"INCB13739",{"EARLY_PHASE1":6966,"PHASE1":6968,"PHASE2":6979,"PHASE3":6981,"PHASE4":6983,"NA":6985},{"trials":6967,"activeCount":96},[],{"trials":6969,"activeCount":96},[6970],{"nctId":6971,"briefTitle":6972,"status":102,"phases":6973,"primaryCompletion":6974,"completion":6974,"start":6975,"conditions":6976,"interventions":6978},"NCT00398619","A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes",[86],"2007-03","2006-11",[6977,5287],"Insulin Resistance",[6964],{"trials":6980,"activeCount":96},[],{"trials":6982,"activeCount":96},[],{"trials":6984,"activeCount":96},[],{"trials":6986,"activeCount":96},[],{"intervention":1313,"totalTrials":194,"cells":6988},{"EARLY_PHASE1":6989,"PHASE1":6991,"PHASE2":6993,"PHASE3":6999,"PHASE4":7001,"NA":7003},{"trials":6990,"activeCount":96},[],{"trials":6992,"activeCount":96},[],{"trials":6994,"activeCount":96},[6995],{"nctId":1303,"briefTitle":1304,"status":283,"phases":6996,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":6997,"interventions":6998},[86,87],[15,1310,1311],[1313,293,294,1314,1315,1316,1280,1317,1313,1318,1319,1320],{"trials":7000,"activeCount":96},[],{"trials":7002,"activeCount":96},[],{"trials":7004,"activeCount":96},[7005],{"nctId":7006,"briefTitle":7007,"status":751,"phases":7008,"conditions":7009,"interventions":7010},"NCT03906344","Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis",[],[],[1313],{"intervention":7012,"totalTrials":152,"cells":7013},"Iticitinib",{"EARLY_PHASE1":7014,"PHASE1":7016,"PHASE2":7018,"PHASE3":7020,"PHASE4":7022,"NA":7024},{"trials":7015,"activeCount":96},[],{"trials":7017,"activeCount":96},[],{"trials":7019,"activeCount":96},[],{"trials":7021,"activeCount":96},[],{"trials":7023,"activeCount":96},[],{"trials":7025,"activeCount":96},[7026],{"nctId":7027,"briefTitle":7028,"status":751,"phases":7029,"conditions":7030,"interventions":7032},"NCT03906318","Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia",[],[7031],"Aplastic Anemia",[7012],{"intervention":7034,"totalTrials":152,"cells":7035},"INCB054329",{"EARLY_PHASE1":7036,"PHASE1":7038,"PHASE2":7040,"PHASE3":7042,"PHASE4":7044,"NA":7046},{"trials":7037,"activeCount":96},[],{"trials":7039,"activeCount":96},[],{"trials":7041,"activeCount":96},[],{"trials":7043,"activeCount":96},[],{"trials":7045,"activeCount":96},[],{"trials":7047,"activeCount":96},[7048],{"nctId":7049,"briefTitle":7050,"status":751,"phases":7051,"conditions":7052,"interventions":7053},"NCT03896815","Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma",[],[],[7034]]